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PREFACE
Steroid profiling is one of the established techniques in doping analysis for detecting
the abuse of steroids that are identical to steroids of endogenous origin. It is based
on the analysis of several steroids that can originate from the endocrine system, in
urine samples. This analysis is mostly aiming at metabolites and/or precursors of
testosterone.
Since the introduction of testosterone as a widely abused doping agent, the
concentration ratio of testosterone versus epitestosterone (T/E ratio) has been
considered as the most sensitive and robust parameter to consider for detection of
testosterone abuse. Despite the fact that the T/E ratio is accepted as analytical
method in doping analysis, it has often played a controversial role in doping cases.
This is mainly caused by insufficient published data that is available about the
parameters that could possibly affect the “natural” T/E ratio, resulting in a significant
chance of false positive cases. Nevertheless, the T/E ratio has been applied since
the early eighties and can still not be displaced by the more recently developed
isotope ratio mass spectrometry for the detection of testosterone.
This thesis discusses several items that are related to the analytical chemistry of
steroid profiling. In part I the main focus is placed on the T/E ratio. Chapter 1
discusses the possible limitations of the T/E ratio by reviewing potential influential
factors on this parameter. One of those factors is the consumption of alcohol. In
Chapter 2 an experiment is described in which the relation between the metabolism
of alcohol and the increase of the T/E ratio is discussed. For this purpose male and
female subjects consumed an average dose of alcohol.
Steroid profiling techniques used today have mostly been developed in the time that
testosterone was one of the few abused compounds identical to endogenous
steroids. T/E ratios higher than the cutoff criterion of six were regarded as specific
evidence of testosterone abuse, unless a naturally high T/E ratio could be proven.
However, in the present time the abuse of substances identical to endogenous
steroids has become much more complicated by the introduction of precursors in the
biosynthesis of testosterone as “food supplements“. An increased T/E ratio as a
result of oral administration of steroids as dehydroepiandrosterone (DHEA) and
androst-4-ene-3,17-dione has been described several times in literature. Therefore,
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the T/E ratio should not be considered as a specific parameter for detection of
testosterone abuse, but more as an indication that manipulation of the endocrine
system has occurred.
Part II of this thesis is focussed on the development of steroid profiling techniques
that provide better possibilities for identification of the steroids administered. Criteria
of sensitivity (defined as the response of a parameter after administration) and
specificity (the response of a parameter after administration of one particular steroid,
compared to the response for other steroids) are used to evaluate new parameters in
steroid profiling.
In Chapter 3 is described that detection of oxygenated metabolites could possibly
provide information of equal sensitivity but higher specificity than non-oxygenated
metabolites. In Chapters 4 to 7, aspects of sensitivity and specificity are investigated
by performing excretion studies in male subjects with DHEA and androst-4-ene-3,17-
dione used as model steroids. Additionally, an excretion study with 3-acetyl-7-keto-
DHEA is evaluated in a case study design in an appendix.
In part III several analytical procedures of steroid profiling are discussed. As gas
chromatography coupled to mass spectrometry (MS of MS/MS) is still considered as
the method of choice for steroid analysis, derivatization is an essential sample
preparation step to improve chromatographic behavior and to increase mass
spectrometric sensitivity. Derivatization is often a bottleneck in the achieved
analytical performance. In Chapter 8, trimethylsilylation reactions upon 3-keto-4-ene
steroids were scaled up from an analytical (µg) to a preparative (mg) scale to gain
fundamental insight into observed differences in product formation. The
thermodynamically versus kinetically controlled formation of 3,5-dienolTMS and 2,4-
dienolTMS derivatives is discussed.
Chapter 9 describes the formation of ethyl thio adducts with steroids upon
derivatization with MSTFA/NH4I/ethanethiol. These analytical artifacts could lead to
interpretation problems in sample analysis.
In the final general discussion (Chapter 10) the perspectives of steroid profiling have
been reviewed.
PART I:
steroid profiling
and
the T/E ratio

1
EVALUATION OF INFLUENTIAL FACTORS ON THE
T/E RATIO AS DETERMINED IN DOPING ANALYSIS
ABSTRACT
The ratio of the concentration of testosterone glucuronide to the concentration of
epitestosterone glucuronide (T/E ratio) as determined in urine is the most frequently used
method to prove testosterone abuse by athletes. A T/E ratio higher than 6 has been
considered as proof for abuse in the past; however, cases of naturally occurring higher T/E
ratios have been described.
Since the introduction of the T/E ratio in doping analysis, the parameters that may or may
not influence the T/E ratio, possibly leading to false-positive results, have been debated. To
achieve more insight on the influencing circumstances, an overview is given to obtain an
objective view on the merits of the urinary T/E ratio.
Relevant analytical aspects of the T/E ratio, potential parameters of endogenous and
exogenous origins, as well as some alternative methods to determine testosterone abuse,
such as the urinary testosterone/luteinizing hormone ratio, gas
chromatography/combustion/isotope ratio mass spectrometry, hair analysis and high-
performance liquid chromatography/mass spectrometry, are discussed.
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INTRODUCTION
During the Moscow Olympic Games of 1980, a high frequency of testosterone (T)
abuse was suspected. By that time, analytical methods to detect the administration
of synthetic anabolic steroids by gas-chromatographic/mass spectrometric (GC-MS)
screening procedures had improved. Therefore, athletes switched therefore to
endogenous steroids like T.
Quantitation of T as a way to detect T abuse was inadequate because of its high
metabolic turnover rate, circadian rhythm of T excretion, and an interindividual
excretion variability. Donike et al. [1] introduced the ratio of urinary testosterone
glucuronide (TG) to epitestosterone glucuronide (EG) concentration, the T/E ratio, as
an indicator of T abuse. It was reported [1] that after oral, rectal or intramuscular T
administration, the excretion of TG increased more than other T metabolites.
Epitestosterone (E) was found not to be a metabolite of T because deuterium labeled
T administration did not result in significant deuterium labeled EG excretion [2].
Production and metabolism of T and E are shown in Figure 1. The origin of E is still
discussed. Although Dehennin [3] showed that half of total E production is of
testicular origin, the remaining 50% is still debated. Administration of
Adrenocorticotrophic Hormone (ACTH) results in an increased EG production,
indicating an adrenal origin [4-5]. Also adrenal insufficiency as observed in Addison’s
disease correlates to significantly deceased T and E excretion rates [6]. Also
peripheral production is possible [4,7-8]. Androst-5-ene-3β,17α-diol
(∆5-17α-AEDIOL) is suggested to be a potential precursor of E (Figure 1), taking into
account the 3β-hydroxy-steroid dehydrogenase/4,5-isomerase activity and
∆5-17α-AEDIOL production in testicular tissue [3].
The mean T/E ratio of urine samples of Caucasian males and females in the first
population study of Donike et al. [1] was 1-2. The values showed a logarithmic
normal distribution with an upper limit value lower than 6 [9-10]. Using these data,
the Medical Commission of the International Olympic Committee (IOC) banned the
use of T in 1982 and stated that a T/E ratio above 6 was sufficient proof for T abuse.
When applying this criterion in research and routine analyses, cases of naturally
occurring T/E ratios above 6 appeared [11-12]. Dehennin et al. [12] administered
testosterone enanthate in several doses intramuscularly to healthy men over a
period of 6 months. They found via linear interpolation between doses that the T/E
ratio exceeded the cutoff point of 6 when natural production (around 45 mg/week)
was doubled by weekly administration of a comparable dose of exogenous T.
Nowadays, the IOC states that a follow up investigation is needed for T/E ratios
above 6. In the follow up, possible elevated T/E ratios due to physiological or
pathological circumstances should be proven. This proof may be supplied by review
INFLUENTIAL FACTORS ON THE T/E RATIO
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of previous tests, endocrinological investigations [13], or unannounced testing over
several months.
The aim of multiple tests is the establishment of an individual reference range of an
athlete, depending on the intraindividual T/E variability [14]. A single T/E ratio that is
higher than the upper limit of the individual reference range (mean + 3 * standard
deviation) indicates T abuse [15-17]. Since its introduction, critics have put forward
several cases in which the T/E ratio was up for discussion because of the assumed
risk of false-positive or false-negative results. Despite this criticism, the T/E ratio has
been the most frequently applied method to detect T abuse. A lot of research has
been done to investigate the factors that could influence the outcome of a T/E ratio
analysis. To get insight into the validity of the T/E ratio, this article gives an overview
on the research that has been done on the presently known influencing parameters.
ANALYTICAL ASPECTS
Methodology
A lot of basic research has been performed for the application of endogenous steroid
analysis [25-29]. In doping screening analyses T and E are usually determined by
GC-MS [30], although radioimmunoassay techniques also have been reported [31].
Several, but basically similar sample cleanup procedures are applied in doping
laboratories (Figure 2). For most accurate determination of the T/E ratio, deuterium
labeled T and E are required as the internal standards. Procedures applying of d3-
-testosterone and d3-epitestosterone have been developed [32-34].
Solid-phase extraction (SPE) is applied to remove the inorganic material from the
urinary matrix. Usually XAD-2 resin or C18 columns are used for the extraction. This
step was introduced at the time that only Helix pomatia was used for enzymatic
hydrolysis in anabolic steroid screening procedures. SPE was needed to remove
inorganic substances that inhibit β-glucuronidase arylsulfatase hydrolysis by Helix
pomatia [35]. Nowadays, SPE is often still applied, but has not been proven
necessary for β-glucuronidase hydrolysis by Escherichia coli and is therefore omitted
by several laboratories from the screening procedures.
As the analytical procedure for the T/E ratio is aimed at TG and EG, removal of non-
conjugated T and E is applied prior to hydrolysis. Therefore, a liquid-liquid extraction
with a solvent like diethyl ether or t-butyl methyl ether is usually applied. Because the
excretion of non-conjugated T and E is below 1% from total excreted T and E,
omitting this step does not result in a significant change in the outcome of the T/E
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ratio. Also, this extraction is often excluded in screening procedures for time
efficiency and is then only applied in confirmation procedures.
Figure 1. Steroid metabolism producing and eliminating T and E [18-24]. Cholesterol is the
first precursor of all steroid hormones. Relevant precursors are
dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEAS),
androst-4-ene-3,17-dione (∆4-AEDIONE), androst-5-ene-3β,17α-diol
(∆5-17α-AEDIOL) and androst-5-ene-3β,17β-diol (∆5-AEDIOL). Some relevant
metabolites are androsterone glucuronide (AOG), androsterone sulfate (AOS),
testosterone glucuronide (TG), testosterone sulfate (TS) and etiocholanolone
glucuronide (EOG). Conversion of ∆4-AEDIONE or T to E is less than 1% of
alternative routes.
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Figure 2. Basic procedure for steroid profiling.
Before isolation, the remaining steroids are deconjugated by an enzymatic
hydrolysis. Several hydrolysis methods are available for application in steroid
analysis [36].  A digestive juice from Helix pomatia was used in the past for its
β-glucuronidase and arylsulfatase activity. However, because a 3β-hydroxysteroid
oxidoreductase and a 3-oxosteroid-5,4-isomerase activity have been observed in this
formulation, use of Helix pomatia is usually avoided in doping screening procedures
[37-40]. Bacterial (E. coli) preparations with a pure β-glucuronidase activity and no
arylsulfatase activity are now generally accepted for hydrolysis. Therefore, the T/E
ratio is usually based on TG and EG. When hydrolysis is controlled by application of
deuterium labeled androsterone glucuronide, hydrolysis can be performed directly in
the urine matrix as has been outlined by Geyer et al. [41]. Following the suggested
Steroid isolation from urinary
matrix by solid-phase extraction
(SPE) using C18 or XAD-2 material
Hydrolysis of steroid conjugates
by β-glucuronidase (E. coli) or
β-glucuronidase/arylsulfatase
(Helix pomatia)
Steroid isolation from buffer
matrix by liquid-liquid extraction
Derivatization and GC-MS analysis
Liquid-liquid extraction to remove
non-conjugated T and E
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method the conjugated and non-conjugated steroids are combined in a single
fraction.
It is suspected that a naturally high TG/EG ratio is associated to a low excretion level
of EG compared to a higher excretion level of epitestosterone sulfate (ES) due to
stimulated sulfotransferase activity in the testes. As a result, Dehennin [42] therefore
suggested the TG/(EG+ES) ratio and the EG/ES ratio in order to collect more
relevant information in subjects with high T/E ratios. It was shown that a
physiologically high TG/EG ratio is associated with an EG/ES ratio below 1. For this
purpose, methanolysis has been suggested as an alternative chemical hydrolyzation
method [43].
After hydrolysis the steroids are extracted into an apolar phase like diethyl ether or t-
butyl methyl ether. Steroids in the dried extract are then derivatized to
trimethylsilylenol-trimethylsilyl (TMSenol-TMS) ethers and injected into a GC-MS
[25]. Applying selected ion monitoring (SIM), T and E are quantified using molecular
ion at m/z 432.
Inter- and intra-laboratory variation
A collaborate study has been done by six international doping laboratories to
describe the within- and between-laboratory variances for determination of the T/E
ratio [44]. Some of the experimental factors that could possibly influence the
outcome were left uncontrolled. Every laboratory analyzed the same 4 urine samples
with different T/E ratios in triplicate. The within-laboratory variation was lower than
the between-laboratory variation (maximum of 8.3% and 11.7% respectively). The
estimate of the urinary T/E ratios differed significantly between laboratories. This
study showed it to be necessary to standardize methods between the laboratories as
much as possible to improve the T/E ratio as a parameter. As described before, full
standardization of methods has still not been achieved between doping laboratories.
Clearly, more attention should be paid to this aspect. In this study boldenone (1-
dehydrotestosterone) and 17α-methyltestosterone were used as internal standard.
Better results have been obtained with application of deuterium labeled T and E [45].
Matrix problems
Linnet [46] described the effect of the urinary matrix on the T/E ratio. Calibration
curves of T and E, which were taken from methanol without extraction from a urinary
matrix, appeared to be non-linear, caused by an increasing relative molar response
of T compared to the internal standard 17α-methyltestosterone with increasing
concentration levels. T and E added to blank urine and taken through an extraction
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procedure, without previous enzymatic hydrolysis, was needed to stabilize the
relative molar response over a wide concentration range. The suggestion was made
to base the calibration curves on T and E added to blank urine. Geyer et al. [47]
suggested the use of so-called artificial urine. Artificial urine samples have been
produced by addition of 1-(N,N-diisopropylamino)-alkanes (DIPAs 14-23, Figure 3) to
calibration standards that elute in the same range as the calibrated steroids. Paraffin
was suggested as another possibility, but it has not been investigated. Use of
artificial urine samples results in higher molar response of the calibrated steroids and
a more linear calibration curve. Another possible method is the use of urine of
postmenopausal women or children to prepare calibration standards.
CH3 N
CH(CH3)2
CH(CH3)2
(CH2)n
Figure 3. 1-(N,N-diisopropylamino)-alkane (DIPAs) with n=13 for DIPA 14 and n=22 for
DIPA 23
Microbial degradation
Bacterial activities in urine may cause significant changes in measured steroid
profiles, as was brought forward in the Diane Modahl case in 1994 [48-49]. Because
urine samples are collected under unsterile conditions, bacteria have the chance to
grow when samples are stored too long at a too high temperature. To minimize
bacterial contamination, urine samples should be stored at -20° C. Bacterial species
from strains as Staphylococcus and Enterococcus are expected to grow in urine
during unfavorable storage conditions [50]. These microorganisms cause urinary
alteration by oxidoreduction reactions of endogenous steroids. The primary reaction
that occurs is the deconjugation of glucuronides and sulfates [51]. Loss of T and E
from the fraction of glucuronides to the fraction of non-conjugated steroids will lower
the measured concentration in the screening procedure. Geyer et al. [52] reported an
increased T/E from 5.3 to 9.8, determined in a combined fraction of conjugated and
non-conjugated steroids. This increase was caused by an increased concentration of
T in the fraction of non-conjugated steroids compared to E [17,52-53]. The
suggested mechanism for the T production is the bacterial hydrolysis of the sulfate
conjugate of ∆5-AEDIOL followed by 3α- and 3β-hydroxy-∆5-steroid-dehydrogenase
and steroid-∆4,5-isomerase activity [54]. In a study by de la Torre et al. [55] no
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production of T and E was observed in several selected bacterial species that are
expected to proliferate in urine as a result of adulteration. So far, no TG/EG
alteration due to bacterial growth has been proven. However, as uncontrolled
hydrolysis and oxidoreduction reactions occur in the urine, an increased T/E ratio
due to bad sample storing can not be excluded.
To prevent false-positive outcomes due to bacterial activity, the analysis of markers
is suggested to prove urine degradation. Markers of bacterial urine degradation are
the accumulation of 5α- and 5β-androstan-3,17-dione [53,56], which are the product
of deconjugation followed by oxidation of androsterone (AO) and etiocholanolone
(EO). Ayotte et al. [57] described 5α-androstan-3,17-dione coeluting with E, both
showing a TMSenol-TMS derivative molecular ion at m/z 432 with significant
abundance. An inaccurate determination of the T/E ratio in a regular screening
procedure from the sum of deconjugated and non-conjugated steroids can be the
result of microbial activities when 5α-androstan-3,17-dione and E coelute. This has
however not appeared to be a problem of general concern because 100%
dimethylpolysiloxane film columns should generally provide a baseline separation.
Other specific ions of 5α- and 5β-androstan-3,17-dione at m/z values 275 and 290
can be implemented in the SIM procedure to detect more specifically urine
contamination by microorganisms. Another sign of bacterial activity could be an
increased urinary pH. However, signs of degradation were reported [56] reported to
appear in only 50% of the urine samples, which had been stored at 37° C for several
days, and showed a pH increased to a value above 8. Moreover, several bacterial
species that have previously been identified in urine, are able to proliferate without
alkalizing the medium [55]. Proving urine sample deterioration is therefore done on
the basis of accumulation of 5α- and 5β-androstan-3,17-dione, visible microbial
growth, the fraction of nonconjugated steroids, and if possible, a high pH value.
FACTORS OF ENDOGENOUS ORIGIN
Age and development
In several kinds of sports, doping control takes place on athletes from adolescent or
pre-adolescent age groups. In order to apply the T/E ratio as conclusive evidence on
youngsters, knowledge is needed about the endocrinology from those age groups.
Dehennin et al. [58] studied the steroid excretion rates from 140 males, aging
between 13 and 20, divided into 5 pubertal stages according to the criteria of Tanner
[59]. They concluded that the excretion rates of T and E as glucuronides or sulfates
increased during pubertal development with no significant differences in the T/E
INFLUENTIAL FACTORS ON THE T/E RATIO

-19-
ratio. This means a stable T/E ratio during pubertal development in boys. Raynaud et
al. [60] reported a significant difference in the correlation slopes of T and E excretion
versus chronological age in boys; T versus age rose approximately twice as fast.
Because of a wide variability of individual values, there was also no significant
difference in the mean T/E ratio between the successive pubertal stages.
Comparable results have been obtained in older studies applying different sample
cleanup protocols and nonselective flame ionization detection techniques [61-62].
Schweizer et al. [63] reported that the changes in T/E between different stages were
insignificant, but with a higher T/E instability at the prepubertal stages, where early
signs of pubertal development can be observed. Lapcik et al. [64] reported a
decrease in the plasma ratio of non-conjugated E to T in males, as determined by
radioimmunoassay. Only non-conjugated T and E were determined. Broad age
classes were used for correlation study, and sexual development was not regarded.
Therefore, no relevant conclusions can be extracted from this study on the
development of the endocrinology in relation to T and E during adolescence.
A study performed with a large number of adolescent girls [65] showed a larger
increase of E excretion at higher Tanner stages. This resulted in a decreasing T/E
ratio during adolescent development. However, a comparable decreasing T/E
variability was detected at higher stages of development in girls as compared to
boys. No significant difference was observed between a population of extensively
exercising girls and the control group.
Endocrinological diseases
For endocrinological diseases in general, the number of recent scientific reports is
very limited. From a series of endocrinological diseases, hirsutism is best described
in relation with the T/E ratio. Hirsutism increases the excretion of T and E, of which
the magnitude correlates to the occurrence of symptoms. France and Knox [66]
reported increased excretion rates of T and E in case of hirsutism with irregular
menses, hirsutism with virilization, and in most cases of hirsutism with regular
menses. Although different sample cleanup procedures and unselective GC
detection were used, from the data can be concluded that there was no influence of
hirsutism on the urinary T/E ratio. Pal [67] studied a group of 90 females with
iodiopathic hirsutism compared to 90 healthy females aged between 16 and 46
years. In subjects with the most prominent hair growth (30%), the excretion of T and
E was above the reference range. No conclusions can be drawn about the T/E ratio.
These results appear to contradict with the results from de Nicola et al. [68], who
reported a much larger increase in E excretion resulting in an approximate 10-fold
decreased T/E ratio in 14 female subjects, using comparable analytical techniques.
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Other endocrine disorders (adrenal adenoma, adrenal carcinoma, adrenal
hyperplasia, adrenal tumor, congenital adrenal hyperplasia, virilizing adrenal tumor
and virilizing ovarian tumor) were reported to increase T and E excretion. However,
glucuronides and sulfates were measured and a limited number of subjects were
used. No specific data regarding the T/E ratio was presented [69]. Hypogonadism is
reported to reduce the excretion rate of T and E in males to an average same extent,
so no major changes in T/E are expected [70], except for an increased analytical
variation in the laboratory because of the lower values.
Ethnic origin
Asian sub-populations excrete T at a lower level than Caucasians, which results in a
relatively low T/E ratio. During the 10th Asian Games in Seoul a mean T/E ratio of
0.76 was observed [71]. This is significantly lower than the mean value of
Caucasians. A T/E distribution from a multiethnic reference population consisting of
two different lognormal distributions has been reported [56,72]. The first with a mode
of 0.16 involving a 95% reference range between 0.07 and 0.25 and the second with
a mode of 1.0 and a 95% reference range between 0.5 and 3.5. Low T excretion in
Asian sub-populations increases the risk of false-negative results after T
administration [73]. The IOC criterion of 6 is therefore questionable when subjects of
Asian origin are concerned. In IOC regulations, however, no ethnic differences are
taken into account. The IOC criteria have been determined using subjects from the
Caucasian population, which is only a minor group of the world population.
Differentiation in enzymatic metabolic activities between Asian and Caucasian
populations, has been extensively studied in case of polymorphism of alcohol
dehydrogenase [74-75] and human cytochrome P450 enzymes such as CYP2D6
and CYP2C19 [76-77]. Polymorfism of metabolic enzymes in relation to doping
analysis is a subject that has not been studied in detail. In addition, no specific data
on other races have been reported.
Menstrual Cycle
Contradictory results on the influence of the menstrual cycle on the urinary T/E ratio
have been obtained. Some reports concluded there were no clear T/E pattern during
the menstrual cycle of a few observed subjects [78-79]. However Catlin et al. [80]
reported a T/E peak during menses in three subjects throughout a total of five
menstrual cycles. However, no quantitative results were reported in this study.
Clearly, more specific research is needed on this subject involving a larger number of
subjects.
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Circadian rhythm
T is produced with a diurnal variation of 20-40% [81-82]. A maximum concentration
in blood is observed around 6.00 to 8.00 a.m. and a minimum around 8.00 to 10.00
p.m., assuming a regular sleeping pattern. The diurnal rhythm is observed with a
high interindividual variation. The circadian rhythm in T production is reflected in a
circadian rhythm in urinary T excretion. A diurnal rhythm is also observed for E [83].
The variation in T/E ratio is expected to be less than 30% [84] in males. The
observed variation in females will be more significant [78] because the higher
analytical variation due to lower urinary concentrations of T and E is superimposed
on the circadian variation.
Pregnancy
T production increases with progressing pregnancy, and after delivery T levels
promptly return to basal concentration [85-86]. The excretion of T and E is elevated
only in the third trimester of the pregnancy [87-88], and the T/E ratio is not influenced
significantly during pregnancy. After delivery, excretion levels drop to basal levels
within a week. One week after delivery, a large shift in T/E due to a faster decrease
in E than T to basal levels has been reported [6]. This effect could be explained by
the increasing sex hormone binding globulin (SHBG) concentration during pregnancy
and the lack of E binding to SHBG.
Exercise
The influence of exercise on the T/E ratio is still unclear. De Boer et al. [89] reported
no significant change in mean T/E ratio that could be attributed to exercise, which
was done by five well-trained volunteers. The exercise was performed on a bicycle
ergometer with a programmed workload to simulate a race course of the Tour the
France. These results were supported by a study performed on 13 cyclists
participating in the Tour de Suisse and the Tour de France in 1992 [90]. Samples
were taken every day before and after the exercise, and no influence on the T/E was
found. Maynar et al. [91] reported decreased urinary concentrations of T and E
during training periods and increased concentrations during competition. These
results were obtained from urine samples of 16 professional racing cyclists.
However, only urinary concentrations were measured instead of excretion rates;
therefore, these results should be confirmed. It was concluded that the T/E ratio
decreased significantly during training and competition. Increasing androgen levels
were suggested to be due to a decreased SHBG level as result of extensive
exercise. Yap et al. [92] reported insignificant decreases of T excretion during
different intensities of physical exercise-stress. The experiment was conducted on 4
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groups of 7 to 12 male athletes. Also psychological stress during competition has
been investigated in a pentathlon pistol shooting experiment [93]. Plasma
testosterone concentrations increased while luteinizing hormone (LH) levels were
constant. The effect was more significant in older subjects. No effect was observed
on the urinary T/E ratio.
These contradictory results should be a challenge for further investigation, especially
because the control of athletes often takes place after a match. A lot of parameters
should be taken into account, for example, exercise duration, intensity and repetition,
the type of exercise, gender, general condition and ethnic background of volunteers.
FACTORS OF EXOGENOUS ORIGIN
Oral contraceptives
Only one preliminary study of Mareck-Engelke [94] with not more than four
volunteers is available, and it showed an elevation of the T/E ratio due to the
application of oral contraceptives as the result of suppressed E excretion. In this
study, morning urine samples were taken through a menstrual cycle, before and
some time after stopping oral contraceptive administration. Administration of oral
contraceptives also resulted in an unstable T/E ratio. In one of the volunteers, the
ratio approached the level of 6 twice in one cycle. The mean T/E increased 2-3 times
due to administration of a single- phase or three-phase contraceptive. Further
research with more volunteers is needed to estimate a risk of false-positive results.
Ketoconazole
In 1992 Oftebro [11] mentioned the application of the ketoconazole test to
discriminate between a “naturally” high T/E ratio and a high T/E ratio due to
administration of T. Originally ketoconazole was developed as an antifungal agent,
but it also appeared to inhibit T biosynthesis [95-96]. Santen et al. [97] observed that
plasma levels of androst-4-ene-3,17-dione decreased after ketoconazole
administration, whereas its precursor 17α-hydroxyprogesterone increased. It was
concluded that this was the result of 17,20-lyase inhibition. Chemically related
antifungal agents like isoconazole, miconazole, econazole and clotrimazole also
inhibit T synthesis in vitro [98], in contrast to the inactive triazole antifungal agent
fluconazole [99-100]. Kicman et al. [101] described the application of ketoconazole in
a test to differentiate between athletes using T and athletes with a naturally high T/E
ratio. Besides the T excretion rate, the E excretion rate was also lowered due to
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ketoconazole administration, but to a lesser extent. This resulted in a decreased T/E
ratio during a few hours. Kicman et al. [101] reported a mean decrease in T/E of 57%
(range 49-66%) 7 hours after a single oral administration of 400 mg ketoconazol in
six male subjects. When supraphysiological dosages of T have been administered
prior to the ketoconazole test, little effect is expected for the T excretion. The E
excretion will decrease similar to the natural situation, resulting in an increased T/E
ratio during a few hours. Usually the protocol for a ketoconazole test describes a
dose of 400 mg ketoconazole or 800 mg as suggested by Oftebro et al. [102]. The
ketoconazole test is used on a confirmatory basis and is performed with voluntarily
permission from the involved athlete.
Ethanol
In 1988, Falk et al. [103] reported the increase of the T/E ratio due to the
consumption of ethanol. The increase was observed at dosages higher than 1 g/kg
bodyweight. A dose of 2 g/kg bodyweight resulted in an increase of 30-90%, which
was, however, insufficient to reach the IOC criterion of 6. Only four male subjects
were used, and urine sampling was done only once every 8 hours. After publication
of this study, some cases appeared of athletes who had an occasional T/E above 6,
which were claimed to be due to ethanol consumption [104-105]. The increase of T/E
is more apparent in females compared to males [104,106-107], which is explained by
the different routes and quantities of T production [107]. Male production of T is
mainly of gonadal origin, whereas peripheral conversion from androst-4-ene-3,17-
dione accounts for 50% of female production of T.
The mechanism for the increased T/E ratio due to ethanol administration is still
unknown. Acute oral ethanol administration produces a suppression of plasma T,
whereas LH levels do not change significantly [108-109]. This supposes a direct
action from ethanol on the steroid production. Several hypotheses have been put
forward to explain the observed changes. Falk et al. [103] suggested the
dependency of the T/E ratio on the actual NADH/NAD+ ratio. It has been proven that
ethanol metabolism increases the ratio of NADH over NAD+, which results in a
suppressed steroid oxidation [110]. This is supported by previous studies, which
have demonstrated increased ratios of urinary 17β-hydroxysteroid and 17-
ketosteroid sulfates [111-113]. Karila et al. [107] suggested two additional
mechanisms. One is that ethanol administration causes an endocrine response to
stress, leading to a stimulation of the hypothalamic-pituitary-adrenal axis. This
hypothesis is supported by the increase of plasma concentrations of adrenal steroids
as cortisol, dehydroepiandrosterone sulfate (DHEAS), dehydroepiandrosterone
(DHEA) and androst-4-ene-3,17-dione (∆4-AEDIONE) in females after intake of 2
g/kg ethanol [114-115]. In alcoholics, cases have been described of alcohol-induced
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overproduction of cortisol, causing pseudo-Cushing’s syndrome. However, the
underlying mechanism is unclear [116]. The second possible mechanism is the direct
inhibition of T metabolism by ethanol, which is  supported by the reduced excretion
rate of the main metabolites of T: AO and EO [115].
Anabolic Androgenic Steroids
DHEA, androst-4-ene-3,17-dione and androst-4-ene-3β,17β-diol
During the last few years, T precursors like DHEA, ∆4-AEDIONE and androst-4-ene-
3β,17β-diol (∆4-AEDIOL) are increasingly used by athletes to improve their
performance. The occurrence of these compounds as ergogenic substances in
sports is mainly based on their manipulation of the endocrine system to increase T
production. Although they are registered in the United States as food additives and
therefore are legal over-the-counter drugs, the IOC has put them on the list of
forbidden substances [117]. The true benefit for the athlete’s performance is,
however, doubted [118]. DHEA, particularly as its sulfate DHEAS, is the most
abundant circulating steroid hormone. Like ∆4-AEDIONE and ∆4-AEDIOL it has no
anabolic and only weak androgenic properties. Natural DHEA production is maximal
at the age of 20-30 years (around 4 mg/day as DHEA and 25 mg/day as DHEAS
[119-120]). After the third decade of life the production declines gradually to 10-20%
at the age of 70-80 [121].
Oral administration of 50-200 mg usually is applied to boost up the T level in plasma
for a few hours. The absorption level is low due to the first pass effect. Therefore,
doses used are quite large compared to other exogenous anabolic steroids.
Clearance of orally administered T precursors is fast, so chromatographic analysis of
the urinary concentration can only be performed in the first hours after
administration, depending on the dose. A urinary DHEA glucuronide concentration of
300 ng/ml has been proposed by Dehennin et al. [122] as a threshold for screening
of DHEA. Bowers reported a high occurrence of false-negatives when this threshold
would be applied [123].
Due to the increased overall T production resulting from DHEA administration, unlike
E production, the T/E ratio is affected. In a case of one male subject, oral
administration of 50 mg DHEA resulted in an increase of the T/E ratio from 0.5 to 3.1
at 3 hours after administration. The T/E had returned to basal value after 20 hours
[124]. However, other studies [2,123,125] also reported cases in which there was a
minimal effect on the T/E ratio. In the study performed by Bowers [123], only one of
four male subjects showed a T/E increase, from 2.4 to 8.1 in a 24 h pooled urine
sample after administration of 50 mg DHEA. The T/E ratio of the other three subjects
stayed far below the threshold of 6 after administration of 50 or 100 mg DHEA. In
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conclusion, there is a risk of a T/E>6 during the first day when 50 mg or more DHEA
is taken. The direct conversion of DHEA via T to metabolites as AO and EO prevents
in many cases an extensive release of T into the circulation, so the T/E ratio will
often remain below 6.
Nowadays, DHEA creams are also available on the market. A possible advantage
could be the administration of DHEA to the muscles and avoiding first passage
through the liver. In this way, DHEA can possibly intracrinologically be metabolized to
potent androgens like T and 5α-dihydrotestosterone (5α-DHT) without getting them
into the circulation [126]. In such a way, a risk of high T/E ratios could be avoided,
but no scientific data is available on this subject. The rapid uptake of steroids after
dermal application is demonstrated by Kapelrud et al [127]. They measured a rapid
T/E increase after topical application of ointments containing T and triamcinolone. In
this formulation, the triamcinolone increased the dermal uptake of T.
A few preliminary studies have been published on ∆4-AEDIONE and ∆4-AEDIOL on
a limited number of subjects [128-130]. Comparable T/E elevations have been
observed on a few subjects after administration of ∆4-AEDIONE or ∆4-AEDIOL
[128]. The maximum increase was much higher when the baseline T/E was above
average. The effect of increasing T excretion compared to E was not observed in
one subject of Asian origin. In this subject, T levels were insignificantly affected as E
excretion showed a large increase that lasted around 5 hours after 50 mg ∆4-
AEDIONE or 100 mg ∆4-AEDIOL administration. This striking difference illustrates
the ethnic differences in metabolic enzyme activities as has already been discussed
in this paper. Uralets et al. [128] also reported the presence of the 17α-epimere
androst-4-ene-3β,17α-diol in the commercial formulation of ∆4-AEDIOL (Androdiol),
resulting in a lower T/E ratio as expected on the basis of the ∆4-AEDIONE excretion
study.
Testosterone metabolite 5α-dihydrotestosterone (5α-DHT)
Metabolites which are abused by athletes are limited to 5α-DHT. Reports [131-132]
studying the determination of 5α-DHT abuse by profiling endogenous steroids stated
that 5α-DHT administration had no significant effect on the urinary TG/EG ratio. 5α-
DHT was administered in these studies intramuscularly as heptanoate (150 mg and
250 mg once) [131,133] and percutaneously (125 mg twice daily) [132].
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“Exogenous” anabolic steroids
The abuse of anabolic steroids of synthetic origin have an extensive effect on
general endocrinology. Long-term anabolic steroid use results in a suppression of
gonadal androgen production due to testicular or ovarian atrophy, which can be
detected in a urinary steroid profile even after cessation of anabolic steroid use
[134]. This hypogonadal state results in a decline of steroid hormone excretion as is
clearly demonstrated for AO and EO [135-136]. The lowered urinary concentration of
T and E creates a higher T/E variability than in normal circumstances. Small
analytical variations will have a greater impact on the outcome of the T/E ratio. De la
Torre et al. [137] showed that administration of metenolone (1-methyl-5α-androst-1-
en-17β-ol-3-one) decreased the T/E ratio. On the other hand when metenolone was
simultaneously administered with stanozolol (17α-methyl-17β-hydroxy-5α-androst-2-
eno[3,2-c]pyrazole), the T/E ratio increased. In both cases, the T excretion
decreased to the same extent. Whereas in case of metenolone administration, the E
excretion remained constant and in case of administration of metenolone and
stanozolol the E excretion declined extensively. These differences can be explained
by the lack of binding of stanazolol to the androgen receptor and to SHBG, resulting
in a general suppression of endogenous steroids by inhibition of metabolizing
enzymes. The strong binding of metenolone to the androgen receptor would result in
a more direct action in target tissues [138]. Increased T/E values have also been
found after metandienone administration. This increase was due to a decreased E
excretion [53].
Masking agents
Evidently, E administration could potentially be used to decrease the T/E ratio.
However, E is not available as a pharmaceutical formulation, it can still be possible
for athletes to obtain this steroid in other ways. Because approximately 1% of T and
30% of E is excreted directly or after glucuronidation, administration of T and E in a
ratio of approximately 30 to 1 does not result in change of T/E [31]. Therefore, E has
been added to the IOC list of forbidden substances as a masking agent for T abuse.
As a consequence a maximum E concentration of 200 ng/ml in urine has been set as
a criterion for E abuse. However, ratios of other excreted androgen metabolites can
also be used to detect the combined abuse of T and E. The ratios of TG/∆5-17α-
AEDIOLG and EG/∆5-17α-AEDIOLG have been introduced with respective threshold
values of 2.5 and 1.5 to determine simultaneous administration of T and E [42].
Administration of 40 mg T undecanoate (equivalent to 20.36 mg T) and 1 mg E or
1.57 mg E undecanoate (equivalent to 1 mg E) resulted in a TG/∆5-17α-AEDIOLG
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and EG/∆5-17α-AEDIOLG exceeding these threshold values, whereas TG/EG
remained below 6 [139].
Two other masking agents are important to mention, probenecid and bromantan.
Probenecid is an uricosuric agent that is used in the treatment of gout. It decreases
the excretion of endogenous and exogenous conjugated steroids by competitive
inhibition of active transport mechanisms in the proximal tubulus. The excretions of
all steroid conjugates are suppressed in the same extent. A decline in excretion to
20% has been reported after administration of two doses of 1 gram probenecid to
four male volunteers [140]. No change of the T/E ratio was observed. However,
because of the lowered excretion and an additional weak diuretic effect, the T/E ratio
might have a higher variance because of analytical variation. The masking agent
bromantan does not show an effect on the T/E ratio. Its main mono hydroxy-
metabolite can, however, coelute with E and therefore interfere with the analysis of
the T/E ratio. The fact that the main bromantan metabolite and E coelute creates an
analytical challenge. It is questionable that bromantan is regarded as a masking
agent, because coelution of compounds appearing on the IOC list of forbidden
substances with other substances is a problem which should be solved by the IOC-
accredited laboratories and should not be a concern of the athlete. Contradictory,
trimethoprim and sulfamethoxazol, of which the metabolites are reported to interfere
with the analysis of T and E, are not placed in the IOC list [52,141]. Extraction with
n-pentane is recommended to prevent this analytical problem.
Gonadotrophins human chorionic gonadotrophin (hCG) and LH
Gonadotrophins like human hCG, follicle stimulating hormone (FSH), and LH
increase gonadal steroid synthesis. hCG is of special interest to athletes because of
its relatively long plasma half-life. T and E production are both increased by hCG
[142]. hCG is administered intramuscularly by athletes to reduce hypogonadotrophic
hypogonadism after anabolic steroid use [143]. Another interesting aspect of hCG is
that it decreases a high T/E due to T administration [144]. Because the T/E ratio can
be decreased to a value far below 6 in this way, hCG can be regarded as a masking
agent for T. Administration of hCG can not be detected by measuring the effects on
the steroid profile, so direct hCG detection is necessary. The possibility of false hCG-
positive cases due to early-stage pregnancy limits this test to male athletes.
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ALTERNATIVE METHODS FOR THE T/E RATIO
Alternative ratios involving T
To determine T administration, other endocrinological parameters have been
introduced besides the T/E ratio. Because T administration suppresses the pituitary
secretion of gonadotrophins Brooks et al. [145] introduced the ratio between urinary
T (non-conjugated plus glucuronide) and LH in 1979 as a parameter, and Kicman et
al. [31] and Perry et al. [146] proved its sensitivity as a marker for T abuse. The T/LH
will increase as a result of T administration. The advantage of this method is the
possibility of detecting the use of combined T and E. In the past, a disadvantage has
been the possibility of cross-reaction in the LH-assay by hCG, resulting in lowered
T/LH values after hCG administration. Research regarding T/LH is restricted to
males. Application to females is not possible due to the midcycle LH peak and the
possible use of oral contraceptives that suppress LH excretion. Another restriction of
the T/LH ratio is the extensively decreased values at lower Tanner classes [58].
Carlström et al. [147-148] introduced the serum T/17α-hydroxyprogesterone
(17OHP) ratio as a parameter. 17OHP is a major testicular precursor of T and is
suppressed after T administration. Its applicability is limited to confirmation
procedures, as the IOC does still not allow the use of blood samples in doping
control screenings, except for hematocrit analyses as applied in health control
procedures. As a confirmation procedure, it has appeared to be a valuable
parameter [149]. Other parameters that are used for confirmation of high T/E ratios
are the less specific AO/T ratio and the T concentration [17].
GC-combustion-isotope ratio MS (GC-C-IRMS)
In recent years, GC-C-IRMS has been developed as an alternative technique for T
detection. This technique made it possible to discriminate exogenous T from
endogenous T by measuring the 13C/12C ratio of the steroid. Eluted compounds from
the GC are combusted in a catalytic furnace to N2 and CO2. For the carbon isotope
ratio determination, masses 44 and 45 are determined with great precision and
accuracy [150]. The measured carbon isotope ratio (13C/12Csample) is related to an
international fossil carbonate standard “Pee Dee belemnite” or “PDB” (13C/12CPDB):
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In a study of Becchi et al. [151] the δ13C‰  from urinary endogenous T was not
greater than -27‰ whereas  δ13C‰  in 9 urine samples from T excretion studies was
greater than -27‰. This difference is explained by the different origin of natural and
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synthetic testosterone. Plant species have different 13C levels [152]. Endogenous T
originates from cholesterol from plant material and meat in the human diet. The
δ13C‰ of endogenous testosterone is therefore a reflection of the average 13C
content in the human diet. Synthetically derived T is mostly derived from soy, which
has a relatively low 13C content. The described carbon isotope ratio method has
been shown to be a powerful way to detect T abuse associated with a T/E>30 [153-
154]. However, the detection of exogenous T by GC-C-IRMS after the T/E had
returned to below 6 after oral administration of testosterone undecanoate has been
reported [155]. Determination of exogenous T with GC-C-IRMS was possible for
more than twice as long as with application of T/E. The cases of a naturally high T/E
have not yet been investigated. A method which measured the carbon isotope ratio
of T metabolites 5α-androstane-3α,17β-diol and 5β-androstane-3α,17β-diol was able
to detect T administration in cases in which the T/E remained below 6 [156]. It must
be said that the five volunteers used were of Chinese ethnicity.  Therefore, the cut-
off limit of T/E=6 is questionable for the used population. Use of volunteers from the
Caucasian race would have been better to compare the isotope ratio technology with
the use of T/E. Confirmation of T administration in the five Chinese volunteers was
possible for eight days. A ratio of δ13C‰ for androstanediols to pregnanediol was
proposed in this study as a discriminating parameter, applying a cutoff limit of 1.1 for
T abuse. The disadvantage of using T metabolites as parameter is that DHEA and
∆4-AEDIONE also metabolize to androstanediols. One would therefore still need the
steroid profile to confirm the abused steroid or apply the isotope ratio technology to
other specific metabolites [157].
Since the 1998 Olympic Winter games in Nagano, the use of GC-C-IRMS has been
widely accepted as a confirmation method of T abuse. However, a relatively large
volume of urine (reported respectively minimum of 25 ml [156] and 2-20 ml
[155,158]) must be available for the analysis and a time-consuming cleanup
procedure is needed to obtain the necessary highly purified steroid fractions. With
the current state of the art, GC-C-IRMS is therefore only applied as a confirmation
method in IOC-accredited laboratories. The T/E is still the method of choice for
screening purposes. Because IRMS was only introduced in doping analysis a few
years ago, insufficient research has been done on the influence of important
parameters as ethnic origin and related food consumption on the isotope ratio of T
and its metabolites. Although Shackleton et al. [156] suggested the lack of racial
influence on the isotope ratio of T metabolites by studying 15 individuals from 11
different nationalities, it is apparent that more research is needed on this subject.
Also, more data should be collected to study the analytical between-laboratory
variation of GC-C-IRMS. Recent studies to study the application of GC-C-IRMS
technology for T screening were performed [159-161]. Although the use of isotope
ratio mass spectrometry for T confirmation purposes is increasing, its application is
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limited to a few IOC accredited laboratories, mainly because of the expense of its
implementation. The T/E ratio is therefore still the most popular method and will
remain to be very important in the near future of doping analysis.
Hair analysis for T
Hair analysis was developed in the forensic sciences to detect drugs of abuse [162].
Recently, high-resolution mass spectrometry (HRMS) was also applied to detect
anabolic steroids post-mortem in hair of a bodybuilder [161]. An interesting new
development is the measurement of T in hair [164]. A clear distinction could be made
between T in child hair, female hair (both <10 pmol/g) and male hair (10-80 pmol/g).
For these analyses 50 mg hair samples were used. Although hair analysis will not be
suitable for screening, it could be a useful technique for confirmation purposes to
obtain extra information besides the T/E ratio.
High-performance liquid chromatography-mass spectrometry (HPLC-MS)
A technique that has recently been introduced in doping control is electrospray
HPLC-MS or HPLC-MS-MS. The great advantage of HPLC-MS over GC-MS is that
derivatization [165] or deconjugation [166] of steroids is not essential, so T/E ratio
analyses can be performed cheaper and faster. In addition, analytical interpretation
is simplified because of absent incomplete hydrolysis or derivatization. T/E ratio
measurements can be performed in a more robust and therefore in a more accurate
way. Glucuronides and sulfates can be measured in one analysis, which makes this
technique very promising for routine and also confirmation analysis. Bowers et al.
[167] studied the analysis of steroids as TG, TS, EG and ES with electrospray HPLC-
MS. A full separation of all steroids without derivatization was possible with detection
limits of 3-25 pg on-column with a capillary packed column, which is very sensitive
compared to conventional quadrupole GC-MS analysis. Qualitatively, best results
were obtained in the positive ion mode. Because, as Dehennin et al. [42-43] already
suggested, naturally high T/E ratios are mostly caused by a relatively low EG level,
whereas ES is relatively high, HPLC-MS is a convenient method to determine
glucuronidated and sulfated T and E in one analysis [168]. In the future electrospray
HPLC-MS will gain importance as a more robust method to determine the T/E ratio.
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CONCLUDING REMARKS
Because the T/E ratio is influenced by many of the discussed parameters, positive
cases of T abuse cause a lot of scientific and legal debate. A lot of research has
been done to improve the analysis and to find alternative methods to replace the T/E
ratio analysis. This resulted in several promising confirmatory methods, such as T/LH
and T/17OHP, the ketoconazole test and especially GC-C-IRMS. In the future more
impact can be expected of HPLC-MS and hair analysis for confirmation. For
screening purposes HPLC-MS is the most promising technique to determine the T/E
ratio because GC-C-IRMS is still rather time consuming and expensive. The T/E ratio
is therefore still the most efficient screening method and will remain to be so in the
near future.
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2
THE INFLUENCE OF ETHANOL CONSUMPTION ON THE
T/E RATIO
ABSTRACT
In doping analysis the ratio of testosterone (T) glucuronide versus epitestosterone (E)
glucuronide (T/E ratio) is applied for the detection of T administration. It is well established
that ethanol consumption also increases the T/E ratio. However, reported observations of
such increased T/E ratios are mostly limited to the application of high dose levels of ethanol
(~2 g/kg bodyweight).
In this experiment a dose of 1.2 g ethanol per kg bodyweight was administered to eight male
and eight female subjects. Collected urine and plasma samples were analyzed for T, E and
several precursors and metabolites of T. Two separate conjugate fractions were analyzed (I:
sulfates, glucuronides and non-conjugated steroids; II: glucuronides and non-conjugated
steroids).
Plasma concentrations of T decreased significantly in case of males, whereas sex hormone
binding globulin increased. No significant effect was observed on plasma E and luteinizing
hormone. Excretion rates of T and androstanediols increased, while those of androsterone
and etiocholanolone decreased. Excretion rates of E, dehydroepiandrosterone and androst-
5-ene-3β,17β-diol were relatively stable. Based on intra- and interindividual data, the T/E
ratio significantly increased (p<0.05) in both males and females, in both studied fractions.
The increase was observed during the first 10-12 hours after start of consumption. Female
subjects showed a significantly larger effect than male subjects. The maximum detected T/E
ratio after administration showed positive (inter-subject) correlation with the mean pre-
administration T/E ratio. It was concluded that the chance of a T/E ratio increasing above the
International Olympic Committee criterion of six is realistic and should be kept in mind for
especially out-of-competition doping controls.
The cause of T/E increase could not be explained by one specific mechanism. The
simultaneous use of cofactors for the enzymatic activity in steroid and ethanol metabolism
seems to play a predominant role, but is not completely understood.
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INTRODUCTION
Since its introduction by Donike et al. [1], the ratio of testosterone glucuronide vs.
epitestosterone glucuronide (T/E ratio) as determined in urine is one of the
established methods in doping analysis to detect testosterone (T) administration. A
T/E ratio above six is considered as an indication of T abuse. In 1988 Falk et al. [2]
reported an increase of the T/E ratio in male subjects due to the consumption of
ethanol. Also, published cases have appeared of athletes who had an incidental T/E
ratio larger than six, that was claimed to be caused by ethanol consumption [3,4].
So far, published studies show a larger effect of ethanol administration on the T/E
ratio of females as compared to males [3,5-6]. It can be expected that this difference
is related to the relatively large contribution of peripheral conversion of androst-4-
ene-4,17-dione (∆4-AEDIONE) to the total female T production [5].
Still limited knowledge is available about the relationship between ethanol and the
T/E ratio. Several suggestions have been made, such as alteration of NAD+
dependent steroid biosynthetic and metabolic pathways by competition with ethanol
metabolism, ethanol inhibition of T metabolism and hypothalamic-pituitary-adrenal
(HPA) axis stimulation [2,5]
The effects of ethanol consumption on the T/E ratio have mostly been observed
applying relatively high dose levels of between 1.5 and 2.0 g/kg bodyweight [2,5,6].
Dose levels of around 1 g/kg were considered as too low to result in a significant
increase [2,5]. This was, however, contradicted by Axelson et al. [7] who observed
significant effects in steroid metabolism at a dose level of 0.3 g/kg. The lack of
observed effect could have been caused by wrong timing of sample collection, as the
first samples were taken at 8-10 hours after the administration period [2,5].
Seppenwoolde-Waasdorp et al. [3] showed that the maximum effect can be
expected within 8 hours after ethanol administration. A significant effect was
observed for both males and females in this study, applying a dose of 1 g/kg
bodyweight. Additionally, Mareck-Engelke et al. [6] illustrated that the T/E ratio
immediately increases after ethanol is detected in urine. Therefore, frequent urine
sampling should be applied, starting before or immediately after administration of the
first dose of ethanol [6].
In this study a dose of 1.2 g/kg was administered to 8 male and 8 female subjects in
a controlled trial setting. A steroid profile of T and E and several precursors and
metabolites were analyzed in urine and plasma. Emphasis was placed on the
maximum effect that can be expected for the T/E ratio. Aspects of first and second
phase metabolism were considered to obtain additional fundamental information
about the endocrine disruption.
ETHANOL AND THE T/E RATIO

-47-
EXPERIMENTAL
Chemicals
5α-Androstan-3α-ol-17-one (androsterone, AO), 5β-androstan-3α-ol-17-one
(etiocholanolone, EO), androst-4-ene-17α-ol-3-one (epitestosterone, E), 5α-
androstane-3α,17β-diol (5α,3α-ADIOL), 5α-androstane-3β,17β-diol (5α,3β-ADIOL),
5β-androstane-3α,17β-diol (5β,5α-ADIOL), androst-5-ene-3β,17β-diol (∆5-AEDIOL),
androst-4-ene-3,17-dione (∆4-AEDIONE), dehydroepiandrosterone-sulfate
(DHEA-S), androsterone-sulfate (AO-S) and androsterone-glucuronide (AO-G) were
purchased from Sigma (St. Louis, USA). Androst-4-ene-17β-ol-3-one (testosterone,
T) was purchased from Organon (Oss, The Netherlands). Androst-5-ene-3β-ol-17one
(dehydroepiandrosterone, DHEA) was purchased from Schering (Germany). The
internal standard was a solution of [2H4]-testosterone (d4-T), [2H4]-etiocholanolone
(d4-EO) and 17α-methyltestosterone (MeT) in methanol, and was kindly provided by
M. Donike. β-Glucuronidase from E. coli (Type VIII-A Purified; 50% glycerol solution;
5.000-20.000 kIU/g) was purchased from Boehringer-Mannheim (Mannheim,
Germany). Trimethylchlorosilane (TMCS, 99%), N-methyl-N-
trimethylsilyltrifluoracetamide (MSTFA), isopropanol and ethanethiol (97%) were
purchased from Sigma-Aldrich Chemie (Steinheim, Germany). Ammonium iodide
(NH4I) was purchased from Fluka Chemie (Buchs, Switzerland). Sodium carbonate,
anhydrous phosphorus pentoxide (P2O5), potassium hydroxide (KOH), potassium
dihydrogenphosphate (KH2PO4), sodium acetate trihydrate, acetic acid (96%), diethyl
ether and methanol (analytical grade) were purchased from Merck (Darmstadt,
Germany). All chemicals were of analytical grade unless indicated otherwise.
Columns for solid-phase extraction were IST Isolute octadecyl (C18) columns (200
mg, non-endcapped) obtained from Sopachem, Lunteren, The Netherlands.
Study design and sample collection
In this study 16 healthy volunteers (8 males and 8 females), in the age of 18-25
years, participated. Informed consent was obtained, and a detailed study protocol
was approved by the Medical Ethical Committee of the University of Utrecht. The
volunteers were not allowed to use or recently have used medication. Smokers and
female contraceptive users were excluded. The weight of the volunteers had to be
within 15% of ideal body weight, as defined in the "Metropolitan Life Insurance
Table". The average daily ethanol consumption was between one and three units, to
limit ethanol habituation. No ethanol was consumed during at least 24 hours before
start of the study. Diets were standardized during the trial.
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The complete trial lasted 2.5 days, the first day being a control day. During this day
no ethanol was consumed. During the second day, between 9 a.m. and 12 a.m.,
1.2 g/kg body weight ethanol was ingested as a 20% mixture with orange juice. On
the control day, the same amount of orange juice was used between 9 a.m. and
12 a.m. Urine samples were taken every 2 hours and overnight. Blood samples were
collected every 4 hours on the control day and every 2 hours during the rest of the
experiment. Time of sample collection and the urine void volume were recorded.
Blood samples were taken in heparinized collection tubes and centrifuged at 1200 g
during 10 minutes immediately after collection. The resulting plasma was collected in
glass tubes and was stored at -20°C until time of analysis. Of each urine sample,
100 ml were collected and also stored at -20°C until time of analysis. During sample
analysis, samples of one subject were always combined in one batch of analyses.
Sample preparation
Protocol I: Combined fraction of conjugated and non-conjugated steroids in urine
A Cl8 solid-phase extraction (SPE) column was conditioned by 2 times 2 ml of
methanol and equilibrated with 2 ml of distilled water, taking care to ensure that the
solid phase remained solvated. The density (d) of the urine samples was measured.
To an aliquot urine (8 ml for d<1.005, 4 ml for 1.005≤d<1.010 and 2 ml for d≥0.010),
50 µl of the internal standard solution was added. After vortexing, each sample was
introduced into an SPE cartridge. After washing the column with 2 ml of distilled
water, the solid phase was dried by allowing air to flow through the cartridge for at
least 2 minutes. The sample was then eluted with 2 ml of methanol and the extract
was evaporated to dryness at 55°C under a stream of nitrogen.
After SPE the collected steroid conjugates were hydrolyzed in order to obtain the de-
conjugated steroids. The dried extract was reconstituted in 1 ml of TMCS in
methanol (1 M) and methanolysis was performed at 55°C for 1 hour. The applied
methanolysis method was based on a method described by Dehennin et al. [8], in
which deconjugation occurs under acid conditions in a water free medium. In the
applied mixture of TMCS and methanol, hydrochloric acid (present as [CH3OH2]+CI-)
is produced that cleaves both glucuronides and sulfates from the steroid nucleus.
After incubation, the mixture was evaporated to dryness at 45°C under a stream of
nitrogen and subsequently 1 ml of phosphate buffer (0.2 M, pH 7.0) was added to
the residue.
Each buffer solution was extracted with 5 ml of diethyl ether by subsequent mixing
for 5 minutes and centrifugation (4000 rpm, 5 min). The organic phase was collected
and evaporated to dryness under a stream of nitrogen at 40°C. Any residual water
was removed by further drying over P2O5/KOH in a vacuum exsiccator overnight.
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The steroids were converted to trimethylsilylenol-trimethylsilyl (TMS-enolTMS)
derivatives by incubation of the dried extract in 50 µl of a mixture of
MSTFA/NH4I/ethanethiol (1000:2:3; v/w/v) at 80°C for 30 min (see also Chapters 8
and 9). The derivatization mixture was transferred to glass vials and injected into the
gas chromatography-mass spectrometry (GC-MS) system.
Protocol II: Fraction of glucuronides and non-conjugated steroids in urine
SPE was applied in the same way as Protocol I. To the dried extract, 1 ml of
phosphate buffer (0.2 M, pH 7.0) and 50 µl of β-glucuronidase solution, that was 10
times diluted with the same buffer, were added and vortexed. Selective hydrolysis of
glucuronides was performed for 30 min at 55°C. Extraction, drying and derivatization
was the same as in Protocol I.
Protocol III: Analysis of hormone parameters in plasma
T was measured after diethyl ether extraction using an in house competitive radio-
immunoassay employing a polyclonal antitestosteron-antibody (Dr. Pratt AZG 3290).
[1α,2α-3H(N)]-Testosteron (NET-387, DuPont NEN Nederland BV) was used as a
tracer following chromatographic verification of its purity. The lower limit of detection
was 0.24 nM and inter-assay variation was 7.6, 5.1, and 8.1% at 0.76, 2.26 and 13.2
nM, respectively (n=20).
Sex hormone binding globulin (SHBG) was measured using the immunometric assay
SPECTRIA SHBG IRMA (68562, Orion Diagnostica, Espoo, Finland). The lower limit
of detection was 5 nM and inter-assay variation was 3.4, 4.0 and 3.2% at 15, 41 and
100 nM respectively (n=20).
Luteinising Hormone (LH) was measured using the Enzymun Test LH (Roche
Diagnostics Nederland BV, Almere, The Netherlands) using the ES-300 Analyser.
Details about this method have been published previously [9].
Protocol IV: Analysis of ethanol in plasma samples
A volume of 1 µl plasma was directly injected (splitless) into a GC with flame
ionization detection (FID), with isopropanol as internal standard (at a concentration of
1‰). The injector temperature was 250°C and the splitless time was 0.5 min. Helium
was used as carrier gas with a pressure of 15 psi. The temperature of the column
was at 60°C with a run-time of 4.5 min. A calibration curve of 5 data points was used
for calibration. Calibration standards were spiked to blank plasma and included in the
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analytical procedure. Sample analysis was performed within one week after
collection.
Gas chromatography and mass spectrometry
For the analysis of the plasma samples a Varian Aerograph GC-FID was used with a
10% Halcomid M18 on Chromosorb WAW 80-100 mesh column (length 1.8 m, inner
diameter 4.6 mm).
For the analysis of the steroids in urine samples a GC-MS system was used, that
existed of a Hewlett Packard gas chromatograph (Model 5890, Agilent Technologies,
Waldbronn, Germany) coupled to a Hewlett Packard quadrupole mass spectrometer
(Model 5972A). The MS was used in selected ion monitoring mode (SIM) and
electron ionization was applied at 70 eV. Gas chromatography was performed with a
HP-1 Ultra column (length 18 m, inner diameter 0.20 mm, film thickness 0.11 µm).
Via electronic pressure control the column flow (helium) was constant at 1 ml/min.
Sample injection of 1 µl was performed in split mode (ratio 1/10). A Hewlett Packard
autosampler (Model 7673, Agilent Technologies, Waldbronn, Germany) was used for
auto-injection. The injector temperature was set to 250°C. The oven temperature
program used was: initial temperature 180°C, 2°/min to 225°C, 30°/min up to 310°C,
held for 5 min. The interface temperature was set to 280°C.
Calibration and quantification
Calibration samples were prepared by adding 100 µl of methanolic standard
solutions to 4 ml demineralized water samples. These samples were included in the
clean-up procedure with the urine samples. For quantification the following ions were
monitored: AO and EO at m/z 434; T, E and DHEA at m/z 432; ∆4-AEDIONE at m/z
430; ∆5-AEDIOL at m/z 239; 5α,3α-ADIOL, 5α,3β-ADIOL and 5β,3α-ADIOL at m/z
241. As qualifier ions were monitored: AO and EO at m/z 419; T, E and DHEA at m/z
417; ∆4-AEDIONE at m/z 415; ∆5-AEDIOL at m/z 434; 5α,3α-ADIOL, 5α,3β-ADIOL
and 5β,3α-ADIOL at m/z 256. Calibration curves contained six data-points, that
covered the respective ranges: AO (100-6000 ng), EO (40-2400 ng), T (5-250 ng), E
(5-250 ng), ∆4 AEDIONE (5-250 ng), DHEA (100-4400 ng), ∆5-AEDIOL
(50-1500 ng), 5α,3α-ADIOL (25-1000 ng), 5α,3β-ADIOL (10-500 ng), 5β,3α-ADIOL
(25-2500 ng). A check for possibly incomplete derivatization, caused by the presence
of residual water in the derivatization mixture, was detected by qualitative monitoring
of mono-TMS-derivatives of AO and EO at m/z 362 and 272. When significant mono-
derivatives were detected as compared to fully derivatized AO and EO, the sample
analysis was rejected.
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A mixture of deuterium labeled T (d4-T, detected at m/z 436), EO (d4-EO, m/z 438)
and non-labeled MeT (detected at m/z 301) in methanol was used as internal
standard solution. Exact concentrations and location of the deuterium atoms were
unknown. d4-T was used for the quantification of T, E and ∆4-AEDIONE in Protocol I,
whereas MeT was used for the same steroids in Protocol II. d4-EO was used as
internal standard for all other steroids in both protocols.
The area ratio of T/d4-T was corrected, because the internal standard solution used
was contaminated with small amounts of interfering non-deuterated T. No
interference by the signal of d4-EO on the area of EO was detected. However, as
large quantities of EO are present in urine samples, there was some interference by
the signal at m/z 438 of non-deuterated EO on the area of d4-EO. As this was
reproducible a correction was performed on the measured area ratio of EO/d4-EO.
Validation experiments
Conversion of deconjugation was studied by hydrolysis of synthetic DHEA-sulfate
(DHEA-S), AO-sulfate (AO-S) and AO-glucuronide (AO-G) with the methods of
Protocol I and II.  Therefore, 1 µg of the studied steroids was subjected to the
respective hydrolysis procedures. Quantification was applied with calibration samples
that were included in the same sample clean-up procedure.
The recovery of the extraction procedure was determined by processing spiked water
samples of 2 ml at low and high concentration levels with Protocol II (excluding
hydrolysis procedure). Recovery was calculated by comparison of the area response
in the studied samples with the response of standards that were directly derivatized.
Stability of the studied steroid derivatives in the reagent at room temperature was
assessed by repeated analysis of a 2 ml urine sample that had been processed by
Protocol I.
Precision and accuracy were based on quality control (QC) samples in water at low,
medium and high concentration levels of the calibration curve. For precision also a
batch of blank urine was used as QC sample.
Statistical analysis
Student’s one-tailed paired t-test was used for evaluation of interindividual mean
plasma results, differences in mean excretion rates and mean steroid ratios with
p<0.05 considered as significant. Mean values were calculated over the period
9 a.m. - 11 p.m. Differences between male and female T/E ratios and intraindividual
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T/E ratios [10-12] were tested with Student’s one-tailed non-paired t-test, with p<0.05
considered as significant.
RESULTS
Validation experiments
β-Glucuronidase hydrolysis for 30 min at 55°C resulted in around 90% conversion of
AO-G and no conversion of DHEA-S and AO-S. Methanolysis resulted in an
approximate 90% conversion of AO-G and 100% conversion of DHEA-S and AO-S.
The extraction recovery determined was > 80% for all steroids studied.
After 20 hours a gradual decrease of area response occurred for all steroids and
internal standards to around 80% at 60 hours after derivatization. This did however
not significantly affect the area ratio of the steroids vs. the respective internal
standards.
The intra- and inter-day precision (both n=5) as determined from water and blank
urine samples was < 15% except for ∆4-AEDIONE (< 30%) in case of Protocol I and
II. The accuracy was between 80 and 120%, except for AO, EO, ∆4-AEDIOL and
∆4-AEDIONE (between 70 and 130%). The relatively low accuracy of AO and EO
can be explained by column overloading. Due to efficiency reasons, no re-analysis of
AO and EO was performed after dilution. Results of ∆4-AEDIONE should be
considered as indicative, as the accuracy and precision were limited and
concentrations in urine samples were always low and often subjected to
chromatographic interference.
Plasma analysis
The results of the plasma analyses are summarized in Table 1. Mean plasma
concentrations did not significantly change except for a decrease in plasma T and
increase in SHBG for males. No significant changes in females were established.
Urine analysis
The excretion data are summarized in Tables 2-4. In general, several changes in the
steroid profile were observed after administration of ethanol. T excretion increased
while E remained stable or even decreased. This lead to an increased mean T/E
ratio. The increase of T excretion was only statistically significant in case of females
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in the total and glucuronide fraction. The increase of the mean T/E ratio was
significant for both males and females.
Table 1: Mean plasma concentrations (± SEM) of endocrinological
parameters
Hormone in plasma Unit Day 1 Day 2
Males
Testosterone nmol/l 19.05 ± 6.65 17.03 ± 5.77  *
Epitestosterone nmol/l 1.54 ± 0.66 1.27 ± 0.42
LH IU/l 5.91 ± 1.94 5.75 ± 1.79
SHBG nmol/l 23.86 ± 6.41 26.57 ± 7.98  **
Females
Testosterone nmol/l 1.60 ± 0.61 1.86 ± 0.91
Epitestosterone nmol/l 0.77 ± 0.42 0.75 ± 0.33
LH IU/l 4.78 ± 1.42 1 4.93 ± 1.98 1
SHBG nmol/l 53.63 ± 29.79 53.13 ± 30.56
* Significant decrease at day 2 (p<0.05)
** Significant increase at day 2 (p<0.05)
1 n=6, as two female subjects were rejected because of a mid-cycle
increased LH concentration.
AO and EO excretion decreased in males and females, while AO/EO remained
constant. The decreased excretion was only statistically significant in case of males.
The excretion of 5α,3α-ADIOL increased for both males and females in the
glucuronide and total fraction. The increase in excretion rate of 5β,3α-ADIOL was
only significant in case of females for both fractions. The 5α,3α-ADIOL/5β,3α-ADIOL
ratio did not change significantly. 5α,3β-ADIOL could only be determined in the total
fraction and in low concentration in the glucuronide fraction of males. No significant
change in excretion rate was established.
Statistical evaluation of the mean excretion rate differences as determined for the
∆5-steroids DHEA and ∆5-AEDIOL in Protocol I was aggravated by the high inter-
subject variation (50-100%). DHEA excretion decreased in case of females in the
total fraction. In the glucuronide fraction the excretion rate of DHEA remained stable.
The ∆5-AEDIOL/DHEA and T/∆4-AEDIONE ratios could only be determined in the
total fraction, due to the low concentration of ∆5-AEDIOL and ∆4-AEDIONE in the
glucuronide fraction. Both ∆5-AEDIOL/DHEA and T/∆4-AEDIONE increased
significantly in case of males and females. In both studied fractions AO/5α,3α-ADIOL
and EO/5β,3α-ADIOL significantly decreased for both sexes.
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In Figures 1-4 and Table 4 the individual data are presented for the T/E ratio in the
studied fractions. The data of maximum plasma ethanol concentrations are also
presented in Table 4. The ethanol concentrations achieved were reproducibly around
1-2‰. In general, the T/E ratio was increased for around 10-12 hours after the first
administration. As presented in Table 4, the difference between the mean T/E ratio
of day 1 and the maximum T/E ratio of day 2 was statistically significant for both
males and females. The effect of ethanol consumption was significantly higher for
females than for males (p=0.024 for the total fraction and p=0.007 for the
glucuronide fraction).
In Figure 5, the inter-subject correlation between the mean T/E ratio during the pre-
administration day (day 1) and the maximum T/E ratio during the administration day
(day 2) is shown for both fractions and sexes. A positive correlation is illustrated, for
males in particular.
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Figure 1: Total fraction of sulfates/glucuronides/non-conjugated steroids: T/E ratio in urine
samples and plasma ethanol concentration in female subjects. Ethanol
administration occurred between 24 and 27 hours.
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Figure 2: Total fraction of sulfates/glucuronides/non-conjugated steroids: T/E ratio in urine
samples and plasma ethanol concentration in male subjects. Ethanol
administration occurred between 24 and 27 hours.
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Figure 3: Fraction of glucuronides/non-conjugated steroids: T/E ratio in urine samples and
plasma ethanol concentration in female subjects. Ethanol administration
occurred between 24 and 27 hours.
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Figure 4: Fraction of glucuronides/non-conjugated steroids: T/E ratio in urine samples and
plasma ethanol concentration in male subjects. Ethanol administration occurred
between 24 and 27 hours.
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Figure 5: The inter-subject correlation between the mean T/E ratio during the pre-
administration day (day 1) and the maximum T/E ratio detected during the
administration day (day 2). The dotted line represents the “no-effect” line with a
slope of 1.
DISCUSSION
Analytical method
Calibration samples were prepared in water. Attempted standard addition to urine
samples resulted in bad reproducibility of the response and therefore in bad
correlation of the calibration curves. In this experiment the main goal was to detect
differences in excretion rates of endogenous steroids, related to basal levels.
Therefore, some bias in accuracy was accepted and the main focus was placed on
the within- and between-batch precision.
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In this study, methanolysis and β-glucuronidase hydrolysis were used as methods to
deconjugate the steroids under investigation. During validation it was shown that
both methods resulted in high conversion of targeted deconjugation of synthetic
DHEA-S, AO-S and AO-G. In the applied Protocols I and II these high conversions
were combined with a high extraction recovery. However, during sample analysis the
recovery of the glucuronide fraction was sometimes higher than of the total fraction in
case of T, EO, 5α,3α-ADIOL and 5β,3α-ADIOL. Possibly, side reactions occurred
during methanolysis. Therefore, interpretation of the results is mostly based on the
separate results of Protocol I and II.
Effect of ethanol on T/E ratio
Our results clearly show a significant increase of the T/E ratio as a result of ethanol
administration based on both intra- and interindividual data. Falk et al. [2] and Karila
et al. [5] did not observe any significant effects applying dose levels of 1.0 and 1.2
g/kg bodyweight, respectively. Subsequently, significance was obtained for a dose
level of 2 g/kg. However, in both studies the first urine sampling was performed
12-13 hours after the first volume of ethanol was administered. As described by
Seppenwoolde-Waasdorp et al. [3] and confirmed by the present study, the
maximum effect of ethanol on steroid excretion can be expected before 11 hours
after the first ethanol intake. As described in Figures 1-4 the T/E ratio increased
immediately after the first administration, and lasted until 8-12 hours afterwards. The
maximum T/E ratio was detected mostly within 5 hours after the detected maximum
ethanol concentration in plasma.
The results of Mareck-Engelke et al. [6] illustrate that 2 g/kg is a very high dose, as 7
out of 11 volunteers could not reach this target dose level because of nausea.
However, when correctly timed sampling is performed, a dose level of 1.0-1.2 g/kg is
sufficient to observe significant steroid excretion differences.
As can be observed in Figure 5, the maximum T/E ratio shows a positive correlation
to the mean basal T/E ratios. The higher slope of the presented least squares
regression lines in case of females, illustrates that the maximum effect on the T/E
ratio as determined in Protocol I and II is larger for females than for males.
The lower urinary T and E concentrations in females, leading to a higher analytical
variability, could explain the higher correlation for the male compared to the female
subjects. The positive correlation shows that the effect of ethanol consumption on
the T/E ratio can be more or less predicted, based on the intra-subject mean T/E
ratio. Theoretically, this information could be used to preliminary judge claims made
by athletes, that a detected high T/E ratio was caused by ethanol consumption.
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Mechanistic considerations
Several hypotheses have been posed for the endocrine response to ethanol
metabolism that can explain the alteration of the T/E ratio. As also described by
others [5,13], increase of T production by LH stimulation is unlikely, as plasma LH
concentrations were stable.
Steroid metabolism and ethanol oxidation are both NAD+-dependent. As a result,
oxidation of ethanol increases the NADH/NAD+ ratio and thereby influences the
metabolic conversion of steroids. The effect of ethanol metabolism on
17β-hydroxysteroid dehydrogenase is described as a shift of the 17β-hydroxy/17-
keto ratio of redox coupled steroid conjugates towards the reduced steroid [14,15].
This effect is also reported for monosulfates of ∆5-AEDIOL/DHEA [16,17], as
determined by plasma concentrations. The 17β-hydroxy/17-keto ratios as determined
for non-conjugated steroids were not increased. Our results showed the shift of the
17β-hydroxy/17-keto ratio in urine by the significantly increased ∆5-AEDIOL/DHEA
and T/∆4-AEDIONE ratio (total fraction of conjugates) and the decreased AO/5α,3α-
ADIOL and EO/5β,3α-ADIOL ratio (in both studied fractions). This clearly shows that
ethanol administration significantly influences steroid transformation.
It is difficult to interpret how these metabolic changes could affect the T/E ratio, as it
in not clear what role oxidoreduction of steroid conjugates plays in steroid
biosynthesis and metabolism. Androst-5-ene-3β,17α-diol (∆5-17α-AEDIOL) that is
produced from DHEA, has been identified as biosynthetic precursor of E [18]. It is
therefore likely that other redox coupled steroid conjugates, as for example ∆5-17α-
AEDIOL/DHEA, are involved in E production as in T production. The same accounts
for E and T metabolism. An explanation of the effect of ethanol metabolism on the
T/E ratio by means of redox effects on steroid conjugates should therefore be
considered as a realistic possibility.
Falk et al. [2] suggested that the T/∆4-AEDIONE ratio will increase as result of an
increased NADH/NAD+ ratio during ethanol metabolism. Therefore, the inter-
conversion of T to E through ∆4-AEDIONE was suggested to be blocked. Although
an increased T/∆4-AEDIONE ratio was obtained in our results, three arguments
counter the statement of Falk et al. First, Andersson et al. [14] showed that the
conjugates of T and ∆4-AEDIONE are not redox coupled, as they are sulfated or
glucuronidated at the C3- and C17-position, respectively. Second, Donike et al. [1]
introduced the T/E ratio as a way to detect T administration on the basis of low a
inter-conversion of T and E. Third, according the hypothesis, the elevation of the T/E
ratio should coincide with a decrease of E excretion. Our results do not indicate this.
Ethanol metabolism will also affect NAD+ dependent glucuronidation, by competition
with UDPglucose dehydrogenase for NAD+ [19]. This does not occur for sulfation. As
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a result, a decreased excretion of extensively glucuronidated steroids as T, E, AO
and EO should occur. This was the case for excretion of AO and EO. The stable
excretion rates of DHEA and ∆5-AEDIOL could also match this hypothesis. However,
it cannot explain the increased T/E ratio as T is glucuronidated more extensively as
E. Theoretically, an opposite effect on the T/E ratio is expected.
Illustrated by Cobb et al. [20] ethanol and particularly its metabolite acetaldehyde
stimulate the hypothalamic-pituitary-adrenal (HPA) axis. In cases of severe and
chronic ethanol abuse this can lead to clinical and biochemical features of Cushing’s
syndrome [21]. Characteristically, HPA stimulation results in adrenal hormone
production and following elevated plasma concentrations of cortisol, DHEA-sulfate,
DHEA and ∆4-AEDIONE. Karila et al. [5] posed the elevated T/E ratio to be caused
by the metabolism of these adrenal steroids to T. However, our results did not show
significantly elevated plasma T concentrations. These findings are confirmed by
earlier published results [22]. Furthermore, as DHEA-sulfate is readily excreted, this
should lead to elevated DHEA urine concentrations in Protocol I. Also increased
production of DHEA is expected to lead to increased formation of AO and EO as
main metabolites (see Chapters 4 and 6). As our results contradicted these
expectations, it is unlikely that the activity of the HPA axis can explain the T/E
alterations.
Direct inhibition of T metabolism, as suggested by Karila et al. [5] is expected to
decrease AO and EO production, which is supported by the decreased excretion
rates of these metabolites in the present experiment. However, the increased
excretion rate of other reduced T metabolites (androstanediols) is in contradiction
with this suggestion.
Also stimulating effects of ethanol metabolism on T metabolism are described. As
suggested by Cronholm et al. [23] in an experiment with rats, coenzyme pools used
in different reductions at C3 of corticosterone and ∆4-AEDIONE are metabolically
related to NADH formed in the ethanol dehydrogenase reaction. The results suggest
that ethanol metabolism could stimulate reduction of 3-keto steroids as T and E. This
hypothesis can explain reduced plasma T concentrations and an increased excretion
of androstanediols independently from the metabolic route to AO and EO. However,
decreased excretion of AO and EO, the relative stable E excretion and the increased
T/E ratio can not be explained by this mechanism.
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CONCLUDING REMARKS
Ethanol consumption leads to increased T/E ratios for several hours in case of both
males and females. In females the maximum effect is higher than for males. This
occurs also at a more realistic dose level as has so far been assumed. The chance
of T/E ratios rising above the cutoff point of 6 is realistic, and should be kept in mind
especially in case of out-of-competition doping controls. Additional screening of
ethanol in urine samples can be considered to prevent false-positive cases of T
abuse. The mechanism that causes the increase of the T/E ratio is unclear.
However, the competition between ethanol metabolism and steroid biosynthesis and
metabolism for enzyme cofactors appear to play a predominant role.
ACKNOWLEDGEMENT
The analytical participation of Prof. Dr. L. Starka and Dr. R. Hampl, who performed
the analyses of epitestosterone in plasma, and the medical assistance of
Dr. T. Brouwer are greatly acknowledged.
LITERATURE
1. M. Donike, K.-R. Bärwald, K. Klostermann, W. Schänzer and J. Zimmermann.
Nachweis von exogenem Testosteron. In Sport: Leistung und Gesundheit, H. Heck, W.
Hollmann, H. Liesen, R. Rost, Eds. Deutscher Ärzte Verlag, Köln, 1983, pp 293-298.
2. O. Falk, E. Palonek and I. Björkhem. Effect of ethanol on the ratio between
testosterone and epitestosterone in urine. Clin. Chem. 34: 1462-1464 (1988).
3. T.J.A. Seppenwoolde-Waasdorp, D. de Boer, H.M.J. van Engelen, A.D. Vrijdag and
R.A.A. Maes. Evaluation of endogenous steroid profiles in urine (2). Effects of ethanol
intake reinvestigated. In Recent advances in doping analysis (3), M. Donike, H. Geyer,
A. Gotzmann and U. Mareck-Engelke, Eds. Sport und Buch Strauss, Köln, 1996,
pp 157-165.
4. A. Leinonen, T. Karila and T. Seppälä. An increased testosterone to epitestosterone
ratio due to high doses of ethanol - a case report on a female powerlifter. In Recent
advances in doping analysis (3), M. Donike, H. Geyer, A. Gotzmann and U. Mareck-
Engelke, Eds. Sport und Buch Strauss, Köln, 1996, pp 167-176.
5. T. Karila, V. Kosunen, A. Leinonen, R. Tähtelä and T. Seppälä. High doses of ethanol
increase urinary testosterone-to-epitestosterone ratio in females. J. Chromatogr. B
687: 109-116 (1996).
ETHANOL AND THE T/E RATIO

-67-
6. U. Mareck-Engelke, H. Geyer, U. Schindler, U. Flenker, R. Iffland and M. Donike.
Influence of ethanol on steroid profile parameters. In Recent advances in doping
analysis (3), M. Donike, H. Geyer, A. Gotzmann and U. Mareck-Engelke, Eds. Sport
und Buch Strauss, Köln, 1996, pp 143-155.
7. M. Axelson, T. Cronholm, B.-L. Sahlberg and J. Sjövall. Changes in the metabolic
profile of steroids in urine during ethanol metabolism in man. J. Steroid Biochem. 14:
155-159 (1981).
8. L. Dehennin, P. Lafarge, Ph. Dailly, D. Bailloux and J.-P. Lafarge. Combined profile of
androgen glucuro- and sulfoconjugates in post-competition urine of sportsmen: a
simple screening procedure using gas chromatography-mass spectrometry. J.
Chromatogr. B  687: 85-91 (1996).
9. J.H. Thijssen, W.G. Wood, A.C. Kessler, H.W. Griesser, O. Bauer, C. Bieglmayer, J.
Eugui, J.L. Mirabel, H. Gaessler and K. Klinga. Multicenter evaluation of new
enzyme-linked immunoassays of follitropin and lutropin in serum or plasma. Clin.
Chem. 37: 1257-1263 (1991).
10. E.K. Harris. Some theory of reference values. I. Stratified (categorized) normal ranges
and a method for following an individual's clinical laboratory values. Clin.Chem. 21:
1457-1464 (1975).
11. H.E. Solberg and R. Grasbeck. Reference values. Adv.Clin.Chem. 27: 1-79 (1989).
12. M. Donike, S. Rauth, U. Mareck-Engelke, H. Geyer and R. Nitschke. Evaluation of
longitudinal studies, the determination of subject based reference ranges of the
testosterone/epitestosterone ratio. In Recent advances in doping analysis, M. Donike,
H. Geyer, A. Gotzmann, U. Mareck-Engelke and S. Rauth, Eds. Sport und Buch
Strauss, Köln, 1994, pp 33-39.
13. J.H. Mendelson, N.K. Mello, and J. Ellingboe. Acute ethanol intake and pituitary
gonadal hormones in normal human females. J.Pharmacol.Exp.Ther. 218: 23-26
(1981).
14. S.H. Andersson, T. Cronholm and J. Sjovall. Effects of ethanol on the levels of
unconjugated and conjugated androgens and estrogens in plasma of men. J. Steroid
Biochem. 24: 1193-1198 (1986).
15. S. Andersson. Effects of Ethanol on androgens and estrogens in vivo. Karolinska
Institutet, Stockholm, 1985.
16. T. Cronholm and J. Sjövall. Effect of ethanol metabolism on redox state of steroid
sulfates in man. Eur. J. Biochem. 13: 124-131 (1970).
17. T. Cronholm and J. Sjövall. Effect of ethanol on the concentrations of solvolyzable
plasma steroids. Biochim. Biophys. Acta 152: 233-236 (1968).
18. Dehennin, L. Secretion by the human testis of epitestosterone, with its sulfoconjugate
and precursor androgen 5-androstene-3 beta,17 alpha-diol. J. Steroid Biochem. Mol.
Biol. 44: 171-177 (1993).
CHAPTER 2

-68-
19. P. Moldeus, B. Andersson and A. Norling. Interaction of ethanol oxidation with
glucuronidation in isolated hepatocytes. Biochem.Pharmacol.  27: 2583-2588 (1978).
20. C.F. Cobb, D.H. van Thiel, M.F. Ennis, J.S. Gavaler and R. Lester. Is acetaldehyde an
adrenal stimulant? Curr. Surg. 36: 431-434 (1979).
21. R. Groote Veldman and A.E. Meinders. On the mechanism of ethanol-induced pseudo-
Cushing’s syndrome. Endocr. Rev. 17: 262-268 (1996).
22. R. Ylikahri, M. Huttunen, M. Harkonen and H. Adlercreutz. Hangover and testosterone.
Br. Med. J. 2: 445 (1974).
23. T. Cronholm. Steroid metabolism in rats given (1-2H2)ethanol. Biliary metabolites of
corticosterone and administered 4-androstene-3,17-dione. Eur. J. Biochem. 27: 10-22
(1972).
PART II:
food supplements
and
steroid profiling

3
SPECIFIC DETECTION OF FOOD SUPPLEMENT STEROIDS
ABSTRACT
Since the nineties steroid containing food supplement products have become widely
available. After the introduction of these products, a frequently occurring abuse has been
suspected in the sports community. Steroids present in food supplements are 19C-steroids
as dehydroepiandrosterone (DHEA), androst-4-ene-3,17-dione (∆4-AEDIONE) and
19-norsteroids as 19-norandrost-4-ene-3,17-dione. In this chapter an overview is given on
the metabolism of food supplement steroids with DHEA and ∆4-AEDIONE in particular.
The detection of DHEA or ∆4-AEDIONE abuse in doping analysis is usually based on easily
available metabolic pathways to e.g. androst-5-ene-3β,17β-diol, testosterone,
epitestosterone, androsterone, etiocholanolone and androstanediols. However, also
oxygenation reactions form relevant routes of biotransformation. DHEA is mostly converted
by respectively 7α-, 7β- and 16α-hydroxylase activity. Also 7-keto-metabolites can be
detected. Oxygenating enzymatic activities related to ∆4-AEDIONE are 6β-, 7α-, 16α- and
16β-hydroxylase.
When ∆4-AEDIONE is converted to estrone by aromatase, small quantities of 19-hydroxy-
androst-4-ene-3,17-dione and 19-nor-androst-4-ene-3,17-dione could possibly be produced
as aromatase intermediate products or byproducts. Detection of these steroids could provide
relevant information about the exogenous or endogenous origin of 19-norsteroids.
Scientific data does not describe occurrence of 4-hydroxy-androst-4-ene-3,17-dione (4-OH-
∆4-AEDIONE) as endogenous steroid. However, it cannot be excluded that 4-OH-∆4-
AEDIONE is produced as metabolite after ∆4-AEDIONE administration.
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INTRODUCTION
Since the abuse of testosterone (T) was first suspected during the Olympic Games of
Moscow in 1980, many other endogenous steroids have been introduced as
ergogenic aid in sports. During the following decade, the abused steroids were
mostly limited to T and 5α-dihydrotestosterone derivatives. During the nineties,
steroid containing food supplement products became widely available. The first
supplement steroids introduced were dehydroepiandrosterone (DHEA) and androst-
4-ene-3,17-dione (∆4-AEDIONE). One or two years later these steroids were
followed by androst-5-ene-3β,17β-diol (∆5-AEDIOL), androst-4-ene-3β,17β-diol
(∆4-AEDIOL) and  androst-5-ene-3,17-dione (∆5-AEDIONE). The common feature of
these steroids is that they are biosynthetic precursors of T and they are claimed to
metabolize to T after oral administration, without pertaining anabolic effects
themselves.
Simultaneous to the developments of the mentioned 19C-steroids, 19-norsteroids
became popular as food supplement steroids. Based on metabolic conversion to
19-nortestosterone (nandrolone), products were developed that contained steroids as
19-nor-androst-4-ene-3,17-dione, 19-nor-androst-4-ene-3β,17β-diol and 19-nor-
androst-5-ene-3β,17β-diol. Nowadays, the concept of the endogenous origin of
nortestosterone’s main metabolite norandrosterone has gained interest and scientific
acceptance [1,2]. This illustrates that besides the mentioned 19C-steroids, also the
19-norsteroids are metabolically related to the endocrine system.
Food supplement steroids are mostly sold in capsules or other formulations requiring
oral administration. As no chemical modification has been performed, as for example
has been the case for 17α-methyl-substituted anabolic steroids, extensive first-pass
metabolism occurs after oral administration. Besides a low absorption, this leads to a
high metabolic and renal clearance and a low half-life time.
In this short overview, a summary will be given of the metabolic pathways of DHEA
and ∆4-AEDIONE. These will serve as model compounds for other supplement
steroids mentioned above, as limited knowledge is available on the oxygenation of
19-nor steroids.
“NON-SPECIFIC” METABOLISM OF FOOD SUPPLEMENT STEROIDS
 In doping analysis a limited number of analytical tools are available to tackle the
detection of endogenous compounds or corresponding biosynthetic precursors. One
of these is isotope ratio mass spectrometry that discriminates between endogenous
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and exogenous origin of steroids [3]. This technique was initially developed for
analytical confirmation of T administration [4] and is still under development as an
efficient screening technique for T [5] and as a confirmation technique for other
endogenous steroids [6,7].
Other analytical tools are based on easily available metabolic pathways of the food
supplement steroids. This mostly implies the metabolism as summarized in Figure 1.
The presented model is limited to 19C-steroids, but the enzymatic activities can be
extrapolated to 19-norsteroids. Metabolites that are mostly studied in relation to
administration of 19C-steroids are T, E, androsterone (AO), etiocholanolone (EO),
5α- and 5β-isomers of dihydrotestosterone (5α-DHT and 5β-DHT) and different
stereoisomers of androstanediol (5α,3α-ADIOL; 5α,3β-ADIOL; 5β,3α-ADIOL and
5β,3β-ADIOL).
Based on the presented metabolism, steroid ratios have been introduced for the
detection of T [8,9] and 5α-DHT [10,11]. Several studies have focussed on the effect
of administration of food supplement 19C-steroids on the ratio of
testosterone/epitestosterone (T/E ratio) [12-16]. Although the T/E ratio mostly
increases, the response is limited. Also the AO/EO ratio or the corresponding 5α/5β-
ratio for androstanediols has been studied [17]. Saturation of 5α-reductase by
androst-4-ene steroids could lead to an increased activity of 5β-reductase.
Administration of high dose levels can therefore be expected to decrease the AO/EO
(5α/5β) ratio. So far, the AO/EO ratio has mostly been studied in a case study design
[15-17] and requires additional investigation.
The main virtue of the described analytical tools is the general detection of unknown
19C-steroids or 19-norsteroids, by applying a rather arbitrary and qualitative pattern
recognition methodology [15,16]. It is difficult to obtain sufficient specific information
from a steroid profile based on the steroids shown in Figure 1, to identify the steroid
that has been administered. The large number of steroids that are available today as
supplement products challenges for more specific analytical methodologies.
Additionally, an increasing number of claims are made of unintentional steroid
administration, due to contamination of permitted (non-steroid) food supplement
products. In general, these claims are supported by some scientific observations
[18,19]. This illustrates a need for more specificity in doping analysis.
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Figure 1: “Non-specific” metabolism of DHEA and ∆4-AEDIONE. Enzymatic activities
involved are: (1) 17β-dehydrogenase; (2) 3,4-isomerase; (3) 3α-dehydrogenase;
(4) 3β-dehydrogenase; (5) 5α-reductase; (6) 5β-reductase.
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Figure 2: Suggested model for “specific” metabolism of DHEA. Involved enzymatic
activities are: (1) 7α-hydroxylase; (2) 7β-hydroxylase; (3) 16α-hydroxylase;
(4) 7-hydroxy dehydrogenase; (5) 3α-dehydrogenase; (6) 3β-dehydrogenase;
(7) 4-5 isomerase; (8) 5α-reductase; (9) 5β-reductase
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“SPECIFIC” METABOLISM OF DHEA AND ∆4-AEDIONE
Endoplasmic reticulum-bound cytochrome P-450 plays a central role in the oxidative
metabolism of lipophilic compounds as steroids [20]. In mammals, the microsomal
cytochromes are predominantly present in hepatic tissues, where they catalyze
NADPH-dependent monooxygenation, e.g. hydroxylation. There are multiple
pathways for this kind of steroid biotransformation, with a high degree of specificity,
depending on the chemical properties of the steroid. Usually, not much knowledge is
present about the possible endocrine function of such metabolites.
DHEA is readily converted to several oxygenated metabolites, as summarized in
Figure 2. The main hydroxylation pathways are 7α-, 7β- and 16α-hydroxylation,
resulting in 7α-hydroxy-DHEA (7α-OH-DHEA), 7β-hydroxy-DHEA (7β-OH-DHEA)
and 16α-hydroxy-DHEA (16α-OH-DHEA) [21-25]. 7α-Hydroxylation is the first and
rate-limiting step in the metabolic pathway of steroids, leading to bile acids [26]. Only
suggestive biological relevance has been described for 7α- or 7β-hydroxylation of
DHEA, as immunomodulatory action of 7α- and 7β-OH-DHEA in semen [27] and
increased production of 7α-OH-DHEA in Alzheimer’s disease [28].
Also 7-keto-DHEA has been detected in human urine samples [29]. It can be
expected that 7-keto-DHEA is produced through 7α-, or 7β-hydroxy dehydrogenation
of the mentioned 7α- or 7β-OH-metabolites of DHEA. Although no biological effect is
known, this steroid is sold nowadays as food supplement steroid, either as 7-keto-
DHEA or 3-acetyl-7-keto-DHEA (see Appendix). The commercially based claim for
the biological effects are the same as for DHEA, but excluding androgenic side
effects. No literature is available about the metabolism to 7-keto-androsterone
(7-keto-AO) and 7-keto-etiocholanolone (7-keto-EO). Based on the described
metabolic steps, these steroids can be expected as main metabolites of 7-keto-
DHEA. However, the presence of these metabolites in human plasma or urine could
also originate from direct 7-oxygenation of AO and EO.
16α-Hydroxylation of DHEA to 16α-OH-DHEA is one of the most described
hydroxylation reactions of DHEA, as this metabolite is present in relatively high
concentrations in urine [23,30,31]. It is a known intermediate product of estriol
(1,3,5(10)-estratriene-3,16α,17β-triol) during pregnancy. Based on the presented
metabolic steps, it is suggested that 16α-hydroxy-androsterone and -etiocholanolone
(16α-OH-AO and 16α-OH-EO) could be detected as main metabolites of 16α-OH-
DHEA. However, as mentioned before, these metabolites could also be produced by
direct 16α-hydroxylase conversion of AO and EO [32].
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Another reported minor oxygenation pathway is 18-hydroxylation, as determined in in
vitro incubation experiments with human liver microsomes [33]. No further in vivo
data are available.
Several oxygenation routes are described for ∆4-AEDIONE. A summary is given in
Figure 3. Based on in vitro experiments with liver microsomes the best-described
reactions are 6β-, 7α-, 16α- and 16β-hydroxylation [20,34]. The fact that the same
pathways are found for the hydroxylation of T [34,35] suggests that these reactions
are specific for androst-4-ene-3-one steroids. For both steroids, the major part is
accounted by 6β-hydroxylation ( 70% for ∆4-AEDIONE [20]). This is also the case
for some synthetic derivatives of T [36]. No data is available about 6α-hydroxylation
and metabolic conversion to 6-keto-∆4-AEDIONE. However, analogous to DHEA
metabolism, the presence of 6-keto-metabolites could occur after dehydrogenation of
6β-OH-∆4-AEDIONE.
In order of decreasing conversion rate, hydroxylation at C16 of ∆4-AEDIONE is the
second route [20,34,35].  In contrast to DHEA metabolism, 16α- as well as 16β-
hydroxylation takes place at ∆4-AEDIONE. Also, multiple hydroxylation to 6β,16α-diol
and 6β,16β-diol metabolites has been reported for rats [37]. As is also suggested
above for the metabolism of DHEA, likely products to be expected are the 16α- and
16β-hydroxy metabolites of AO and EO.
Described by Ryan et al. [38], local production of estrogens occurs from androgens,
catalyzed by an aromatase complex in human placenta tissue. However, this reaction
has also been established in vitro in microsomes obtained from other tissues [38].
The conversion of ∆4-AEDIONE to estrone (3-hydroxy-1,3,5(10)-oestratriene-17-one)
is expected to occur with 19-hydroxy-∆4-AEDIONE (19-OH-∆4-AEDIONE) as one of
the intermediate products or byproducts [39,40]. Kelly et al. [41] showed that 19-OH-
∆4-AEDIONE is readily excreted in urine as glucuronide and sulfate conjugate. The
conversion of ∆4-AEDIONE to 19-OH-∆4-AEDIONE is, however, relatively small and
it is expected that little 19-OH-∆4-AEDIONE leaves the site of aromatization. It
cannot be ruled out that conjugation occurs at C19 [40], and it is unknown whether
these conjugates can be deconjugated by the applied enzymatic β-glucuronidase and
solvolysis methods of hydrolysis [40,41].
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Figure 3: Suggested model of “specific” metabolism of ∆4-AEDIONE. Supposedly involved
enzymatic activities are: (1) 6α-hydroxylase; (2) 6β-hydroxylase;
(3) 16α-hydroxylase; (4) 6-hydroxy dehydrogenase. (5) 19-hydroxylase;
(6) 4-hydroxylase; (7) 3α-dehydrogenase; (8) 5α-reductase; (9) 5β-reductase;
(10) 17β-dehydrogenase
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During aromatization also small quantities of 19-norsteroids (19-nortestosterone and
19-nor-∆4-AEDIONE) are produced. This has been shown by in vitro tests on
aromatase rich tissues as the ovarian follicle [42] and by the placenta [43]. Dehennin
et al. [1] posed the production of small quantities of 19-nor-steroids by less
aromatase rich tissues as adipose tissue, skin, testis, adrenal, liver and muscle.
Based on this theory, production of 19-norsteroids could be accompanied by
production of similar quantities of 19-OH-∆4-AEDIONE and 19-OH-T. Detection of
these steroids could perhaps aid the analytical discrimination between urine samples
taken after 19-norsteroid administration and samples containing only 19-norsteroids
of endogenous origin. For this purpose, quantification of 19-hydroxy-steroids down to
low ng/ml levels is necessary.
Metabolism of estrogens by hydroxylation at C4 is an important metabolic step,
leading to the production of catecholestrogens [44,45]. Hydroxylation at the
∆4-double bond in ∆4-AEDIONE, leading to 4-hydroxy-∆4-AEDIONE (4-OH-∆4-
AEDIONE) has never been reported. During development studies on this steroid as
aromatase inhibitor for treatment of breast cancer, no 4-OH-∆4-AEDIONE was
detected as endogenous substance [46]. A limit of quantification of 0.3 ng/ml was
reported by Dowsett et al. for the applied radioimmunoassay of non-conjugated
4-OH-∆4-AEDIONE [47]. This was done by an assay for ∆4-AEDIONE that showed
25% cross-reactivity for 4-OH-∆4-AEDIONE. This suggests that 4-hydroxylation
either does not occur, or in very small amounts, or that conjugation prevents
radioimmunoassay detection.
Poon et al. [48] showed that orally administered 4-OH-∆4-AEDIONE shows extensive
first and second phase metabolism. This suggests that if production of 4-OH-∆4-
AEDIONE would occur after ∆4-AEDIONE administration, this would probably lead to
efficient excretion as conjugates. As conjugation occurs at C4, it is not clear whether
enzymatic deconjugation results in a high recovery. Concluding, insufficient results
are available to exclude the endogenous origin of 4-OH-∆4-AEDIONE and the
conversion to 4-OH-∆4-AEDIONE after oral administration of ∆4-AEDIONE.
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PROFILING SPECIFIC METABOLITES OF DEUTERIUM
LABELED DEHYDROEPIANDROSTERONE (DHEA)
ABSTRACT
During recent years a number of products containing the steroid dehydroepiandrosterone
(DHEA) have appeared on the food supplement market. The International Olympic
Committee placed this steroid on the list of forbidden substances. However, establishment of
oral DHEA administration in doping control is aggravated by extensive metabolic clearance,
and an assumed non-specific metabolism. In this study, a preliminary investigation is
performed to construct a DHEA-selective profile of non-oxygenated metabolites
(androsterone, etiocholanolone, testosterone, epitestosterone, androst-5-ene-3β,17β-diol,
5α-androst-3α,17β-diol and 5β-androstan-3α-17β-diol) and oxygenated DHEA metabolites
(7α-hydroxy-DHEA, 7β-hydroxy-DHEA, 16α-hydroxy-DHEA, 7-keto-DHEA, 16α-hydroxy-
androsterone, 16α-hydroxy-etiocholanolone and 7-keto-androsterone).
Labeled DHEA (3β-hydroxy-[16,16-2H2]androst-5-en-17-one) was administered to 2 male
volunteers (25.5 and 52.5 mg, respectively) and urine samples were collected. Sample
analysis was performed on the total fraction of glucuronides, sulfates and non-conjugated
steroids with gas chromatography-mass spectrometry. The most sensitive parameters during
the first 10 hours after administration were androsterone, etiocholanolone, testosterone, 7β-
hydroxy-DHEA and 7-keto-DHEA. Etiocholanolone and 5α-androst-3α,17β-diol showed the
highest sensitivity during 10 to 30 hours after administration. The total conversion of DHEA to
the studied metabolites was 39.7-42.8%. The conversion of DHEA to oxygenated and non-
oxygenated metabolites was 0.8-1.32% and 38.4-42.0%, respectively. Although the
conversion to oxygenated metabolites is limited, profiling these specific steroids may lead to
additional information about the identity of the administered steroid.
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INTRODUCTION
An increasing number of steroid containing products has appeared on the food
supplement market. The first supplements sold contained dehydroepiandrosterone
(DHEA) and androst-4-ene-3,17-dione (∆4-AEDIONE), later followed by androst-5-
ene-3β,17β-diol (∆5-AEDIOL), androst-4-ene-3β,17β-diol (∆4-AEDIOL), the nor-
steroids 19-nor-androst-4-ene-3,17-dione and 19-nor-androst-4-ene-3β,17β-diol [1,2].
The proclaimed pharmacological effect by metabolism to steroids with potential
anabolic activity made these products mostly popular amongst bodybuilders. During
the years 1997 to 1999 the mentioned steroids have been placed on the IOC list of
forbidden substances.
Analytical methods have been developed to establish the abuse of steroid
supplements as DHEA by profiling of main metabolites as androsterone (AO),
etiocholanolone (EO), testosterone (T) and androstanediols [1-6]. However,
establishment of DHEA abuse in doping control is aggravated by extensive first-pass
metabolism after oral administration, fast renal and metabolic clearance of DHEA and
metabolites, and an assumed non-specific metabolism compared to other orally
administered steroids as ∆4-AEDIONE [1,2].
The generally applied determination of glucuronides and/or sulfates of non-specific
metabolites of DHEA as AO, EO, T and ∆4-AEDIONE [1-6], is generally insufficient to
obtain quality information about the identity of the administered steroid. A study
performed by Shackleton et al. [7] described a method based on gas
chromatography-isotope ratio mass spectrometry to confirm administration of T, E,
DHEA and dihydrotestosterone. However, the described method was also not
specific for any of the studied steroids.
Several studies have been performed for the use of the testosterone/epitestosterone
ratio (T/E ratio) as a marker of DHEA or ∆4-AEDIONE abuse [4,5,8]. In theory, the
T/E ratio could be a non-specific but sensitive parameter since T is a known
metabolite of DHEA, ∆4-AEDIONE, ∆5-AEDIONE, ∆4-AEDIOL and ∆5-AEDIOL and
no E production has been proven after administration of testosterone. In reality, the
T/E ratio appears to be an insensitive parameter of DHEA abuse [8].
The complication for doping analysis caused by the wide spread use of steroid
supplements demands for profiling procedures of higher specificity. Determination of
oxygenated metabolites of potentially used steroids could supply the necessary
information for identification of abused steroids.
In this study, a preliminary investigation is performed to construct a conclusive profile
of selected oxygenated and non-oxygenated DHEA metabolites, that are
commercially available, in order to look for conclusive parameters for the detection of
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DHEA abuse. Therefore, 3β-hydroxy-[16,16-2H2]androst-5-en-17-one (d2-DHEA) was
administered to 2 healthy male volunteers and urine samples were collected at set
times before and after administration. Analysis of the collected urine samples was
performed with gas chromatography-mass spectrometry (GC-MS).
EXPERIMENTAL
Chemicals
Reference steroids: Androst-5-en-3β-ol-17-one (dehydroepiandrosterone, DHEA),
androst-4-en-17α-ol-3-one (epitestosterone, E), 5α−androstan-3α-ol-17-one
(androsterone, AO), 5β−androstan-3α-ol-17-one (etiocholanolone, EO), androst-4-
ene-3,17-dione (androstenedione, ∆4-AEDIONE), androst-5-ene-3β,17β-diol
(androstenediol, ∆5-AEDIOL) and 17α-methyl-androst-4-en-11α,17β-diol-3-one (11α-
hydroxy-methyltestosterone, 11α-OH-MeT) were obtained from Sigma, St. Louis,
Missouri, USA. Androst-4-en-17β-ol-3-one (testosterone, T), androst-5-ene-3β,7α-
diol-17-one (7α-hydroxy-dehydroepiandrosterone, 7α-OH-DHEA) and androst-5-ene-
3β,7β-diol-17-one (7β-hydroxy-dehydroepiandrosterone, 7β−OH-DHEA) were
obtained through courtesy of  Organon, Oss, The Netherlands). Androst-5-en-3β-ol-
7,17-dione (7-keto-dehydroepiandrosterone, 7-keto-DHEA), 5α-androstan-3α-ol-
7,17-dione (7-keto-androsterone, 7-keto-AO), androst-5-ene-3β,16α-diol-17-one
(16α-hydroxy-dehydroepiandrosterone, 16α−OH-DHEA), 5α−androstane-3α,16α-
diol-17-one (16α-hydroxy-androsterone, 16α-OH-AO), 5β−androstane-3α,16α-diol-
17-one (16α-hydroxy-etiocholanolone, 16α-OH-EO) were obtained from Steraloids,
Newport, Rhode Island, USA. 3β-Hydroxy-[16,16-2H2]androst-5-en-17-one (isotopic
purity 97.3%) was obtained from C/D/N Isotopes, Pointe-Claire, Quebec, Canada.
Chemicals: N-Methyl-N-trimethylsilyltrifluoroacetamide (MSTFA), ethanethiol (97%),
phosphorous pentoxide, tert-butyldimethylsilyl chloride (TBDMSCl) and imidazole
were obtained from Sigma-Aldrich Chemie Company, Steinheim, Germany.
Ammonium iodide was obtained from Fluka Chemie, Buchs, Switzerland. Potassium
hydroxide, sodium acetate trihydrate, glacial acetic acid (96%), diethyl ether, acetic
acid and methanol were obtained from Merck, Darmstadt, Germany. Acetonitril was
obtained from J.T. Baker B.V., Deventer, The Netherlands. All chemicals were of
analytical grade, unless indicated otherwise.
Hydrolysis was performed with Helix pomatia (type HP-2, containing 110.000 IU/ml β-
glucuronidase and 1000-5000 IU/ml arylsulfatase), obtained from Sigma-Aldrich,
Steinheim, Germany.
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Columns for solid-phase extraction were IST Isolute C18 columns (200 mg, non-
endcapped) obtained from Sopachem, Lunteren, The Netherlands.
Sample collection
Two male volunteers (subject 1: 29 years, 88 kg; subject 2: 21 years, 75 kg),
collected urine samples every 2 hours during 3 days. On the second day at 9 a.m.
3β-hydroxy-[16,16-2H2]androst-5-en-17-one (d2-DHEA) was orally administered
(volunteer 1, 25.5 mg; volunteer 2, 52.5 mg). For each collected urine sample the
exact void time, volume and specific gravity (Urine Specific Gravity Refractometer,
Atago, Japan) were recorded. Samples were stored at -20°C until time of analysis.
Sample preparation
The volume of urine that was sampled for the analysis was determined on the basis
of specific gravity (d) of the urine, according to:
5*
1d
020.0Volume
−
= ml (1)
A maximum volume of 15 ml was applied. This was done to enable quantitative
analysis of metabolites in low concentration in diluted urine samples. Solid-phase
extraction was performed with C18 columns. Before applying urine samples, the
column material was preconditioned by washing with 4 ml of methanol and
equilibrating with 2 ml of water. Inorganic material was removed from the column by
washing with 2 ml of water. The organic material was collected by elution with 4 ml of
methanol. After evaporation to dryness, 2 ml of acetate buffer (0.1 M, pH 5.2) was
added to the extract. Hydrolysis was performed by adding 100 µl of Helix pomatia
and incubating for 1 hour at 55°C. Steroids were isolated from the buffer solution by
extracting with 5 ml of diethyl ether twice. After extraction the phase separation was
stimulated by centrifugation (4000 rpm, 5 min). The organic layer was removed and
evaporated to dryness under a gentle stream of nitrogen at 40°C. The extract was
dried overnight over P2O5/KOH under reduced pressure.
To retain the deuterium atoms in the steroid structures and to obtain suitable
peakshape and mass spectrometric fragmentation, a non-enolizing derivatization
procedure to tert-butyldimethylsilyl-derivatives was selected (Method A). A modified
procedure of Dehennin et al. [4] was applied. Derivatization was performed by
addition 100 µl of TBDMSCl/imidazole/acetonitrile (30:30:1000; m/w/v) to the extract
and incubating at 60°C for 60 min. Afterwards the reaction was stopped by addition
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of 10 drops of water and extraction was performed with 1.6 ml of heptane. After
vortexing, the organic layer was removed and evaporated to dryness. To the dry
extract 50 µl of heptane were added and transferred in autosampler vials after
vortexing.
Due to co-elution a different silylation method based on enolization was selected for
derivatization of T, E, 5α,3α-ADIOL and 5α,3β-ADIOL (Method B). Enolizing
conditions could be applied in this case, because these are steroids with an
androstan-17β-ol moiety and therefore the deuterium atoms are retained under
enolizing conditions. Loss of deuterium atoms would have occurred, in case of
androstan-17-one steroids. The same cleanup procedure was performed.
Derivatization was performed by incubation of the extract in 100 µl of
MSTFA/NH4I/ethanethiol (1000:2:3; v/w/v).
Gas chromatography and mass spectrometry
Selected ion monitoring was performed with a Hewlett Packard gas chromatograph
(Model 5890, Agilent Technologies, Waldbronn, Germany) coupled to a Hewlett
Packard quadrupole mass spectrometer (Model 5972A). Ionization was performed in
electron impact mode at 70 eV. Analysis was performed by selected ion monitoring of
specific ions, representing the respective deuterated and non-deuterated metabolites
(see Table 1). A check for possibly incomplete derivatization of Method B was
performed by detection of ions representing mono-TMS derivatives of AO and EO at
m/z 362.
Gas chromatography was performed with a HP-1 fused silica column (length 18 m,
inner diameter 0.2 mm, film thickness 0.11 µm). Via electronic pressure control the
column flow (helium) was constant 1 ml/min.  Sample injection of 1 µl was performed
in split mode (ratio 1/10). A Hewlett Packard autosampler (Model 7673, Agilent
Technologies, Waldbronn, Germany) was used for auto-injection. The injector
temperature was set to 250°C. The oven temperature program used was: initial
temperature 180°C, 2°/min to 225°C, 30°/min up to 310°C, held for 5 min. The
interface temperature was set to 280°C.
The quality of d2-DHEA was checked by GC-MS in full scan mode prior to
administration. No impurities could be detected in a concentrated sample.
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Table 1: Monitored m/z values of labeled and non-labeled steroids. Method A
(TBDMS-derivatization) was used for the analysis of labeled androstan-
17-one steroids. Method B (TMS-enolTMS derivatization) was used for
all non-labeled steroids and labeled androstan-17β-ol steroids.
Steroid derivative m/z value
non-labeled
Method A
m/z value
labeled
Method A
m/z value
non-labeled
Method B
m/z value
labeled
Method B
number of
deuterium
atoms in
derivative (n)
AO 347.3 349.3 434.3 - 2
EO 347.3 349.3 434.3 - 2
DHEA 345.3 347.3 432.3 - 2
∆5-AEDIOL 461.3 463.3 434.3 - 2
T - - 432.3 434.3 2
E - - 432.3 434.3 2
5α,3α-ADIOL - - 241.2 243.2 2
5α,3β-ADIOL - - 241.2 243.2 2
7α-OH-DHEA 399.3 401.3 430.3 - 2
7β-OH-DHEA 400.3 402.3 430.3 - 2
7-keto-AO 361.3 363.3 430.3 - 2
7-keto-DHEA 359.3 361.3 517.4 - 2
16α-OH-DHEA 343.3 344.3 505.4 - 1
16α-OH-AO 345.3 346.3 507.4 - 1
16α-OH-EO 345.3 346.3 507.4 - 1
Quantification of non-labeled endogenous metabolites ([d0-Mendo])
Calibration samples were prepared by adding 100 µl of methanolic standard solutions
to 4 ml demineralized water samples. These samples were included in the cleanup
procedure with the urine samples. Quantification of non-labeled endogenous steroids
([d0-Mendo]) was performed using two calibration curves for each steroid.
One curve containing five data-points, covered respective ranges: AO (467-2333 ng),
EO (469-2347 ng), T (20-100 ng), E (10-50 ng), DHEA (459-2293 ng), ∆5-AEDIOL
(509-2547 ng), 16α-OH-DHEA (248-1240 ng), 7α-OH-DHEA (25-125 ng), 7β-OH-
DHEA (75-375 ng), 16α-OH-AO (307-1533 ng), 16α-OH-EO (195-973 ng), 7-keto-AO
(15-75 ng), 7-keto-DHEA (40-200 ng). The second calibration curve contained 6
data-points and covered the respective ranges: AO (2333-56000 ng), EO
(2347-56320 ng), T (100-2400 ng), E (50-1200 ng), DHEA (2293-55040 ng), ∆5-
AEDIOL (2547-61120 ng), 16α-OH-DHEA (1240-29760 ng), 7α-OH-DHEA (125-3000
ng), 7β-OH-DHEA (375-9008 ng), 16α-OH-AO (1533-36800 ng), 16α-OH-EO (973-
23360 ng), 7-keto-AO (75-1808 ng), 7-keto-DHEA (200-4800 ng). 11α-OH-MeT (500
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ng) was used as internal standard. Weighted regression analysis (1/x2) was used for
calculation of the response curves.
Quantification of labeled steroids
The labeled steroids [d2-Mexo] were quantified in an indirect way, since synthetic
labeled metabolites were not available and construction of calibration curves for the
labeled steroids was impossible except for DHEA. The concentration of the labeled
metabolites was established by quantification of the concentration of the non-labeled
metabolites [d0-Mendo] and recording the area ratio of the detected labeled metabolite
(A(M+2)) vs. the non-labeled metabolite (A(M)). The concentration of labeled DHEA
was calculated with equation (2).
072.0]Md[
]Md[
*27.0)M(A
)2M(A
endo
0
exo
2 +
−
−
=
+ (2)
Equation (2) was deduced by applying the mean area ratio A(M+2)/A(M) determined
in pre-administration samples (=0.072 for DHEA) and A(M+2)/A(M) in a standard of
DHEA and d2-DHEA (=0.57*([d2-Mexo]/[d0-Mendo]). The calculation was performed with
the assumption that no proton-deuterium exchange occurred, so no non-labeled
metabolites of exogenous origin were detected ([d0-Mexo]=0). This was considered
valid, as 2 deuterium atoms were present in the steroid structure of the metabolites,
with the exception of the 16α-hydroxy-steroids. Metabolites 16α-OH-DHEA, 16α-OH-
AO and 16α-OH-EO were therefore excluded from the quantification procedure.
Equation (2) was corresponding to the results of Dehennin et al. [4]. Comparable
equations were used for other metabolites, assuming that the isotope effect was
constant for all metabolites. The mean area ratio A(M+2)/A(M) determined in pre-
administration samples was specifically calculated for each metabolite.
Validation
Quality control (QC) samples have been prepared according the following procedure:
A healthy male subject was administered two capsules of each 100 mg of DHEA.
Three pooled urine samples were prepared: QCL (collected during 16 hours before
time of administration), QCH (collected during 0-8 hours after time of administration)
and QCM (collected during 8-16 hours after time of administration). The QC samples
were divided over sample tubes and stored with the other urine samples of the
experiment at –20°C until time of analysis.
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The intra-assay precision was below 10% for all parameters, except for 7α-OH-
DHEA (QCL) that was <15%. The respective inter-assay precisions were all <20%
except for AO and EO (QCH), 7-keto-AO (QCL) and the 16α-OH-steroids that were
<25%. A relatively high variability of AO and EO in QCH was caused by column
overloading. Due to efficiency reasons no re-analysis of AO and EO was performed
after dilution.
The recovery was >95% for all steroid parameters except 16α-OH-DHEA (>90%). All
steroid derivatives were stable at room temperature at least 70 hours, except 7-keto-
DHEA that was stable at least 24 hours.
Previously, significant 3β-hydroxylase-∆5-4-isomerase activity in Helix pomatia was
reported, resulting in an artificial 20% T production from ∆5-AEDIOL [9]. Use of Helix
pomatia for the analysis of a total fraction of non-conjugated steroids and their
glucuronides and sulfates, has been validated in this experiment by checking side
product formation, after incubation of reference steroids, for every used batch
(incubation for 2 hours). No products from 3β-hydroxylase-∆5-4-isomerase activity
were detected. Artificial hydroxylation reactions were not significant (<1%).
Statistical analysis
The calculated [d2-Mexo]+[d0-Mendo] values of post-administration samples compared
to the mean and standard deviation values of pre-administration samples were tested
for significance with Student’s one tailed t-test, with p<0.05 considered as significant.
Testing of differences in A(M+2)/A(M) values were also tested with Student’s one
tailed t-test, with p<0.01 considered as significant. Assumed normality of excretion
rates was tested with the Kolmogorov test (p<0.05).
RESULTS
The relative effect of labeled DHEA administration to two male subjects was
established by recording the area ratio A(M+n)/A(M) of  the ions at m/z values
described in Table 1. In Figures 1a and b the area ratio A(M+n)/A(M) is graphically
presented as a function of time, before and after oral administration of labeled DHEA,
respectively for non-oxygenated and oxygenated metabolites. Clear differences were
observed in kinetic behavior. The response of most metabolites returned to baseline
before 30 hours after time of administration. Exceptions were DHEA, ∆5-AEDIOL,
EO, 5α,3α-ADIOL and 5β,3α-ADIOL that were still significantly elevated at 50 hours
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after time of administration (p<0.01). Oxygenated metabolites all approached
baseline level before 30 hours after time of administration.
Compounds that showed a large increase in A(M+n)/A(M) were DHEA, AO, EO, T,
5α,3α-ADIOL, 5β,3α-ADIOL, 7β-OH-DHEA, 7-keto-DHEA and 7-keto-AO.
Metabolites showing a moderate to no response were ∆5-AEDIOL, E, 7α-OH-DHEA,
16α-OH-DHEA, 16α-OH-AO and 16α-OH-EO. Concentration of labeled 7-keto-AO
was below limit of detection during the pre-administration period in subject 2 and
during the complete collection period in subject 1. Labeled 7α-OH-DHEA was below
limit of detection during the whole collection period in subject 2 and could only be
established in some urine samples of subject 1.
The total excretion rate of labeled DHEA metabolites and the excretion rate of
endogenous metabolites ([d2-Mexo]+[d0-Mendo]) is graphically presented as a function
of time in Figures 2a and b. The metabolites 5α,3α-ADIOL, 5β,3α-ADIOL, 16α-OH-
DHEA, 16α-OH-AO and 16α-OH-EO were not quantified. The effect of labeled DHEA
administration is less pronounced than as presented in Figures 1a and b, as it is
superposed on the bias caused by random biological variation and circadian rhythm
in steroid excretion. Circadian rhythm is most clearly visible in case of DHEA and ∆5-
AEDIOL. In Figure 3, the AO/EO and T/E ratios of the calculated [d2-Mexo]+[d0-Mendo]
values are presented as a function of time.
From the data of [d2-Mexo] the conversion of d2-DHEA to the respective metabolites
after 24 hours was calculated (see Tables 2 and 3). The conversion to oxygenated
metabolites is relatively small compared to non-oxygenated metabolites. The
conversion to the latter is, however, mostly contributed by the production of AO and
EO.
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Figure 1a: The area ratio A(M+n)/A(M) of labeled vs. non-labeled DHEA or non-oxygenated
metabolites of DHEA as a function of time, in subject 1 (       ) and subject 2
(       ). d2-DHEA was administered at time-point 0 hours.
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Figure 1b: The area ratio A(M+n)/A(M) of labeled vs. non-labeled DHEA or oxygenated
metabolites of DHEA as a function of time, in subject 1 (      ) and subject 2
(       ).
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Figure 2a: Excretion rates of the combined labeled [d2-Mexo] and non-labeled  [d0-Mendo]
DHEA and non-oxygenated metabolites of DHEA as a function of time, in subject
1 (       ) and subject 2 (        ). d2-DHEA was administered at time-point 0 hours.
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Figuur 2b: Excretion rates of the combined labeled [d2-Mexo] and non-labeled [d0-Mendo]
oxygenated metabolites of DHEA as a function of time, in subject 1 (     ) and
subject 2 (       ).
Figure 3: Ratios of metabolite concentrations calculated as [d2-Mexo]+[d0-Mendo], as a
function of time, in subject 1 (       ) and subject 2 (       ). d2-DHEA was
administered at time-point 0 hours.
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Table 2: Conversion (%) of DHEA to the respective metabolites after 24 hours.
N.D. = not determined.
Metabolite (M) Subject 1 (25.5 mg) Subject 2 (52.5 mg)
DHEA 2.6 0.36
∆5-AEDIOL 0.48 0.15
AO 19.9 12.0
EO 21.5 26.1
T 0.16 0.10
E < 0.01 < 0.01
7α-OH-DHEA 0.03 N.D.
7β-OH-DHEA 0.34 0.45
7-keto-DHEA 0.46 0.72
7-keto-AO N.D. 0.15
Table 3: Conversion (%) of DHEA to different groups of metabolites after 24 hours.
Group of metabolites Subject 1 (25.5 mg) Subject 2 (52.5 mg)
AO and EO 41.4 38.1
non-oxygenated 42.0 38.4
oxygenated 0.83 1.3
Total DHEA conversion 42.8 39.7
Total recovery DHEA + metabolites 45.4 40.0
DISCUSSION
Excretion kinetics
In this study the kinetics of DHEA and several of its metabolites were investigated.
The excretion behavior of the sum of conjugated and non-conjugated DHEA and
several of its metabolites as described in Figures 1a and b differ fundamentally.
Roughly, the observed patterns can be divided in three classes:
1. No change in excretion. No or little production of the metabolite takes place
after administration of d2-DHEA, as accounts for E, 7α-OH-DHEA and 16α-
OH-DHEA.
2. Rapid and short increase of excretion.  Within 10 hours after administration of
d2-DHEA the respective compound is cleared in high speed, leading to a
relatively fast return to baseline values, as accounts for AO, T, 7β-OH-DHEA,
7-keto-DHEA, 7-keto-AO, 16α-OH-AO and 16α-OH-EO.
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3. Rapid and prolonged increase of excretion. Within 10 hours after
administration of d2-DHEA the excretion of the respective compound increases
quickly and returns slowly to baseline values, as accounts for DHEA, EO,
AEDIOL, 5α,3α-ADIOL and 5β,3α-ADIOL.
The differences between the kinetic patterns can be explained by the extensive first
and second phase metabolic steps of DHEA. Our results show that orally
administered DHEA is almost completely converted into metabolites. Through
extensive first-pass metabolism, oral administration of DHEA will predominantly lead
to production of DHEA sulfate (DHEA-S) [10]. In blood DHEA-S is mainly bound to
albumin, in contrast to DHEA [11]. This results in much lower clearance rates for
DHEA-S (13 L/day) compared to DHEA (2,000 L/day) and justifies our observation of
prolonged excretion of small amounts of DHEA [12]. Conversion of DHEA to first
phase metabolites followed by rapid sulfation and/or conversion of DHEA-S to other
sulfated metabolites and their subsequent binding to albumin, could explain the
prolonged excretion of certain metabolites [13-17]. Those metabolites that will be
conjugated with glucuronic acid, are not bound to serum proteins and thus will be
excreted rapidly. That could justify the rapid and short excretion of other metabolites.
Our data show a more prolonged excretion of EO than of AO, which indicates that a
relation exists between EO and DHEA. It could suggest a relatively higher production
of the sulfate of EO compared to that of AO. This presumption is however not
supported by earlier results of Rosenfeld et al. [18] and  Dehennin et al. [4] who
performed separate analyses of glucuronides and sulfates after DHEA
administration. Other possibilities are a rapid and stereoisomer specific conversion of
relatively long circulating DHEA and an enterohepatic circulation of EO-glucuronide,
resulting in lower clearance efficiency [19].
Sensitivity and specificity
When a parameter is selected as marker for substance abuse, the demands of
sensitivity and selectivity should be fulfilled. In this respect, an evaluation of classical
parameters for the detection of the abuse of endogenous steroids such as the ratios
between AO and EO and between T and E, respectively, is of interest. Both ratios
are known to have a limited specificity to establish administration of T, DHEA or
∆4-AEDIONE [1-5,8]. However, in terms of sensitivity they could be of use. In this
investigation, the AO/EO ratio initially showed a small increase followed by a
significant decrease below baseline level for at least 30-50 hours after DHEA
administration (Figure 3). The T/E ratio was increased significantly during 10 hours
and was therefore only of use for a shorter period than the AO/EO ratio. These
characteristics have also been reported by Kazlauskas et al. [3].
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The specificity and sensitivity of metabolites as parameter can be interpreted from
Figures 1 and 2. The difference between the post-administration A(M+2)/A(M) ratio
and the mean pre-administration ratio in Figure 1, is a measure of relative response
towards DHEA administration.
Responding parameters, besides DHEA itself, in terms of sensitivity were the
metabolites AO, EO, T, 5α3α-ADIOL, 5β,3α-ADIOL, ∆5-AEDIOL, 7β-OH-DHEA, 7-
keto-DHEA and 7-keto-AO. Because of the high biological variation due to a high
amplitude circadian rhythm, the response of DHEA and ∆5-AEDIOL resulted in only a
limited sensitivity (Figure 2). 7-Keto-AO showed a large response in one subject, but
could not be detected before and after administration in the other subject. The most
sensitive parameters were therefore, AO, EO, T and the 7-oxygenated metabolites
7β-OH-DHEA and 7-keto-DHEA. No conclusions could be drawn about 5α,3α-ADIOL
and 5β,3α-ADIOL as those were not quantified in this study.
Interpretation of the 16α-OH metabolites was not possible in these experiments as
one deuterium was metabolically removed from the steroid structure due to the
hydroxylation. A significant isotope effect due to deuterium-proton exchange can not
be disregarded ([d2-Mendo]≠0) for these metabolites. Equation (2) is therefore not
applicable for 16α-OH-metabolites and have been excluded from further
interpretation. Furthermore, significant physiological isotope effects have been
reported in case of deuterium labeled substance administration [20]. Due to these
physiological isotope effects the rate of metabolic deuterium removal is expected to
be lower than the rate of equivalent proton removal, leading to a limitation of 16α-
hydroxylation in this particular case.
In terms of specificity it could be argued that the non-oxygenated metabolites are not
of interest, because they originate from various steroids. The oxygenated metabolites
7-keto-AO, 16α-OH-AO and 16β-OH-EO seem to be specific as they are reduced
metabolites of 7-keto-DHEA and 16α-OH-DHEA. However, they could also be
oxygenated metabolites of AO and EO. This is partly illustrated by 16α-hydroxylation
of AO by human liver microsomes, as performed by Einarsson et al.  [21]. The
metabolites 7-keto-DHEA, 7α-OH-DHEA, 7β-OH-DHEA and 16α-OH-DHEA can
theoretically be expected to be the most specific metabolites as they are directly
converted from DHEA [21-25].  Moreover, as the double bond is retained at the ∆5-
position in the steroid structure during metabolic conversion, a high sensitivity for
DHEA and a low sensitivity towards ∆4-steroids as ∆4-AEDIONE and T can be
expected. Based on this investigation at least the 7-oxygenated metabolites appear
promising enough to study aspects of specificity in more detail.
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PROFILING SPECIFIC METABOLITES OF DEUTERIUM
LABELED ANDROST-4-ENE-3,17-DIONE
ABSTRACT
Androst-4-ene-3,17-dione (∆4-AEDIONE) is a steroid that is easily obtainable as food
supplement product. Because of assumed anabolic properties, the International Olympic
Committee has placed ∆4-AEDIONE on the list of forbidden substances. So far, no
techniques have become available to detect ∆4-AEDIONE abuse in a selective way. In this
study, a preliminary investigation is performed to construct a ∆4-AEDIONE selective profile of
non-oxygenated metabolites (dehydroepiandrosterone, androsterone, etiocholanolone,
testosterone, epitestosterone, androst-5-ene-3β,17β-diol, 5α-androst-3α,17β-diol and
5β-androstan-3α-17β-diol) and oxygenated metabolites (6α/β-hydroxy-∆4-AEDIONE, 4-
hydroxy-∆4-AEDIONE, 16α-hydroxy-∆4-AEDIONE, 6-keto-∆4-AEDIONE, 6α/β-hydroxy-
testosterone, 16α-hydroxy-androsterone, 16α-hydroxy-etiocholanolone, 11β-hydroxy-
androsterone and 11β-hydroxy-etiocholanolone).
Deuterium labeled ∆4-AEDIONE ([2,2,4,6,6,16,16-7H2]-androst-4-ene-3,17-dione) was
administered to 2 healthy male volunteers (25.0 and 52.0 mg, respectively) and urine
samples were collected. Sample analysis was performed of the total fraction of glucuronides,
sulfates and non-conjugated steroids with gas chromatography-mass spectrometry. The
most sensitive parameters during the first 10 hours after administration were androsterone,
etiocholanolone, testosterone, 6α/β-hydroxy-∆4-AEDIONE, 4-hydroxy-∆4-AEDIONE and
6α/β-hydroxy-testosterone. Differences in excretion kinetics were observed between the
studied metabolites. The total conversion of ∆4-AEDIONE to the studied metabolites was
39.3-42.1% after 48 hours. The conversion to oxygenated and non-oxygenated metabolites
was 0.24-0.90% and 39.1-41.2%, respectively. Although the conversion to oxygenated
metabolites was limited, the sensitivity and expected specificity for ∆4-AEDIONE detection of
the corresponding metabolites make these potential parameters for possible use in doping
analysis applications.
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INTRODUCTION
The introduction of steroid containing food supplements on an easily accessible
market had a great impact on doping analysis and the doping control system.
Androst-4-ene-3,17-dione  (∆4-AEDIONE) was one of the first supplement steroids
that was commercially available for athletes. The International Olympic Committee
(IOC) placed ∆4-AEDIONE on the List of Forbidden Substances in 1997. The
steroids that appeared on the food supplement market extended to androst-5-ene-
3β,17β-diol, androst-4-ene-3β,17β-diol and nor-steroids 19-nor-androst-4-ene-3,17-
dione and 19-nor-androst-4-ene-3β,17β-diol [1,2].
Non-specific metabolism, extensive first-pass metabolism and fast renal and
metabolic clearance aggravate the analysis of orally administered supplement
steroids. Analytical procedures for detecting ∆4-AEDIONE have mostly been limited
to straightforward steroid profiling techniques, as originally developed for other
endogenous steroids as testosterone (T), epitestosterone (E) [3,4] and
5α-dihydrotestosterone [5,6] in urine samples. A typical steroid profile that is
analyzed in doping analysis includes, besides the mentioned mother compounds,
metabolites as androsterone (AO), etiocholanolone (EO) and androstanediol
epimers. This approach leads to mostly unspecific and therefore insufficiently
conclusive information about the identity of the administered steroid.
In this study, a preliminary investigation is performed to construct a more steroid
specific profile of selected oxygenated and/or non-oxygenated metabolites of
∆4-AEDIONE. Therefore, [2,2,4,6,6,16,16-7H2]-androst-4-ene-3,17-dione (d7-∆4-
AEDIONE) was administered to 2 healthy male volunteers and urine samples were
collected at set times before and after administration. Analysis of the collected urine
samples was performed with gas chromatography-mass spectrometry (GC-MS).
EXPERIMENTAL
Chemicals
Reference steroids: Androst-5-en-3β-ol-17-one (dehydroepiandrosterone, DHEA),
androst-4-en-17α-ol-3-one (epitestosterone, E), 5α−androstan-3α-ol-17-one
(androsterone, AO), 5β−androstan-3α-ol-17-one (etiocholanolone, EO), androst-4-
ene-3,17-dione (androstenedione, ∆4-AEDIONE), androst-5-ene-3β,17β-diol
(androstenediol, ∆5-AEDIOL), 5α-androstan-3α,11β-diol-17-one (11β-hydroxy-
androsterone, 11β-OH-AO), 5β-androstan-3α,11β-diol-17-one (11β-hydroxy-
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etiocholanolone, 11β-OH-EO) and 17α-methyl-androst-4-en-11α,17β-diol-3-one
(11α-hydroxy-methyltestosterone, 11α-OH-MeT) were obtained from Sigma, St.
Louis, Missouri, USA. Androst-4-en-17β-ol-3-one (testosterone, T) was obtained
through courtesy of Organon, Oss, The Netherlands. Androst-4-en-6α-ol-7,17-dione
(6α-hydroxy-androstenedione, 6α-OH-∆4-AEDIONE), androst-4-en-6β-ol-7,17-dione
(6β-hydroxy-androstenedione, 6β-OH-∆4-AEDIONE), androst-4-ene-6,7,17-trione
(6-keto-androstenedione, 6-keto-∆4-AEDIONE), androst-4-en-6β,17β-ol-7-one (6β-
hydroxy-testosterone, 6β-OH-T), androst-4-en-4-ol-3,17-dione (4-hydroxy-
androstenedione, 4-OH-∆4-AEDIONE), androst-4-en-16α-ol-3,17-dione (16α-
hydroxy-androstenedione, 16α-OH-∆4-AEDIONE), 5α−androstane-3α,16α-diol-17-
one (16α-hydroxy-androsterone, 16α-OH-AO), 5β−androstane-3α,16α-diol-17-one
(16α-hydroxy-etiocholanolone, 16α-OH-EO) were obtained from Steraloids, Newport,
Rhode Island, USA. [2,2,4,6,6,16,16-7H2]-Androst-4-ene-3,17-dione (d7-∆4-
AEDIONE, isotopic purity 98.4%) was obtained from C/D/N Isotopes, Pointe-Claire,
Quebec, Canada.
Chemicals: N-Methyl-N-trimethylsilyltrifluoroacetamide (MSTFA), ethanethiol (97%)
and phosphorous pentoxide were obtained from Sigma-Aldrich Chemie Company,
Steinheim, Germany. Ammonium iodide was obtained from Fluka Chemie, Buchs,
Switzerland. Potassium hydroxide, sodium acetate trihydrate, glacial acetic acid
(96%), diethyl ether, acetic acid and methanol were obtained from Merck, Darmstadt,
Germany. All chemicals were of analytical grade, unless indicated otherwise.
Hydrolysis was performed with Helix pomatia (type HP-2, containing 110.000 IU/ml β-
glucuronidase and 1000-5000 IU/ml arylsulfatase), obtained from Sigma, St. Louis,
Missouri, USA.
Columns for solid-phase extraction were IST Isolute C18 columns (200 mg, non-
endcapped) obtained from Sopachem, Lunteren, The Netherlands.
Sample collection
Two male volunteers (subject 1: 29 years, 88 kg; subject 2: 21 years, 75 kg),
collected urine samples every 2 hours during 3 days. On the second day at 9 a.m. d7-
∆4-AEDIONE was orally administered (subject 1, 25.0 mg; subject 2, 52.0 mg). For
each collected urine sample the exact void time, volume and specific gravity (Urine
Specific Gravity Refractometer, Atago, Japan) was recorded. Samples were stored at
-20°C until time of analysis.
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Sample preparation
The volume of urine sampled for the analysis was determined on the basis of specific
gravity (d) of the urine, according to:
5*
1d
020.0Volume
−
= ml (1)
A maximum volume of 15 ml was applied. Solid-phase extraction was performed with
C18 columns. Before applying urine samples, the column material was preconditioned
by washing with 4 ml of methanol and equilibrated with 2 ml of demineralized water.
Inorganic material was removed from the column by washing with 2 ml of water. The
remaining compounds were collected by elution with 4 ml of methanol. After
evaporation to dryness, 2 ml of acetate buffer (0.1 M, pH 5.2) was added to the
extract. Hydrolysis was performed by addition 100µl of Helix pomatia followed by
incubation for 1 hour at 55°C. Steroids were isolated from the buffer solution by
extraction with 5 ml of diethyl ether twice. After extraction the phase separation was
optimized by centrifugation (4000 rpm, 5 min). The organic layer was removed and
evaporated to dryness under a stream of nitrogen at 40°C. The extract was dried
overnight over P2O5/KOH under reduced pressure. Derivatization was performed by
incubation of the extract in 100 µl of MSTFA/NH4I/ethanethiol (1000:2:3; v/w/v) at
80°C for 30 min.
Gas chromatography and mass spectrometry
Selected ion monitoring (SIM) was performed with a Hewlett Packard gas
chromatograph (Model 5890, Agilent Technologies, Waldbronn, Germany) coupled to
a Hewlett Packard quadrupole mass spectrometer (Model 5972A). Ionization was
performed in electron ionization mode at 70 eV. Analysis was performed by SIM
analysis of specific ions representing the respective deuterated and non-deuterated
metabolites (see Table 1). The number of deuterium atoms in Table 1 was based on
maximum response after screening of all possible m/z values from [M]•+ to [M+7]•+. A
check for possibly incomplete derivatization was performed by detection of ions
representing mono-TMS derivatives of AO and EO at m/z 362.
Gas chromatography was performed with a HP-1 fused silica column (length 18 m,
inner diameter 0.2 mm, film thickness 0.11 µm). Via electronic pressure control the
column flow (helium) was constant at 1 ml/min.  Sample injection of 1 µl was
performed in split mode (ratio 1/10). A Hewlett Packard autosampler (Model 7673,
Agilent Technologies, Waldbronn, Germany) was used for auto-injection. The injector
temperature was set to 250°C. The oven temperature program used was: initial
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temperature 180°C, 2°/min to 225°C, 30°/min up to 310°C, held for 5 min. The
interface temperature was set to 280°C.
The quality of d7-∆4-AEDIONE was checked by gas chromatography-mass
spectrometry (GC-MS) in full scan mode prior to administration. No impurities could
be detected in a concentrated sample.
Quantification of non-labeled endogenous metabolites ([d0-Mendo])
Calibration samples were prepared by adding 100 µl of methanolic standard solutions
to samples of 4 ml of demineralized water. These samples were included in the
cleanup procedure with the urine samples. Quantification of non-labeled endogenous
steroids ([d0-Mendo]) was performed using two calibration curves for each steroid.
One curve containing five data-points, covered respective ranges: ∆4-AEDIONE
(10-50 ng), AO (645-3227 ng), EO (629-3147 ng), T (80-400 ng), E (20-100 ng),
DHEA (493-2467 ng), ∆5-AEDIOL (432-2160 ng), 16α-OH-∆4-AEDIONE (25-125
ng), 6α-OH-∆4-AEDIONE (10-50 ng), 6β-OH-∆4-AEDIONE (10-50 ng), 6β-OH-T
(12-60 ng), 16α-OH-AO (347-1733 ng), 16α-OH-EO (339-1016 ng), 6-keto-∆4-
AEDIONE (20-100 ng). The second calibration curve contained 6 data-points and
covered the respective ranges: ∆4-AEDIONE (50-960 ng), AO (3227-61951 ng), EO
(3147-60415 ng), T (400-7680 ng), E (100-1,920 ng), DHEA (2467-47360 ng), ∆5-
AEDIOL (2160-41472 ng), 16α-OH-∆4-AEDIONE (125-2400 ng), 6α-OH-∆4-
AEDIONE (50-960 ng), 6β-OH-∆4-AEDION (50-960 ng), 6β-OH-T (60-1152 ng), 16α-
OH-AO (1733-33280 ng), 16α-OH-EO (1016-32512 ng), 6-keto-∆4-AEDIONE
(100-1920 ng). 11α-OH-MeT (500 ng) was used as internal standard. Weighted
regression analysis (1/x2) was used for calculation of the calibration curve.
As described in Chapter 8, androst-4-ene-3-one steroids that are hydroxylated on C6
lose the stereochemical integrity at this position after derivatization under enolizing
conditions [7,8]. This resulted in the conversion of 6α-OH-∆4-AEDIONE and 6β-OH-
∆4-AEDIONE to identical 3,5,16-triene-3,6,17-triol TMS products (6α/β-OH-
AEDIONE). This was also the case for 6α-OH-T and 6β-OH-T (6α/β-OH-T). The
applied range of quantification for 6α/β-OH-∆4-AEDIONE was therefore 20-100 ng
and 100-1920 ng, respectively for the used calibration curves.
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 Table 1: Monitored m/z values of labeled and non-labeled derivatives of
∆4-AEDIONE and metabolites.
Steroid derivative m/z value
non-labeled
m/z value
labeled
number of deuterium
atoms in derivative (n)
∆4-AEDIONE 430.3 435.3 5
AO 434.3 440.3 6
EO 434.3 440.3 6
DHEA 432.3 437.3 5
∆5-AEDIOL 434.3 440.3 6
T 432.3 438.3 6
E 432.3 438.3 6
5α,3α-ADIOL 241.2 246.2 5
5α,3β-ADIOL 241.2 246.2 5
6α/β-OH-∆4-AEDIONE 518.4 522.4 4
4-OH-∆4-AEDIONE 518.4 522.4 4
16α-OH-∆4-AEDIONE 503.4 507.4 4
6-keto-∆4-AEDIONE 516.4 520.4 4
16α-OH-AO 507.4 512.4 5
16α-OH-EO 507.4 512.4 5
6α/β-OH-T 520.4 525.4 5
11β-OH-AO 522.4 528.4 6
11β-OH-EO 522.4 528.4 6
Quantification of labeled steroids
The concentration of labeled steroids [dn-Mexo] that were excreted could only be
quantified in an indirect way, since synthetic labeled metabolites were not available.
The values of [dn-Mexo] were established by calculation of the concentration of
unlabeled metabolites [d0-Mendo], and the area ratio of the detected labeled
metabolites (A(M+n)) vs. the respective non-labeled metabolites (A(M)). [d0-Mendo]
was established by calibration as described above. Calculation of [dn-Mexo] was
performed with equation (2) (see also Dehennin et al. [9]).
0
endo
0
exo
n R]Md[
]Md[
*795.0)M(A
)nM(AR +
−
−
=
+
= (2)
Equation (2) was deduced by applying the mean area ratio A(M+2)/A(M), as
determined in pre-administration samples (=R0) and A(M+n)/A(M) in standard of
∆4-AEDIONE and d7-∆4-AEDIONE (=0.795*([dn-Mexo]/[d0-Mendo]). The calculation was
performed with the assumption that no proton-deuterium exchange occurred, so no
non-labeled metabolites of exogenous origin were detected ([d0-Mexo]=0). This was
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considered valid, as 4-6 deuterium atoms were present in the steroid structure of the
metabolites.
R0 was equal to zero for most metabolites, as [dn-Mendo] was negligible. Due to
insufficient specificity of the applied GC-MS method, R0>0 in case of ∆4-AEDIONE,
DHEA, E, 16α-OH-∆4-AEDIONE and 6α/β-OH-∆4-AEDIONE.
Validation
Quality control (QC) samples were prepared according the following procedure: A
healthy male subject was administered two capsules of each 100 mg of
∆4-AEDIONE. Three pooled urine samples were prepared: QCL (collected during 16
hours before time of administration), QCH (collected during 0-8 hours after time of
administration) and QCM (collected during 8-16 hours after time of administration).
The QC samples were divided over sample tubes and stored with the other urine
samples of the experiment at –20°C until time of analysis.
The intra-assay precision was below 10% for all parameters, except 16α-OH-AO
(QCH) and 6α/β-OH-T (QCL and QCM) were <15%. ∆4-AEDIONE (all QC samples)
was <20% and 6-keto-∆4-AEDIONE (QCM) was <40%. The respective inter-assay
precisions were <20 %; except for AO and EO (QCH), 4-OH-∆4-AEDIONE and 6α/β-
OH-∆4-AEDIONE (QCL) and 16α-OH-steroids that were <25%; ∆4-AEDIONE and 6-
keto-∆4-AEDIONE (QCL and QCM) were <35%. Based on these results the decision
was made to exclude ∆4-AEDIONE and 6-keto-∆4-AEDIONE from the quantification
procedure. The relatively high variability of AO and EO in QCH was caused by
column overloading.
The recovery was >95% for all steroid parameters. All steroid derivatives were stable
at room temperature for at least 70 hours. As also described in Chapter 4, the
significance of side-reactions occurring in the Helix pomatia incubation mixture was
tested. No products from 3β-hydroxylase-∆5-4-isomerase activity were detected.
Artificial hydroxylation reactions were not significant (<1%).
Statistical analysis
The calculated [dn-Mexo]+[d0-Mendo] values of post-administration samples compared
to the mean and standard deviation values of pre-administration samples were tested
for significance with Student’s one tailed t-test, with p<0.05 considered as significant.
Assumed normality of excretion rates was tested with the Kolmogorov test (p<0.05).
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RESULTS
In Figure 1 the recorded A(M+n)/A(M) ratio of ∆4-AEDIONE is shown as a function of
time for both subjects. In blank urine samples only low concentrations of
∆4-AEDIONE were detected. Also, after administration minor quantities of d7-∆4-
AEDIONE were recovered.
Figure 1: The area ratio A(M+n)/A(M) of labeled vs. non-labeled ∆4-AEDIONE as a
function of time, in subject 1 (     ) and subject 2 (     ). d7-∆4-AEDIONE was
administered at time-point 0 hours.
In Figures 2a and b the recorded A(M+n)/A(M) ratio is shown as a function of time for
the non-oxygenated and oxygenated metabolites. In these results [d0-6-keto-∆4-
AEDIONE] was below the limit of detection in both subjects, and was therefore
excluded. Due to chromatographic co-elution of 5α,3α-ADIOL and 5β,3α-ADIOL
could only be determined in samples of one subject.
Excretion of the labeled steroids returned to baseline within 20 hours, except for
5α,3α-ADIOL, 5β,3α-ADIOL, ∆5-AEDIOL and EO that were increased for more than
30 hours after time of administration. The maximum response of AO was around 10%
higher than that of EO, but between 5-35 hours after time of administration the
response of EO was higher. The parameters that showed the largest response in
A(M+n)/A(M) were AO, EO, T, 6α/β-OH-∆4-AEDIONE, 6α/β-OH-T and 4-OH-∆4-
AEDIONE.
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In Figures 3a and b the total excretion rate of labeled and endogenous metabolites
([dn-Mexo]+[d0-Mendo]) is presented as a function of time for both subjects. The
parameters ∆4-AEDIONE, 6-keto-∆4-AEDIONE, 5α,3α-ADIOL, 5β,3α-ADIOL, 11β-
OH-AO and 11β-OH-EO were not included in the quantification procedure. As the
excretion of labeled ∆4-ADIONE metabolites is superposed on the biological variation
of non-labeled steroid excretion, the presented response in Figures 3a and b is less
pronounced as presented in Figures 2a and b. The excretion rate of all metabolites
was back to baseline level at around 10 hours after administration. The metabolites
that show the most significant effect were AO, EO, T, 6α/β-OH-∆4-AEDIONE, 4-OH-
∆4-AEDIONE and 6α/β-OH-T.
The calculated AO/EO and T/E ratio based on [dn-Mexo]+[d0-Mendo] values are shown
in Figure 4. In subject 1 the AO/EO showed an increase during the first 10 hours with
a maximum of 40%, followed by a decrease (40% maximum) until 25-30 hours after
time of administration. In subject 2 the AO/EO ratio was only decreased (70%
maximum decrease) during 25-30 hours after time of administration. For subject 1
and 2, the T/E ratio was increased from 0.9 to 2.4 (170%) and 2.5 to 14.2 (470%),
respectively.
In Tables 2 and 3 an outline is given of the calculated conversion of ∆4-AEDIONE to
the respective metabolites after 24 and 48 hours, as calculated by the total excreted
amount for each metabolite vs. the applied dose. For the major part, ∆4-AEDIONE
was converted to AO and EO. Only 1-2 % was converted to other studied
metabolites. Conversion to oxygenated metabolites was 0.2-0.9%. The total recovery
of ∆4-AEDIONE that was converted after 48 hours was 39-42%. Of the total
conversion, 90-95% occurred within the first 24 hours after administration.
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Figure 2a: The area ratio A(M+n)/A(M) of labeled vs. non-labeled, non-oxygenated
metabolites of ∆4-AEDIONE as a function of time, in subject 1 (      ) and subject
2 (       ). d7-∆4-AEDIONE was administered at time-point 0 hours.
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Figure 2b: The area ratio A(M+n)/A(M) of labeled vs. non-labeled, oxygenated metabolites
of ∆4-AEDIONE as a function of time, in subject 1 (       ) and subject 2 (       ).
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Figure 3a: Excretion rates of the combined labeled [dn-Mexo] and non-labeled [d0-Mendo], non-
oxygenated metabolites of ∆4-AEDIONE as a function of time, in subject 1 (      )
and subject 2 (       ). d7-∆4-AEDIONE was administered at time-point 0 hours.
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Figuur 3b: Excretion rates of the combined labeled [dn-Mexo] and non-labeled [d0-Mendo], non-
oxygenated metabolites of ∆4-AEDIONE as a function of time, in subject 1 (       )
and subject 2 (        ).
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Figure 3: Ratio’s of metabolite concentrations calculated as [dn-Mexo]+[d0-Mendo], as a
function of time, in subject 1 (      ) and subject 2 (     ). d7-∆4-AEDIONE was
administered at time-point 0 hours.
Table 2: Conversion (%) of ∆4-AEDIONE to the respective metabolites after 24 hours.
Metabolite (M) Subject 1
25.0 mg)
after 24 hours
Subject 1
25.0 mg)
after 48 hours
Subject 2
(52.0 mg)
after 24 hours
Subject 2
(52.0 mg)
after 48 hours
DHEA 0.02 0.02 <0.01 <0.01
∆5-AEDIOL 0.70 1.2 0.35 0.57
AO 26.8 27.0 16.1 16.5
EO 10.3 10.8 21.6 24.0
T 0.05 0.05 0.16 0.16
E <0.01 <0.01 <0.01 <0.01
6α/β-OH-∆4-AEDIONE <0.01 <0.01 0.04 0.04
6α/β-OH-T <0.01 <0.01 0.03 0.03
4-OH-∆4-AEDIONE 0.12 0.12 0.59 0.59
16α-OH-∆4-AEDIONE <0.01 <0.01 0.01 0.01
16α-OH-AO 0.07 0.07 0.10 0.11
16α-OH-EO 0.05 0.05 0.10 0.11
Table 3: Conversion (%) of ∆4-AEDIONE to different groups of metabolites.
Metabolites Subject 1
(25.0 mg)
after 24 hours
Subject 1
(25.0 mg)
after 48 hours
Subject 2
(52.0 mg)
after 24 hours
Subject 2
(52.0 mg)
after 24 hours
AO and EO 37.1 37.8 37.7 40.5
non-oxygenated 37.9 39.1 38.2 41.2
oxygenated 0.24 0.24 0.87 0.89
Total 38.1 39.3 39.1 42.1
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DISCUSSION
Excretion kinetics
Our results show different patterns for the excretion of produced metabolites (Figures
2a and b). DHEA, E, 16α-OH-∆4-AEDIONE, 11β-OH-AO and 11β-OH-EO showed
no, or a limited response to ∆4-AEDIONE administration (compare class 1 in Chapter
4). A rapid and short increase of excretion was observed for AO, T, 6α/β-OH-∆4-
AEDIONE, 4-OH-∆4-AEDIONE, 6α/β-OH-T and 16α-OH-AO (class 2). Within 10
hours after administration, the respective metabolites were cleared in high speed,
leading to relatively fast return to baseline values. The other studied metabolites
∆5-AEDIOL, EO, 5α,3α-ADIOL, 5β,3α-ADIOL and 16α-OH-EO showed a rapid and
prolonged increase of excretion (class 3). Within 10 hours after administration the
respective metabolites were cleared in relatively low speed, leading to a slow return
to baseline level. This was illustrated most clearly in case of labeled ∆5-AEDIOL,
which could be detected up to 100 hours post-administration (data not shown).
As has also been described in Chapter 4, kinetic differences can be explained by the
extensive first and second phase metabolism of ∆4-AEDIONE. Our results show that
∆4-AEDIONE is almost completely metabolized, to mostly non-oxygenated
metabolites. As in agreement with Uralets et al. [1], negligible amounts of labeled ∆4-
AEDIONE itself were recovered.
A low renal clearance was shown previously for sulfate conjugates of DHEA, T,
pregnenolone, estrone and cholesterol as compared to glucuronides, because in
blood those steroids are mainly bound to albumin [10-13]. In contrast to DHEA
metabolism, insufficient data are available about the second phase metabolism of
orally administered ∆4-AEDIONE. As no separate analysis of the different conjugates
was performed in this experiment, no further evidence was obtained.
As also reported by Uralets et al. [1] AO and EO are main metabolites of
∆4-AEDIONE. In the present experiment, data show a more prolonged excretion of
EO compared to AO, leading to an AO/EO ratio that was significantly decreased until
30 hours after administration. This can be accounted to a relatively high production of
the EO sulfate as compared to AO sulfate.  Another explanation could be found in
enterohepatic circulation of EO-glucuronide, resulting in lower clearance efficiency
[14].
Sensitivity and selectivity
When sensitivity of a parameter is defined as the maximum response of either
A(M+n)/A(M) or ([dn-Mexo] + [d0-Mendo]), then AO, EO, T, 6α/β-OH-∆4-AEDIONE, 4-
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OH-∆4-AEDIONE and 6α/β-OH-T can be regarded as most sensitive (see Figures 1
and 2). The T/E ratio can also be considered as a sensitive parameter in this
experiment.
The detection of 6α-OH-∆4-AEDIONE glucuronide after ∆4-AEDIONE administration
was previously reported in a case study [15]. However, regarding the applied
derivatization procedure the identification is unclear as 6α-OH-∆4-AEDIONE and 6β-
OH-∆4-AEDIONE form an identical derivative (see Chapter 8). Also no excretion data
were reported.  In our results the combined 6α/β-OH-∆4-AEDIONE showed a
relatively high sensitivity. This was also the case for 6α/β-OH-T. As explained in
Chapter 3, the sensitivity of these steroids can most likely be assigned to the 6β-OH-
metabolites.
4-OH-∆4-AEDIONE was also detected as a sensitive metabolite, as illustrated by its
higher relative response in subject 2 than for AO and EO. The endogenous origin of
this steroid has not been described previously. It has, however, frequently been
applied as an effective aromatase inhibitor in cancer therapy. In a clinical trial report,
no endogenous 4-OH-∆4-AEDIONE was detected in plasma before administration of
this steroid [16]. However, hydroxylation at C4 is a relevant metabolic route for
estrogens, leading to catecholestrogens [17,18]. As described in Chapter 3,
insufficient evidence is available to exclude the endogenous origin of 4-OH-∆4-
AEDIONE or the conversion to this steroid after oral administration of ∆4-AEDIONE.
No production of ∆5-steroids was expected, as the conversion of ∆5- to ∆4-steroids is
usually considered as an irreversible step in steroid biosynthesis. However, limited
amounts of labeled ∆5-AEDIOL and negligible amounts of labeled DHEA were
formed. This could suggest a relatively slow conversion of ∆4-AEDIONE to DHEA,
possibly followed by immediate other metabolic steps as 17-hydrogenation to ∆5-
AEDIOL or hydroxylation (as have been studied in Chapter 4).
In a previously reported case study [19], 11β-OH-AO and 11β-OH-EO were
mentioned as suspected metabolites of ∆4-AEDIONE. The involved steroid
11β-hydroxylation is an important step in cortisol biosynthesis. In this case, the
relative response of those steroids was very limited, which can be explained by the
localization of 11β-hydroxylase activity in adrenal tissue [20].
Specificity for ∆4-AEDIONE was in the first place expected for oxygenated
derivatives of this steroid, as 6α/β-OH-∆4-AEDIONE, 4-OH-∆4-AEDIONE, 16α-OH-
∆4-AEDIONE and 6-keto-∆4-AEDIONE. All those parameters except 6-keto-∆4-
AEDIONE extensively responded to ∆4-AEDIONE administration. Prior to the
experiment also 19-hydroxy-androst-4-ene-3,17-dione was evaluated in a pilot study
(data not shown). This potential metabolite [21-23] could not be identified in blank
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and post-administration samples, and was therefore excluded from this experiment.
The reduced metabolites 16α-OH-AO and 16α-OH-EO were expected to be either
reduced metabolites of 16α-OH-∆4-AEDIONE or 16α-hydroxy metabolites of AO and
EO, respectively. Whether 6α/β-OH-T are reduced metabolites of 6α/β-OH-∆4-
AEDIONE or are 6α/β-OH-metabolites of testosterone, is also not clear.
Care should be taken with the extrapolation of these data to a situation of non-
labeled ∆4-AEDIONE administration. Significant physiological isotope effects have
been reported in case of deuterium labeled substance administration [24]. Due to
these physiological isotope effects the rate of metabolic deuterium removal is lower
than of equivalent hydrogen removal, leading to a possible limitation of 4-, 6α-, 6β
and 16α-hydroxylation in this particular case.
SUMMARY
Several oxygenated steroids were introduced that could provide sensitive and
specific information about administration of ∆4-AEDIONE, although the conversion to
those steroids was limited (<1%). The highest sensitivity for detection of ∆4-
AEDIONE was obtained for AO, EO, T, 6α/β-OH-∆4-AEDIONE, 4-OH-∆4-AEDIONE
and 6α/β-OH-T.
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6
SPECIFIC DETECTION OF DEHYDROEPIANDROSTERONE
(DHEA) ADMINISTRATION BY PROFILING OXYGENATED
METABOLITES
ABSTRACT
In Chapters 4 and 5 several steroids were presented that could be used as sensitive
parameters for establishing the abuse of dehydroepiandrosterone (DHEA) and androst-4-
ene-3,17-dione (∆4-AEDIONE). In this experiment these steroids were analyzed in urine
samples taken before and after administration of 100 mg of DHEA to 8 male subjects.
Sample analysis was performed on the total fraction of glucuronides, sulfates and non-
conjugated steroids with gas chromatography-mass spectrometry.   
In 24 hours, 39.5 ± 7.8 % was recovered from the administered dose as the total of DHEA
and its metabolites. The conversion to non-oxygenated steroids was 19.7 ± 6.0 % and to
oxygenated steroids 2.8 ± 0.9 %
The parameters that showed the best sensitivity for DHEA were 7β-hydroxy-DHEA, androst-
5-ene-3β,17β-diol, 7-keto-androsterone, 6α/β-hydroxy-∆4-AEDIONE, 16α-hydroxy-
androsterone, 16α-hydroxy-etiocholanolone, androsterone, etiocholanolone and DHEA itself.
Sensitivity was described as the relative increase in 24-hours excretion rate after
administration, as compared to the mean basal excretion rate. 4-Hydroxy-∆4-AEDIONE,
6α/β-hydroxy-T and T that were previously described as sensitive parameters for
∆4-AEDIONE administration, showed a relatively low increase in excretion after
administration.
The 7β-hydroxy-DHEA/7α-hydroxy-DHEA and T/E ratio significantly increased. Mean intra-
subject T/E ratios of the pre-administration period correlated with the corresponding
maximum T/E ratios after DHEA administration.
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INTRODUCTION
Metabolic precursors of testosterone have become commercially available as food
supplements during the nineties. One of the pioneering steroids on this market was
dehydroepiandrosterone (DHEA), which has been considered as a doping agent
since the International Olympic Committee (IOC) added it to the List of Forbidden
Substances in 1997.
In the past, steroid profiling was usually focussed on the analysis of reduced
metabolites as androst-5-ene-3β,17β-diol (∆5-AEDIOL), testosterone (T),
epitestosterone (E), androsterone (AO), etiocholanolone (EO) and androstanediol
stereoisomers [1]. However, the number of steroids found in food supplements that
are expected to metabolize to several of these reduced compounds has increased to
over five (DHEA, ∆5-AEDIOL, androst-5-ene-3,17-dione, androst-4-ene-3,17-dione,
androst-4-ene-3β,17β-diol, pregnenolone) [1,2].
In Chapter 3 several oxygenated steroids were introduced that were related to the
metabolism of DHEA and ∆4-AEDIONE. These could serve as parameters in steroid
profiling to enable identification of either DHEA or ∆4-AEDIONE as administered
doping agent. In Chapters 4 and 5 was illustrated that oxygenated metabolites
provide sufficient sensitivity as compared to the mentioned non-oxygenated
metabolites. Sensitivity was described as the relative increase in 24-hours excretion
rate after administration, as compared to the basal excretion rate.
In Chapter 4, the best sensitivity for DHEA was ascribed to 7β-hydroxy-DHEA (7β-
OH-DHEA) and 7-keto-DHEA, AO, EO and T. No preliminary conclusions could be
drawn about the specificity of oxygenated steroids for DHEA, as these studied
steroids were not analyzed after ∆4-AEDIONE administration.
In this experiment 100 mg of DHEA was administered to 8 healthy male subjects.
The collected urine samples were analyzed with gas chromatography-mass
spectrometry (GC-MS) for DHEA metabolites (see Chapter 4) in addition to
oxygenated metabolites of ∆4-AEDIONE (see Chapter 5). Excretion data were
compared for a preliminary evaluation of the specificity of these metabolites as
parameters for DHEA. Additionally a re-evaluation was performed of the effect of oral
DHEA administration on the T/E ratio.
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EXPERIMENTAL
Chemicals
Reference steroids: Androst-5-en-3β-ol-17-one (dehydroepiandrosterone, DHEA),
androst-4-en-17α-ol-3-one (epitestosterone, E), 5α−androstan-3α-ol-17-one
(androsterone, AO), 5β−androstan-3α-ol-17-one (etiocholanolone, EO), androst-4-
ene-3,17-dione (androstenedione, ∆4-AEDIONE), androst-5-ene-3β,17β-diol
(androstenediol, ∆5-AEDIOL) and 17α-methyl-androst-4-en-11α,17β-diol-3-one (11α-
hydroxymethyltestosterone, 11α-OH-MeT) were obtained from Sigma, St. Louis,
Missouri, USA. Androst-4-en-17β-ol-3-one (testosterone, T), androst-5-ene-3β,7α-
diol-17-one (7α-hydroxy-DHEA, 7α-OH-DHEA) and androst-5-ene-3β,7β-diol-17-one
(7β-hydroxy-DHEA, 7β-OH-DHEA) were obtained through courtesy of Organon, Oss,
The Netherlands). Androst-4-en-4-ol-3,17-dione (4-hydroxy-androstenedione, 4-OH-
∆4-AEDIONE), androst-4-en-6α-ol-7,17-dione (6α-hydroxy-androstenedione, 6α-OH-
∆4-AEDIONE), androst-4-en-6β-ol-7,17-dione (6β-hydroxy-androstenedione, 6β-OH-
∆4-AEDIONE), androst-4-en-16α-ol-3,17-dione (16α-hydroxy-androstenedione, 16α-
OH-∆4-AEDIONE), androst-4-ene-6,7,17-trione (6-keto-androstenedione, 6-keto-∆4-
AEDIONE), androst-5-ene-3β,16α-diol-17-one (16α-hydroxy-DHEA, 16α-OH-DHEA),
androst-5-en-3β-ol-7,17-dione (7-keto-DHEA), androst-4-en-6β,17β-ol-7-one (6β-
hydroxy-testosterone, 6β-OH-T), 5α−androstane-3α,16α-diol-17-one (16α-hydroxy-
androsterone, 16α-OH-AO), 5β−androstane-3α,16α-diol-17-one (16α-hydroxy-
etiocholanolone, 16α-OH-EO) and 5α-androstan-3α-ol-7,17-dione (7-keto-
androsterone, 7-keto-AO) were obtained from Steraloids, Newport, Rhode Island,
USA.
Chemicals: N-Methyl-N-trimethylsilyltrifluoroacetamide (MSTFA) was obtained from
Aldrich Chemical Company, Milwaukee, Winsconsin, USA. Ammonium iodide was
obtained from Fluka Chemie, Buchs, Switzerland. Ethanethiol was obtained from
Acros Organics, New Jersey, USA. Diethyl ether was obtained from Merck,
Darmstadt, Germany. Hydrolysis was performed with Helix pomatia (type HP-2,
containing 110.000 IU/ml β-glucuronidase and 1000-5000 IU/ml arylsulfatase),
obtained from Sigma, St. Louis, Missouri, USA. Columns for solid-phase extraction
were IST Isolute C18 columns (200 mg, non-endcapped) obtained from Sopachem,
Lunteren, The Netherlands.
Sample collection
Urine samples of 8 male (ages 22-31 years, mean 25.4, standard error of the mean
(SEM) 3.9; weights 57-105 kg, mean 75.4, SEM 15.9) were collected every 2 hours
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and overnight during two successive days. On the second day at 9 a.m. an in-house
prepared capsule containing 100 mg of DHEA was administered orally. For each
collected urine sample the exact void time, volume and specific gravity (Urine
Specific Gravity Refractometer, Atago, Japan) was recorded. Samples were stored at
-20°C until time of analysis. Informed consent was obtained from the volunteers.
Sample preparation
The volume of urine that was sampled for the analysis was determined on the basis
of specific gravity of the urine samples, according to:
5*
1d
020.0V
−
=  ml
A maximum volume of 15 ml was applied. 11α-OH-MeT (500 ng) was added to the
samples as internal standard. Solid-phase extraction was performed with C18
columns. Before applying urine samples, the column material was preconditioned by
washing with 4 ml of methanol and equilibrated with 2 ml of water. Inorganic material
was removed from the column by washing with 2 ml of water. The remaining
compounds were collected by elution with 4 ml of methanol. After evaporation to
dryness, 2 ml of acetate buffer (0.1 M, pH 5.2) were added to the extract. Hydrolysis
was performed by addition of 100 µl of Helix pomatia followed by incubation for
1 hour at 55°C. Steroids were isolated from the buffer solution by extraction with 5 ml
of diethyl ether, twice. After extraction the phase separation was optimized by
centrifugation (4000 rpm, 5 min). The organic layer was removed and evaporated to
dryness under a stream of nitrogen at 40°C. The extract was dried overnight over
P2O5/KOH under reduced pressure. Derivatization was performed by incubation of
the extract in 100 µl of MSTFA/NH4I/ethanethiol (1000:2:3; v/w/v) at 80°C for 30 min.
Gas chromatography and mass spectrometry
Selected ion monitoring (SIM) was performed with a Hewlett Packard gas
chromatograph (Model 5890, Agilent Technologies, Waldbronn, Germany) coupled to
a Hewlett Packard quadrupole mass spectrometer (Model 5972A). Ionization was
performed in electron ionization  (EI) mode at 70 eV. Quantification of steroids was
performed by monitoring ions at the following m/z values: 430 (∆4-AEDIONE, 7α-OH-
DHEA, 7β-OH-DHEA and 7-keto-AO), 432 (T, E and DHEA), 434 (AO, EO and ∆5-
AEDIOL), 518 (6α/β-OH∆4-AEDIONE, 4-OH-∆4-AEDIONE), 520 (6α/β-OH-T, 16α-
OH-DHEA), 507 (16α-OH-AO and 16α-OH-EO), 517 (7-keto-DHEA), 503 (16α-OH-
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∆4-AEDIONE) and 534 (11α-OH-MeT). A check for possibly incomplete
derivatization was performed by detection of ions representing mono-TMS
derivatives of AO and EO at m/z 362.
Gas chromatography was performed with a HP-1 fused silica column (length 18 m,
inner diameter 0.2 mm, film thickness 0.11 µm). Through electronic pressure control
the column flow (helium) was constantly 1 ml/min.  Sample injection of 1 µl was
performed in split mode (ratio 1/10). A Hewlett Packard autosampler (Model 7673,
Agilent Technologies, Waldbronn, Germany) was used for autoinjection. The injector
temperature was set to 250°C. The oven temperature program used was: initial
temperature 180°C, 2°/min to 225°C, 30°/min up to 310°C, constant for 5 min. The
interface temperature was set to 280°C.
The quality of DHEA was checked by GC-MS analysis in full scan mode prior to
administration. No impurities could be detected in a concentrated derivatized sample
of the substance.
Calibration, quantification and validation
The obtained urine samples were analyzed for DHEA and ∆4-AEDIONE metabolites
in two separate analyses. The calibration procedure for 7α-OH-DHEA, 7β-OH-DHEA,
7-keto-DHEA, 16α-OH-DHEA and 7-keto-AO is described in Chapter 4. Calibration of
all other metabolites is described in Chapter 5. The corresponding validation data are
described in the same chapters (intra- and inter-assay variability, recovery, stability
and side reactions during hydrolysis).
As mentioned in Chapter 5 and worked out in detail in Chapter 8, the applied
derivatization method results in loss of stereochemical integrity at C6 of ∆4-steroids.
Therefore, 6α- and 6β-hydroxy-steroids are combined in one single derivative
(indicated as 6α/β-OH).
Statistical analysis
Absolute difference in total 24-hours excretion rate were tested by Student’s one-
tailed paired t-test with p<0.05 considered as significant. Normalized excretion
differences, confidence intervals and individual T/E ratio differences were tested by
Student’s one-tailed (non-paired) t-test with p<0.05 considered as significant.
Assumed normality of excretion rates was tested with the Kolmogorov test (p<0.05).
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RESULTS
The absolute 24-hours excretion rate before and after administration are listed in
Table 1. As a marker of sensitivity, the difference in 24 hours excretion was
normalized with the basal excretion (expressed as %).
Of the non-oxygenated steroids, DHEA and ∆5-AEDIOL showed the largest
normalized excretion difference. Urinary concentrations of AO and EO were relatively
high, but the effect of administration on the excretion rate was limited. With exception
of 6α/β-OH-∆4-AEDIONE, ∆4-steroids showed the least normalized difference with a
minimum for T and E. Significantly increased excretion of oxygenated metabolites
occurred , ranging from 55% for 6α/β-OH-T to 1163% for 7β-OH-DHEA.
For each studied parameter the mean DHEA conversion was calculated (see Table
1). In 24 hours of urine sample collection after time of administration, 39.5 ± 7.8 %
(mean ± SEM) from the administered dose was recovered as the total of DHEA and
its metabolites. The conversion to oxygenated steroids was small as compared to
non-oxygenated steroids (see Table 2).
Calculated upper confidence limits (p<0.05), based on pre-administration excretion
values, are listed in Table 3. The time period in which excretion exceeded the
reference range was similar for most steroids (0-14 hours, see Table 3), except for
DHEA, ∆5-AEDIOL and EO (24 hours) and T and E (6-8 hours).
In Figures 1 and 2 the mean excretion rates are shown for each individual time
interval (in µg/hour).  Because the timing of sample collection did not match the 2
hours interval as presented in the figures, two subjects were omitted from these
results.
In Table 4, data are shown of the T/E ratio for each individual subject. A significant
increase was observed for all subjects. Data for steroid ratios that were calculated for
each time interval are shown in Figure 3. Where relatively small effects were
observed for the T/E, AO/EO and 16α-OH-AO/16α-OH-EO ratio, the 7β-/7α-OH-
DHEA ratio was significantly elevated for 14 hours.
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Table 1: Excretion data before and after administration of DHEA to 8 male Caucasian
subjects. Results are placed in order of decreasing difference in excretion rate.
Absolute and normalized excretion differences were all statistically significant
(p<0.05).
Parameter µg/24 hours
before
administration
mean ± SEM
µg/24 hours
after
administration
mean ± SEM
normalized
difference (%)
in excretion rate
mean ± SEM
conversion
(% of DHEA)
mean ± SEM
DHEA 1896.2 ± 1576.4 18880.5 ± 7185.1 2182 ± 2309   16.98 ± 6.29
7β-OH-DHEA     47.6 ± 39.0     470.5 ± 314.2 1163 ± 721     0.40 ± 0.27
∆5-AEDIOL   427.7 ± 325.2   2192.6 ± 690.4   615 ± 488     1.71 ± 0.62
7-keto-AO     10.7 ± 8.9       40.4 ± 12.8   502 ± 449     0.03 ± 0.02
6α/β-OH-∆4-AEDIONE       2.2 ± 1.5       11.2 ± 3.3   474 ± 272   0.009 ± 0.003
16α-OH-AO   127.1 ± 63.3     628.9 ± 250.2   451 ± 237     0.47 ±  0.20
16α-OH-EO   176.3 ± 108.9     670.8 ± 487.0   394 ± 336     0.47 ± 0.46
AO 3010.6 ± 1055.1 13240.7 ± 4033.1   388 ± 244   10.16 ± 3.77
EO 2659.9 ± 1187.8 10524.2 ± 2146.1   370 ± 236     7.81 ± 2.61
7α-OH-DHEA     32.6 ± 20.5     126.5 ± 61.8   334 ± 132     0.09 ± 0.04
16α-OH-DHEA   933.0 ± 665.5   2103.7 ± 800.0   318 ± 494     1.11 ± 0.54
7-keto-DHEA     89.0 ± 54.6     214.1 ± 91.8   189 ± 154     0.12 ± 0.07
4-OH-∆4-AEDIONE     39.8 ± 8.1       94.1 ± 18.7   143 ± 64   0.052 ± 0.018
16α-OH-∆4-AEDIONE     25.9 ± 8.5       46.9 ± 22.3     87 ± 59   0.020 ± 0.017
6α/β-OH-T       3.0 ± 2.1         4.9 ± 3.2     55 ± 34 0.0017 ± 0.0014
T     62.5 ± 30.4       91.1 ± 40.6     49 ± 30   0.029 ± 0.021
E     41.3 ± 9.3       48.4 ± 14.8     17 ± 20   0.007 ± 0.009
Table 2: Conversion of DHEA to different groups of
metabolites during first 24 hours (n=8).
Group of metabolites Average DHEA
conversion (%)
AO and EO 18.0 ± 6.0
non-oxygenated metabolites 19.7 ± 6.0
oxygenated metabolites 2.8 ± 0.9
total of all metabolites 22.5 ± 6.1
total recovery DHEA + metabolites 39.5 ± 7.8
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Table 3: Confidence limits (p<0.05) for the mean excretion rate
(µg/hour), calculated over the pre-administration day; and the
post-administration time period in which the excretion rate of
the respective steroid exceeded the upper confidence limit.
Parameter Calculated upper
confidence limit
(p<0.05, in µg/hour)
Period (hours) of significant
post-administration elevation
of excretion
DHEA 133.81 0-24
7β-OH-DHEA 3.34 0-14
∆5-AEDIOL 31.00 0-24
7-keto-AO 0.76 0-14
6α/β-OH-∆4-AE 0.14 0-24
16α-OH-AO 7.50 0-14
16α-OH-EO 11.13 0-14
16α-OH-DHEA 62.01 0-12
AO 162.13 0-14
EO 152.13 0-24
7α-OH-DHEA 2.07 0-14
7-keto-DHEA 5.61 0-10
4-OH-∆4-AEDIONE 1.94 0-14
16α-OH-∆4-AEDIONE 1.38 0-10
6α/β-OH-T 0.20 0-10
T 3.66 2-8
E 2.04 0-6
Table 4: Individual results for the T/E ratio before and after DHEA
administration.
Subject Mean T/E
day 1
SEM T/E
day 1
Maximum T/E
day 2
Normalized
difference (%)
1 0.091 0.0089 0.14 54
2 1.1 0.094 2.0 82
3 2.1 0.33 4.2 100
4 2.3 0.30 4.1 78
5 2.7 0.25 4.1 52
6 2.2 0.24 3.2 45
7 2.1 0.22 6.1 190
8 1.0 0.12 1.8 80
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Figure 1: Excretion rate in µg/hour (mean ± SEM, n=6) of non-oxygenated steroids, before
and after DHEA administration (at time point 24 hours). Increased mean
excretion rates with statistical significance (p<0.05) are indicated as hatched
columns (        ).
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Figure 2a: Excretion rates in µg/hour (mean ± SEM, n=6) of oxygenated steroids,
before and after DHEA administration (at time point 24 hours).
Increased mean excretion rates with statistical significance (p<0.05) are
indicated as hatched columns (       ).
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Figure 2b:Excretion rates in µg/hour (mean ± SEM, n=6) of oxygenated steroids, before and
after DHEA administration (at time point 24 hours). Increased mean excretion
rates with statistical significance (p<0.05) are indicated as hatched columns
(        ).
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Figure 3: Ratio’s (mean ± SEM, n=6) of excretion rates of several steroids, before and after
DHEA administration (at time-point 24 hours). Increased mean excretion rates
with statistical significance (p<0.05) are indicated as hatched columns (       ).
Decreased mean excretion rates (p<0.05) are indicated by diagonal striping
(        ).
DISCUSSION
DHEA conversion
The 40% total recovery of DHEA and its metabolites was comparable to the results in
Chapter 4. However, in the present experiment a higher recovery for DHEA
(17.0 ± 6.3% vs. 0.3% and 2.6% in Chapter 4) and a lower conversion to AO and EO
was calculated. Also, a relatively high conversion to oxygenated metabolites was
obtained compared to Chapter 4. As reported by Dehennin et al. [3] recovery of
seemingly non-metablized DHEA can mostly be ascribed to excretion of DHEA-
sulfate. Sulfate transferase could have less affinity for deuterium labeled DHEA as for
DHEA itself, resulting in a relatively low second phase metabolism of DHEA and a
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relatively high conversion to AO and EO. These can be regarded as isotope effects
as has been discussed in Chapters 4 and 5 [4].
Sensitivity and specificity
AO and EO are metabolites of multi-origin that are excreted in large amounts (0.5-10
µg/ml) [5,6]. Published data mostly assign sensitivity to these metabolites for
detection of DHEA [1,3,7-9]. However, as presented in Table 1, several other
steroids showed a larger difference in mean excretion rate. Besides the ∆5-steroids
DHEA, ∆5-AEDIOL and 7β-OH-DHEA, these were oxygenated derivatives of AO and
EO, i.e. 7-keto-AO, 16α-OH-AO and 16α-OH-EO. The high sensitivity of 6α/β-OH-∆4-
AEDIONE is striking and can only be explained by the metabolism of ∆4-AEDIONE.
This experiment confirms the conclusion of Chapter 4 that studying quantitatively
minor routes of DHEA metabolism (oxygenation) can provide information of
comparable sensitivity as the major routes.
Before DHEA administration, 7α-OH-DHEA concentration was smaller than 7β-OH-
DHEA, resulting in a basal 7β-OH-DHEA/7α-OH-DHEA level between 1 and 2. The
different sensitivity of the two stereoisomers for DHEA was illustrated by the
significantly increased 7β-OH-DHEA/7α-OH-DHEA ratio to an average of 7,
immediately after administration.
Such a difference in sensitivity was less obvious for AO/EO and 16α-OH-AO/16α-
OH-EO, which only slightly exceeded the respective confidence limits. As also
described in Chapter 4 the increase was followed by a decrease to a level that was
significantly below baseline until 24 hours after administration.
With exception of 6α/β-OH-∆4-AEDIONE, the sensitivity of ∆4-steroids was low
(<150%). Of these steroids 4-OH-∆4-AEDIONE, 6α/β-OH-T and T were identified as
sensitive parameters for establishing ∆4-AEDIONE administration in Chapter 5.
Therefore, these metabolites can be considered as specific parameters for
∆4-AEDIONE.
T/E ratio
In this experiment, T and E showed little sensitivity. The negligible conversion of
orally administered DHEA to T in males was reported before, based on plasma data
[10-12]. In females a small but significant T production was observed [13,14].
Several previously reported studies have focussed on the alteration of the T/E ratio
after oral DHEA administration, with contradicting results. Bosy et al. [15] and
Dehennin et al. [3] did not record significant changes after administration of 50 mg of
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DHEA to 7 male volunteers. In other studies with limited numbers of subjects
increased T/E ratios were observed for a dose regimen of 50-150 mg [1,8,9].
Our results showed a significantly increased T/E ratio in all 8 subjects with a
maximum increase of 45-190% (see Table 4). Only one subject marginally passed
the IOC criterion for the T/E ratio of 6. However, in doping analysis the T/E ratio and
the corresponding cutoff level are based on the analysis of isolated glucuronides. In
that case, the maximum T/E ratio should be higher than as observed in this
experiment [16].  As shown in Figure 4, intra-subject mean T/E ratios during the pre-
administration day correlate with the corresponding maximum T/E ratios after
administration (coefficient of determination of 0.7448). This model implicates that a
rough estimation can be made for the expected maximum T/E ratio, based on the
intraindividual mean basal T/E ratio and the particular dose level.
Figure 4: Correlation of the intra-subject mean T/E ratio during the pre-administration day
(day 1) with the maximum T/E ratio during the post-administration day (day 2)
SUMMARY
In addition to AO and EO, the steroids DHEA, ∆5-AEDIOL and 7β-OH-DHEA, 7-keto-
AO, 16α-OH-AO and 16α-OH-EO provided sensitive information about administration
of DHEA. Furthermore, 4-OH-∆4-AEDIONE, 6α/β-OH-T and T were indicated as
specific parameters of ∆4-AEDIONE administration. In contrast to other previously
reported studies, the T/E ratio significantly increased in all eight subjects. The extent
of increase depended on the intra-subject mean T/E ratio before administration.
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7
SPECIFIC DETECTION OF ANDROST-4-ENE-3,17-DIONE
ADMINISTRATION BY PROFILING OXYGENATED
METABOLITES
Abstract
For the selective detection of androst-4-ene-3,17-dione (∆4-AEDIONE) administration, the
analysis of several oxygenated metabolites in urine was suggested previously to apply in
steroid profiling techniques. In this experiment, excretion studies with ∆4-AEDIONE were
performed with 5 male subjects, to provide information about sensitivity and specificity of
these metabolites as parameters in steroid profiling. Analysis with gas chromatography with
mass spectrometric detection was applied upon the combined fraction of glucuronides,
sulfates and non-conjugated steroids.
Sensitivity, defined as the relative increase in 24-hours excretion rate after administration
compared to the mean basal excretion rate, was ascribed to 4-hydroxy-∆4-AEDIONE,
6α/β-hydroxy-∆4-AEDIONE, androsterone, etiocholanolone and testosterone.
The metabolites that provided the best specificity for ∆4-AEDIONE were testosterone,
6α/β-hydroxy-testosterone and 4-hydroxy-∆4-AEDIONE. The most specific steroid ratio was
7β-hydroxy-DHEA/7α-hydroxy-DHEA. DHEA, androst-5-ene-3β,17β-diol, 7β-hydroxy-DHEA
and 7-keto-androsterone were confirmed as specific parameters for DHEA.
The T/E ratio was increased after administration in all studied subjects. A high correlation
was observed between the mean T/E ratio during the pre-administration period, and the
maximum T/E ratio that was detected after administration. This implicates that the expected
maximum T/E ratio can be estimated, based on the intraindividual mean basal T/E ratio.
One Asian subject showed relatively low basal excretion rate values. Also, the effect of
∆4-AEDIONE administration on metabolite excretion was relatively large. Except a low basal
T/E ratio, no relevant difference was observed in its response after administration.
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INTRODUCTION
Recent years, an increasing number of steroids of endogenous origin are marketed
as food supplements. Since 1997 several of these steroids, such as
dehydroepiandrosterone (DHEA) and androst-4-ene-3,17-dione (∆4-AEDIONE), have
been placed on the list of forbidden substances of the International Olympic
Committee. Usually applied profiling of non-specific androgens, as testosterone (T),
epitestosterone (E), androsterone (AO) and etiocholanolone (EO) [1,2] provides
insufficiently specific information, to enable identification of the administered steroid.
In Chapter 3 several oxygenated steroids were introduced that could serve as
specific parameters for detection of DHEA or ∆4-AEDIONE abuse. Despite the fact
that oxygenation reactions are quantitatively minor metabolic routes, it was shown in
Chapters 4 and 5 that the analysis of these steroids provides a comparable range in
sensitivity as the described non-specific parameters.  Therefore, screening a profile
of oxygenated metabolites could be useful to supply additional information needed
for identification.
In this study, specificity and sensitivity of the presented profile of oxygenated
metabolites (Chapter 5) for detection of ∆4-AEDIONE administration was
investigated. Therefore, excretion studies with ∆4-AEDIONE were performed with 5
male subjects. The metabolism was studied by analyzing the collected urine samples
for non-oxygenated and oxygenated metabolites of ∆4-AEDIONE (see Chapter 5)
and DHEA (see Chapters 4 and 6).
The Asian race is often described as example of genetically determined variation in
steroid metabolism. In doping analysis, this is most obvious for the relatively low T/E
ratio as compared to other populations (see Chapter 1) [3]. In a case study by Uralets
et al. [1], a different metabolism of ∆4-AEDIONE in Asian subjects was suggested,
leading to significantly different effects on the T/E ratio. In the present study,
differences in (non-)oxygenative ∆4-AEDIONE metabolism between one Asian and
four Caucasian subjects was investigated.
EXPERIMENTAL
Chemicals
Reference steroids: Androst-5-en-3β-ol-17-one (dehydroepiandrosterone, DHEA),
androst-4-en-17α-ol-3-one (epitestosterone, E), 5α−androstan-3α-ol-17-one
(androsterone, AO), 5β−androstan-3α-ol-17-one (etiocholanolone, EO), androst-4-
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ene-3,17-dione (androstenedione, ∆4-AEDIONE), androst-5-ene-3β,17β-diol
(androstenediol, ∆5-AEDIOL) and 17α-methyl-androst-4-en-11α,17β-diol-3-one (11α-
hydroxymethyltestosterone, 11α-OH-MeT) were obtained from Sigma, St. Louis,
Missouri, USA. Androst-4-en-17β-ol-3-one (testosterone, T), androst-5-ene-3β,7α-
diol-17-one (7α-hydroxy-DHEA, 7α-OH-DHEA) and androst-5-ene-3β,7β-diol-17-one
(7β-hydroxy-DHEA, 7β-OH-DHEA) were obtained through courtesy of Organon, Oss,
The Netherlands). Androst-4-en-4-ol-3,17-dione (4-hydroxy-androstenedione, 4-OH-
∆4-AEDIONE), androst-4-en-6α-ol-7,17-dione (6α-hydroxy-androstenedione, 6α-OH-
∆4-AEDIONE), androst-4-en-6β-ol-7,17-dione (6β-hydroxy-androstenedione, 6β-OH-
∆4-AEDIONE), androst-4-en-16α-ol-3,17-dione (16α-hydroxy-androstenedione, 16α-
OH-∆4-AEDIONE), androst-4-ene-6,7,17-trione (6-keto-androstenedione, 6-keto-∆4-
AEDIONE), androst-5-ene-3β,16α-diol-17-one (16α-hydroxy-DHEA, 16α-OH-DHEA),
androst-5-en-3β-ol-7,17-dione (7-keto-DHEA), androst-4-en-6β,17β-ol-7-one (6β-
hydroxy-testosterone, 6β-OH-T), 5α−androstane-3α,16α-diol-17-one (16α-hydroxy-
androsterone, 16α-OH-AO), 5β−androstane-3α,16α-diol-17-one (16α-hydroxy-
etiocholanolone, 16α-OH-EO) and 5α-androstan-3α-ol-7,17-dione (7-keto-
androsterone, 7-keto-AO) were obtained from Steraloids, Newport, Rhode Island,
USA.
Chemicals: N-Methyl-N-trimethylsilyltrifluoroacetamide (MSTFA), ethanethiol (97%),
and phosphorous pentoxide were obtained from Sigma-Aldrich Chemie Company,
Steinheim, Germany. Ammonium iodide was obtained from Fluka Chemie, Buchs,
Switzerland. Potassium hydroxide, sodium acetate trihydrate, glacial acetic acid
(96%), diethyl ether, acetic acid and methanol were obtained from Merck, Darmstadt,
Germany. All chemicals were of analytical grade, unless indicated otherwise.
Hydrolysis was performed with Helix pomatia (type HP-2, containing 110.000 IU/ml β-
glucuronidase and 1000-5000 IU/ml arylsulfatase), obtained from Sigma-Aldrich,
Steinheim, Germany.
Columns for solid-phase extraction were IST Isolute C18 columns (200 mg, non-
endcapped) obtained from Sopachem, Lunteren, The Netherlands.
Sample collection
Urine samples of 5 male subjects (age 22-39 years) were collected every 2 hours
and overnight, during two days. On the second day at 9 a.m. an in-house prepared
capsule containing 100 mg of ∆4-AEDIONE was administered orally. For each
collected urine sample the exact void time, volume and specific gravity (Urine
Specific Gravity Refractometer, Atago, Japan) was recorded. Samples were stored at
-20°C until time of analysis.
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Sample preparation
The volume of urine that was sampled for the analysis was determined on the basis
of specific gravity of the urine, according to:
5*
1d
020.0V
−
=  ml
A maximum volume of 15 ml was applied. 11α-OH-MeT (500 ng) was added to the
samples as internal standard. Solid-phase extraction was performed with non-
endcapped C18 columns. Before applying urine samples, the column material was
preconditioned by washing with 4 ml of methanol and equilibrated with 2 ml of water.
Inorganic material was removed from the column by washing with 2 ml of water. The
remaining compounds were collected by elution with 4 ml of methanol. After
evaporation to dryness, 2 ml of acetate buffer (0.1 M, pH 5.2) were added to the
extract. Hydrolysis was performed by addition 100µl of Helix pomatia followed by
incubation for 1 hour at 55°C. Steroids were isolated from the buffer solution by
extraction with 5 ml of diethyl ether, twice. After extraction, the phase separation was
optimized by centrifugation (4000 rpm, 5 min). The organic layer was removed and
evaporated to dryness under a stream of nitrogen at 40°C. The extract was dried
overnight over P2O5/KOH under reduced pressure. Derivatization was performed by
incubation of the extract in 100 µl of MSTFA/NH4I/ethanethiol (1000:2:3; v/w/v) at 80
°C for 30 min. The derivatization mixture was injected into the gas chromatography-
mass spectrometry (GC-MS) system for analysis.
Gas chromatography and mass spectrometry
Selected ion monitoring (SIM) was performed with a Hewlett Packard gas
chromatograph (Model 5890, Agilent Technologies, Waldbronn, Germany) coupled
top a Hewlett Packard quadrupole mass spectrometer (Model 5972A). Ionization was
performed in electron ionization  (EI) mode at 70 eV. Quantification of steroids was
performed by monitoring ions at the following m/z values: 430 (∆4-AEDIONE, 7α-OH-
DHEA, 7β-OH-DHEA and 7-keto-AO), 432 (T, E and DHEA), 434 (AO, EO and ∆5-
AEDIOL), 518 (6α/β-OH∆4-AEDIONE, 4-OH-∆4-AEDIONE), 520 (6α/β-OH-T, 16α-
OH-DHEA), 507 (16α-OH-AO and 16α-OH-EO), 517 (7-keto-DHEA), 503 (16α-OH-
∆4-AEDIONE) and 534 (11α-OH-MeT). A check for possibly incomplete
derivatization was performed by detection of ions representing mono-TMS
derivatives of AO and EO at m/z 362.
Gas chromatography was performed with a HP-1 fused silica column (length 18 m,
inner diameter 0.2 mm, film thickness 0.11 µm). Through electronic pressure control
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the column flow (helium) was constantly 1 ml/min.  Sample injection of 1 µl was
performed in split mode (ratio 1/10). A Hewlett Packard autosampler (Model 7673,
Agilent Technologies, Waldbronn, Germany) was used for autoinjection. The injector
temperature was set to 250°C. The oven temperature programme used was: initial
temperature 180°C, 2°/min to 225°C, 30°/min up to 310°C, constant for 5 min. The
interface temperature was set to 280°C.
The quality of ∆4-AEDIONE was checked by gas chromatography-mass
spectrometry (GC-MS) in full scan mode prior to administration. No impurities could
be detected in a concentrated sample.
Calibration, quantification and validation
The obtained urine samples were analyzed for DHEA and ∆4-AEDIONE metabolites
in two separate analyses. The calibration procedure for 7α-OH-DHEA, 7β-OH-DHEA,
7-keto-DHEA, 16α-OH-DHEA and 7-keto-AO is described in Chapter 4. Calibration of
all other metabolites is described in Chapter 5. The corresponding validation data are
also described in Chapter 4 and 5 (intra- and inter-assay variability, recovery, stability
and side reactions during hydrolysis).
Statistical analysis
Absolute differences in total 24-hours excretion rate were tested by Student’s one-
tailed paired t-test with p<0.05 considered as significant. Normalized excretion
differences, confidence limits and differences in individual data for the T/E ratio were
tested by Student’s one-tailed t-test with p<0.05 considered as significant. One
subject of Asian origin was excluded from the calculation of mean excretion rates,
normalized excretion differences, conversion and confidence limits. Assumed
normality of excretion rates was tested with the Kolmogorov test (p<0.05).
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RESULTS
The 24-hour pre- and post-administration excretion data are listed in Table 1. As a
marker of sensitivity, the difference in 24-hours excretion was normalized with the
basal excretion (expressed as %). For each parameter the mean conversion of
∆4-AEDIONE was calculated.
The oxygenated steroids 4-OH-∆4-AEDIONE and 6α/β-OH-∆4-AEDIONE showed the
largest normalized excretion difference. Negligible sensitivity was observed for 7β-
OH-DHEA, 7-keto-DHEA and 16α-OH-DHEA. From the administered dose,
39.5 ± 3.2% was recovered as the total of all ∆4-AEDIONE metabolites in 24 hours
after time of administration. The observed conversion was mostly explained by the
metabolism to AO and EO. Relatively little ∆4-AEDIONE was converted to
oxygenated metabolites (see Table 2).
Table 1: Excretion data before and after administration of ∆4-AEDIONE of four male
Caucasian subjects. Results are placed in order of decreasing difference in
excretion rate.
Parameter µg/24 hours
before
administration
mean ± SEM
µg/24 hours
after
administration
mean ± SEM
normalized
difference (%)
in excretion rate
mean ± SEM
conversion (%
∆4-AEDIONE)
mean ± SEM
4-OH-∆4-AEDIONE 37.4 ± 7.9   491.5 ± 239.3   1304 ± 875   0.43 ± 0.23 *
6α/β-OH-∆4-AEDIONE   4.7 ± 2.1   48.9 ± 16.9  1016 ± 389   0.042 ± 0.015 *
EO   3073.3 ± 1880.3 19867.6 ± 3322.0    697 ± 372 16.68 ± 2.62 *
AO 3077.7 ± 680.5 22983.7 ± 4377.1    677 ± 245 19.77 ± 4.49 *
T   38.8 ± 13.3    214.3 ± 132.1    426 ± 145   0.18 ± 0.12 *
6α/β-OH-T   4.2 ± 1.3 11.9 ± 3.5  186 ± 44   0.007 ± 0.002 *
16α-OH-AO   209.6 ± 179.8   471.3 ± 208.3    184 ± 121   0.62 ± 0.60 *
DHEA   779.3 ± 796.7   1747.0 ± 2020.4  114 ± 60   0.97 ± 1.24 **
7-keto-AO    3.6 ± 1.3   7.2 ± 2.5  104 ± 60   0.003 ± 0.002 *
16α-OH-EO   322.3 ± 186.7   564.9 ± 227.6    98 ± 60    0.63 ± 0.60 *
7α-OH-DHEA   48.6 ± 40.2   64.7 ± 39.5    88 ± 94    0.015 ± 0.032
E 59.1 ± 8.9 85.6 ± 9.6    68 ± 23    0.034 ± 0.008 *
16α-OH-∆4-AEDIONE   33.8 ± 16.1    48.6 ± 23.1    46 ± 19    0.014 ± 0.010 *
∆5-AEDIOL   342.6 ± 142.3   488.0 ± 323.8    35 ± 39    0.14 ± 0.20
16α-OH-DHEA   664.3 ± 691.7   658.2 ± 433.1    28 ± 39 -0.006 ± 0.34
7-keto-DHEA    64.9 ± 24.4   62.4 ± 12.3      5 ± 33   -0.002 ± 0.013
7β-OH-DHEA   37.6 ± 16.2 34.9 ± 8.7     -1 ± 20   -0.002 ± 0.007
*  = Statistical significance for the 24-hours excretion rate, as well as for the normalized difference
(%).
** = Only statistical significance for the normalized difference (%).
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Table 2: Conversion of ∆4-AEDIONE to different
groups of metabolites during the first 24
hours after administration (n=4).
Group of metabolites ∆4-AEDIONE conversion
(mean ± SEM; in %)
AO and EO 36.5 ± 3.4
non-oxygenated 37.8 ± 3.6
oxygenated 1.76 ± 1.42
total 39.5 ± 3.2
Estimated upper confidence limits (p<0.05, n=4), based on 24-hours excretion values
are listed in Table 3. All metabolite excretion rates returned to baseline level within
24 hours after administration.
Table 3: Confidence limits (p<0.05) for the mean excretion rate (µg/hour),
calculated over the pre-administration day; and the post-
administration time period in which the excretion rate of the
respective steroid exceeded the upper confidence limit.
Parameter Upper confidence limit
( p<0.05; in µg/hour)
Period (hours) of significant
post-administration elevation
of excretion
4-OH-∆4-AEDIONE 2.08 14-24
6α/β-OH-∆4-AEDIONE 0.332 8-10
EO 252.62 12-14
AO 173.32 12-14
T 2.50 10-12
6α/β-OH-T 0.262 8-10
16α-OH-AO 14.38 8-10
DHEA 85.25 4-6
7-keto-AO 0.24 6-8
16α-OH-EO 28.72 4-6
7α-OH-DHEA 4.69 4-6
E 2.75 6-8
16α-OH-∆4-AEDIONE 2.47 4-6
∆5-AEDIOL 23.70 4-6
16α-OH-DHEA 73.50 -
7-keto-DHEA 4.32 -
7β-OH-DHEA 2.64 -
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In Figures 1 and 2 the mean excretion rates are shown for each individual time
interval (in µg/hour). The ratios AO/EO, 16α-OH-AO/16α-OH-EO, T/E and 7β-OH-
DHEA/7α-OH-DHEA are shown in Figure 3. Both AO/EO and 16α-OH-AO/16α-OH-
EO showed a non-significant increase followed by a decrease under baseline levels.
The T/E ratio showed a significant increase and 7β-OH-DHEA/7α-OH-DHEA a
significant decrease. T/E ratio data for each studied individual are presented in
Table 4.
In Table 5, the 24-hours excretion data before and after administration are listed for
the Asian subject. Relatively low basal excretion rates and high normalized excretion
differences were observed for most studied steroids. The T/E ratio was low compared
to the Caucasians, but no relevant kinetic differences were observed for any of the
studied steroid ratios (see Figure 4).
A high correlation was observed between intra-subject mean T/E ratios during the
pre-administration day and the corresponding maximum T/E ratios after
administration is (coefficient of determination of 0.9882, see Figure 5). No such
correlation was found for AO/EO, 16α-OH-AO/16α-OH-EO or 7β-OH-DHEA/7α-OH-
DHEA (data not shown). As indicated in Figure 5 the effect on the T/E ratio in the
Asian subject also matched this correlation.
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Figure 1: Excretion rates in µg/hour (mean ± SEM, n=4, Caucasians) of main non-
oxygenated steroids, before and after ∆4-AEDIONE administration (at time point
24 hours). Increased mean excretion rates with statistical significance (p<0.05)
are indicated as hatched columns (       ).
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Figure 2a: Excretion rates in µg/hour (mean ± SEM, n=4, Caucasians) of oxygenated
steroids, before and after ∆4-AEDIONE administration (at time point 24 hours).
Increased mean excretion rates with statistical significance (p<0.05) are indicated
as hatched columns (       ).
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Figure 2b: Excretion rates in µg/hour (mean ± SEM, n=4, Caucasians) of oxygenated
steroids, before and after ∆4-AEDIONE administration (at time point 24 hours).
Increased mean excretion rates with statistical significance (p<0.05) are indicated
as hatched columns (       ).
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Figure 3: Ratios (mean ± SEM) of excretion rates of several steroids, before and after ∆4-
AEDIONE administration (at time point 24 hours). Increased mean excretion
rates with statistical significance (p<0.05) are indicated as hatched columns
(       ). Decreased mean excretion rates (p<0.05) are indicated by diagonal
stipings (        ).
Table 4: Individual results for the T/E ratio before and after ∆4-AEDIONE
administration.
volunteer mean T/E ± SEM
day 1
CV (%)1)
day 1
maximum T/E
day 2
difference (%)
1 0.58 ± 0.06 10 2.82 386
2 1.04 ± 0.05 5 6.00 477
3 0.68 ± 0.28 41 3.49 413
4 0.73 ± 0.07 10 3.85 427
 52) 0.14 ± 0.01 7 0.63 350
1) Expressed as coefficient of variation (CV = SEM/mean*100%)
2)
 Subject of Asian origin
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Table 5: Excretion data of one male Asian before and after ∆4-AEDIONE administration .
Parameter µg/24 hours
before
administration
mean ± SEM
µg/24 hours
after
administration
mean ± SEM
normalized
difference (%)
in excretion rate
mean ± SEM
conversion (% ∆4-
AEDIONE)
mean ± SEM
4-OH-∆4-AEDIONE 10.7 971 8975 0.53
6α/β-OH-∆4-AEDIONE 3.58 64.2 1693 0.045
EO 1356 15128 1016 16.23
AO 1451 12813 783 18.17
T 5.59 20.4 265 0.14
6α/β-OH-T 4.25 15.7 269 0.008
16α-OH-AO 132 806 511 0.53
DHEA 1078 2428 125 1.04
7-keto-AO 4.90 6.50 33 0.004
16α-OH-EO 208 692 233 0.56
7α-OH-DHEA 24.2 174 619 0.041
E 39.6 73.1 85 0.034
16α-OH-∆4-AEDIONE 25.4 43.3 70 0.015
∆5-AEDIOL 439 702 60 0.17
16α-OH-DHEA 470 650 38 0.029
7-keto-DHEA 35.3 48.0 36 -0.015
7β-OH-DHEA 29.3 38.6 32 0.000
Figure 4: Ratios of excretion rates for the Asian subject. ∆4-AEDIONE was administered at
time point 24 hours.
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Figure 5: Correlation of the intra-subject mean T/E ratio during the pre-administration day
(day 1) with the maximum T/E ratio during the post-administration day (day 2).
The subject of Asian origin is indicated with “A”.
DISCUSSION
Conversion of ∆4-AEDIONE
In this study, a 2-4 times larger dose level of ∆4-AEDIONE was applied than in the
case of deuterium labeled ∆4-AEDIONE administration in Chapter 5. However, the
calculated conversion was comparable. The total recovery of metabolites after 24
hours was reproducibly around 40%, of which the largest part was accounted for the
metabolism to AO and EO (see Table 2). Quantitatively, the conversion to
oxygenated metabolites contributed only in minor extent to the total metabolism that
was observed. A comparison with the total conversion of DHEA in Chapters 4 and 6
shows that absorption of these orally administered steroids is comparable.
No data on ∆4-AEDIONE concentrations have been provided as concentrations in
blank urine samples were always low (estimated as <20-30 ng/ml). Also, the
chromatographic separation was often poor due to interference. This resulted in poor
reproducibility. Based on estimation, maximum excretion rates were always smaller
than 0.6-0.7 µg/hour, whereas baseline excretion rate was estimated as 0.1-0.2
µg/hour. This confirmed the results of Chapter 5 that ∆4-AEDIONE is almost
completely metabolized after oral administration.
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Sensitivity and specificity
As the conversion of ∆4-AEDIONE is explained for the major part by the metabolism
to AO and EO, these steroids have primarily been reported as sensitive parameters
for establishing ∆4-AEDIONE abuse [1,5,6]. In this experiment, AO and EO showed
around 700% increase in 24-hours excretion rate. The only metabolites that showed
a higher sensitivity than AO and EO were 6α/β-OH-∆4-AEDIONE and 4-OH-∆4-
AEDIONE (see Table 1). This is in agreement with the metabolism of deuterium
labeled ∆4-AEDIONE (Chapter 5).
Comparison of the presented data in Table 1 with the excretion data of DHEA
administration (Table 2 in Chapter 6) shows that the normalized excretion difference
of AO and EO was twice as high in this experiment. This illustrates a limited
specificity of AO and EO for ∆4-AEDIONE, which was greatly exceeded by
parameters as 4-OH-∆4-AEDIONE, 6α/β-OH-T and T.
The low sensitivity of 16α-OH-∆4-AEDIONE was in the same order of magnitude as
E (around 50% increase). Therefore, 16α-OH-∆4-AEDIONE could potentially be used
in a steroid ratio analogous to the T/E ratio [7] to correct for intraindividual variability
of steroid excretion. A potential steroid ratio with high sensitivity for ∆4-AEDIONE
could be 4-OH-∆4-AEDIONE/16α-OH-∆4-AEDIONE. However, in this experiment the
intraindividual variability of this ratio was not significantly lower than for the individual
excretion values (see Table 5). Based on these results a preliminary conclusion
should be drawn that the suggested ratio cannot be used to correct for intraindividual
excretion differences.
Table 6: Intra-subject mean and variability1) of excretion rates for 4-OH-∆4-AEDIONE and
16α-OH-∆4-AEDIONE, and the corresponding ratio. All values were calculated
from samples collected during day 1 (pre-administration samples, n=8).
4-OH-∆4-AEDIONE 16α-OH-∆4-AEDIONE 4-OH-∆4-AEDIONE /16α-∆4-AEDIONE
subject   mean   CV
(µg/hour)    (%)
  mean   CV
(µg/hour)    (%)
mean   CV
   (-)         (%)
1   1.38  40 2.04   18 0.66   26
2   1.85  18 1.05   16 1.85   35
3   2.06  25 2.10     24 1.00   16
4   1.43  32 0.73   39 2.09   25
  52)   0.50  76 1.25   40 0.43   61
1) Expressed as coefficient of variation (CV = SEM/mean*100%)
2) Subject five is the subject of Asian origin.
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The ∆5-steroids DHEA, ∆5-AEDIOL, 7α-OH-DHEA, 7β-OH-DHEA, 16α-OH-DHEA
and 7-keto-DHEA showed low sensitivity. This confirms the observation made in
Chapter 6 that ∆4-AEDIONE does not significantly metabolize to ∆5-steroids. The
conversion of ∆5- to ∆4-steroids are considered as irreversible in biosynthesis, which
corresponds to a high specificity of these ∆5-steroids for DHEA.
The 7β-OH-DHEA/7α-OH-DHEA ratio is also a specific parameter, because it
increased significantly after DHEA administration in Chapter 6 (330 ± 286%; n=8),
whereas in the present study the ratio showed an opposite effect (-78 ± 12%; n=4).
T/E ratio
The excretion of both T and E was significantly increased in this experiment.
Increased production of T after oral ∆4-AEDIONE administration was reported
previously, based on plasma sample analyses [8]. In only one subject a maximum
T/E ratio was detected that reached the cutoff level of six. However, this cutoff level
is based on the analysis of isolated glucuronides and is therefore not applicable in
this experiment.
The presented data of a case study with 3 subjects presented by Uralets et al. [1]
suggest a positive correlation between the detected maximum T/E ratio after
∆4-AEDIONE administration with the pre-administration mean basal T/E ratio. As
illustrated in Figure 5, this suggestion is confirmed by the high correlation for these
five subjects (r2 = 0.9882). Comparable results were observed in case of DHEA
administration in Chapter 6.
Extrapolation of this linear model to higher basal T/E ratios implies that an estimation
can be made for the expected maximum T/E ratio, based on the intraindividual mean
basal T/E ratio and the particular dose level. It should, however, also be considered
that this estimation could be abused for the frequent administration of relatively high
dose levels of ∆4-AEDIONE and at the same time preventing an increase of the T/E
ratio to a level higher than six.
Ethnic origin
As was also described previously [3], the mean T/E ratio in blank urine samples of
the Asian subject was relatively low (around 0.1). Uralets et al. [1] reported a
decrease of the T/E ratio in a subject of Asian origin as a result of ∆4-AEDIONE
administration. In our study, the effect of ∆4-AEDIONE on the T/E ratio was not
essentially different from Caucasians, as based on the correlation presented in
Figure 5. Thus, according the results of this case there is no reason to suspect inter-
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racial differences in the effect of ∆4-AEDIONE administration on the detected
maximum T/E ratio.
SUMMARY
Sensitive metabolites of ∆4-AEDIONE were 4-OH-∆4-AEDIONE, 6α/β-OH-∆4-
AEDIONE, AO, EO and T. The main specific metabolites of ∆4-AEDIONE were T,
6α/β-OH-T and 4-OH-∆4-AEDIONE. The 7β-OH-DHEA/7α-OH-DHEA ratio was a
specific parameter, because of its opposite effect after DHEA or ∆4-AEDIONE
administration.
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TRIMETHYLSILYLATION OF 3-KETO-ANDROST-4-ENE
STEROIDS: THERMODYNAMIC VERSUS KINETIC CONTROL OF
ENOLIZATION
ABSTRACT
Trimethylsilylation in a mixture of MSTFA/NH4I/ethanethiol cannot be applied for the selective
analysis of the steroids androst-4-ene-6α-ol-3,17-dione and androst-4-ene-6β-ol-3,17-dione,
as the stereochemical integrity of C6 is lost due to 3,5-dienol formation. In contrast, the
stereochemical integrity of C6 is retained upon using MSTFA/KOAc/imidazole, since in that
case the 2,4-dienol is formed.
The different routes of product formation were confirmed with androst-4-ene-3,17-dione. In
addition to usual gas chromatography-mass spectrometry, 1H- and 13C-NMR were applied to
analyze and characterize the derivatization products. To that purpose derivatization was
scaled up from analytical (µg) to preparative (mg) scale.
Fundamental insight in the course of rate limiting enolization followed by trimethylsilylation,
was obtained from preparative silylation reactions using the mentioned reagents on the
17-methyl ether of testosterone as a model compound. MSTFA/NH4I/ethanethiol yielded the
3,5-dienolTMS derivative as the only product, whereas in the case of
MSTFA/KOAc/imidazole the 2,4-dienolTMS derivative was the predominant product.
An isomerization experiment that was performed to gain insight into the relative stability of
both products revealed that the 3,5-enolTMS derivative is more stable than its 2,4-enolTMS
isomer.
Hydrogen-deuterium exchange experiments that were performed upon the model compound
to study the role of acidity during trimethylsilylation, proved protons at C2 to be more acidic
than protons at C6. The latter accounts for predominant formation of the 2,4-dienolTMS
derivative during trimethylsilylation under basic conditions (MSTFA/KOAc/imidazole), as
proton abstraction occurs preferentially at C2
.
 The silylation under basic conditions is
therefore a kinetically controlled reaction, leading to the least stable enol intermediate and
TMS derivative. Silylation under acidic conditions (MSTFA/NH4I/ethanethiol) is solely
determined by the stability of the intermediate enol and endproduct and is therefore under
thermodynamic control.
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INTRODUCTION
In Chapters 5 and 7, androst-4-ene-6α-ol-3,17-dione (6α-OH-∆4-AEDIONE) and
androst-4-ene-6β-ol-3,17-dione (6β-OH-∆4-AEDIONE) were studied as metabolites
of androst-4-ene-3,17-dione (∆4-AEDIONE). However, these steroids could not be
specifically analyzed with gas chromatography-mass spectrometry (GC-MS),
because both compounds reacted to the same 3,5-dienol ether upon derivatization
with MSTFA/NH4I/ethanethiol (1000:2:3; v/w/v).
As noticed before by Schänzer et al. [1], steroids hydroxylated at C6 can retain the
stereochemical information on that atom when the derivatization is performed in a
mixture of MSTFA/KOAc/imidazole (1000:20:20; v/w/w). Applying this procedure, 2,4-
dienol ethers were identified as main products (see Scheme 1).
Scheme 1: Formation of 3,5-dienolTMS derivatives (route 1) and 2,4-dienolTMS derivatives
(route 2) upon incubation in MSTFA/NH4I/ethanethiol and
MSTFA/KOAc/imidazole, respectively.
O
O
OH
OTMS
TMSO
OTMSO
O
OH
OTMS
TMSO
OTMS
OTMS
TMSO
OTMS
1
2
1
2
TRIMETHYLSILYLATION OF 3-KETO-ANDROST-4-ENE STEROIDS

-161-
MSTFA/NH4I/ethanethiol (mostly 1000:2:3 v/w/v) is frequently applied in steroid and
doping analysis, in particular for trimethylsilylation of hydroxyl as well as enol groups.
Derivatization with this reagent or others of comparable constitution has proven to be
a robust and efficient method that provides good chromatography and mass
spectrometric sensitivity. However, not much information is available about the
underlying reaction mechanism.
The application of MSTFA/NH4I/ethanethiol is based on investigations on
derivatization by Donike et al. [2]. They compared several reagents for derivatization
and described trimethylsilyliodide (TMSI) as the most reactive trimethylsilylating
reagent.
However, application of TMSI is impractical, as it is highly sensitive to hydrolysis by
water and decomposition by oxygen and light. Therefore, TMSI should be kept in the
absence from air and light. Decomposition of TMSI would result in extensive iodine
formation, that can lead to the formation of non-volatile steroid-iodide adducts. To
avoid these side-reactions, ethanethiol, present as S-TMS-ethanethiol in the
derivatization medium, is added to reduce iodine, leading to TMSI formation [3].
In the MSTFA/NH4I/ethanethiol mixture, TMSI is formed in situ by reaction of iodide
with MSTFA. In Scheme 2 a mechanism is suggested for TMSI formation and its
subsequent reaction with steroid enols. The reaction with non-enol hydroxyl groups
proceeds basically via the same mechanism. According this mechanism also HI is
formed, giving rise to acidic conditions in the derivatization medium.
Scheme 2: Mechanisms of the reaction of TMSI with steroid enols and the in situ formation
of TMSI from MSTFA and iodide.
(H3C)3SiOH O
I
O Si(CH3)3
HI
(H3C)3Si N
CH3
C
O
CF3 HI (H3C)3Si N
CH3
C
O
CF3
H
I
H3C NH
C
O
CF3(H3C)3Si
+
+ +
+ +
+
I
H
Si(CH3)3
I
CHAPTER 8

-162-
Scheme 3: In situ TMS-imidazole formation from imidazole and MSTFA.
Scheme 4: Trimethylsilylation of steroid enols by TMS-imidazole.
TMSI cannot be used under basic conditions, as it would immediately be
decomposed by nucleophilic substitution of the present ions (OH− or AcO−) on the
trimethylsilylgroup (TMS). However, to apply basic conditions
MSTFA/KOAc/imidazole can be used with trimethylsilylimidazole (TMS-imidazole) as
in situ formed silylating agent from MSTFA and imidazole (see Scheme 3). A
mechanism of silylation by TMS-imidazole is presented in Scheme 4.
As the way of silylation by the two derivatization reagents is not fundamentally
different (compare Schemes 2 and 4), it is unlikely that silylation is responsible for the
observed differences in product formation. Therefore, it has to be assumed that the
enolization that has to take place prior to silylation of the 3-keto-group, is the critical
factor.
It is well established [4] that enolization of ketones can be catalyzed by acid as well
as base. Thus, in the case of 3-keto-4,5-ene-steroids enolization under acidic
conditions is initiated by protonation of the oxygen atom of the α,β-unsaturated
ketone (see Scheme 5). Subsequent deprotonation can occur in 3 evident ways: from
the oxygen atom, leading to the starting compound; from C2, leading to the 2,4-
dienol; and from C6, leading to the 3,5-dienol.
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Scheme 5: Mechanism of acid catalyzed enolization of 3-keto-4,5-ene-steroids.
For several reasons it has to be expected that proton-loss from C6 will occur. Firstly,
it is most likely that the mesomeric structure carrying the positive charge on C5 has
the highest relative stability. Secondly, it has to be expected that the 3,5-dienol,
which is the result of proton-loss from C6, is more stable than the 2,4-dienol resulting
from proton-loss at C2. The reason for the last mentioned higher stability is two-fold:
the conjugated double bonds in the 3,5-dienol are in the energetically favored s-trans
configuration and the A-ring is less strained by the presence of only one double
bond.
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Scheme 6: Mechanism of base catalyzed enolization of 3-keto-4-ene-steroids.
As illustrated in Scheme 6, enolization of 3-keto-androst-4-ene steroids under basic
conditions can occur in two ways: proton extraction from either C2 or C6 leads to the
2,4-dienol or 3,5-dienol, respectively. Which route is predominant is solely
determined by the acidity of the involved protons at C2 and C6.
In this study, derivatization of 6α-OH-∆4-AEDIONE, 6β-OH-∆4-AEDIONE and
∆4-AEDIONE with both reagents was investigated on an analytical (µg) as well as a
preparative (mg) scale. The latter enabled us to analyze the products not only by
means of GC-MS, but also with Nuclear Magnetic Resonance (NMR) spectroscopy.
Moreover, the influence of the acidity of both the steroid and the derivatization
reagent on the course of the derivatization reaction was investigated. This was
achieved by performing hydrogen-deuterium exchange experiments on the model
steroid 17-methoxy-testosterone (methoxy-T).
After derivatization of the latter compound on a preparative scale with both reagents,
the relative stability of the 2,4-dienolTMS derivative with respect to that of its
3,5-dienolTMS isomer was investigated by performing an isomerization experiment.
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EXPERIMENTAL
Chemicals
Steroids: Androst-4-ene-3,17-dione (∆4-AEDIONE) and testosterone (T) were
obtained from Sigma, St. Louis, Missouri, USA. Androst-4-en-6α-ol-3,17-dione
(6α-OH-∆4-AEDIONE), androst-4-en-6β-ol-3,17-dione (6β-OH-∆4-AEDIONE) were
obtained from Steraloids, Newport, Rhode Island, USA.
Chemicals: All other chemicals were of analytical grade, unless indicated otherwise.
Solvents were dried using standard procedures. N-Methyl-N-
trimethylsilyltrifluoroacetamide (MSTFA), ethanethiol (97%), imidazole, phosphorous
pentoxide, potassium acetate, magnesium sulfate and triethylamine hydrochloride
were obtained from Sigma-Aldrich Chemie Company, Steinheim, Germany.
Ammonium iodide was obtained from Fluka Chemie, Buchs, Switzerland. Sodium
hydride (60% dispersion in mineral oil), methyl iodide (99% stabilized) and phenol
(99%) were obtained from Acros Organics, Geel, Belgium. Potassium hydroxide,
diethyl ether, tetrahydrofuran (THF), hexane, heptane, chloroform, acetone, benzene
and methanol were obtained from Merck, Darmstadt, Germany. Diethyl ether, THF,
benzene and toluene were of technical quality and were purified by predrying over
powdered potassium hydroxide, followed by distillation from the sodium ketyl of
benzophenone. Deuterated acetonitrile CD3CN (1H: 1.93 ppm; 13C: 1.28 and 118.1
ppm), deuterated chloroform CDCl3 (1H: 7.27 ppm; 13C: 77.0 ppm), deuterated
methanol CD3OD (1H: 3.30 ppm; 13C: 49.0 ppm) and deuterated benzene C6D6 (1H:
7.15 ppm; 13C: 128.0 ppm) were obtained from ARC Laboratories, Amsterdam, The
Netherlands  (isotopic purity ≥99.8%).
Gas chromatography and mass spectrometry
Analysis with gas chromatography-mass spectrometry (GC-MS) was performed in full
scan mode with a Hewlett Packard gas chromatograph (Model 5890, Agilent
Technologies, Waldbronn, Germany) coupled to a Hewlett Packard quadrupole mass
spectrometer (Model 5972A). Ionization was performed in electron ionization  (EI)
mode at 70 eV.
Gas chromatography was performed with a HP-1 fused silica column (length 18 m,
inner diameter 0.2 mm, film thickness 0.11 µm). Through electronic pressure control
the column flow (helium) was constantly 1 ml/min.  Sample injection of 1 µl was
performed in split mode (ratio 1/10). A Hewlett Packard autosampler (Model 7673,
Agilent Technologies, Waldbronn, Germany) was used for autoinjection. The injector
temperature was set to 250°C. The oven temperature program used was: initial
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temperature 180°C, 2°/min to 225°C, 30°/min up to 310°C, constant for 5 min. The
interface temperature was set to 280°C.
NMR
All routine NMR spectra were recorded on a Bruker AC 300 spectrometer (1H: 300.13
MHz; 13C: 75.47 MHz) at 298 K in the appropriate solvent to be mentioned in the
description of the specific experiment. Chemical shifts are relative to external
tetramethylsilane. 13C-1H NMR correlation experiments (HETCOR) were performed at
298 K in appropriate solvents using a Varian Inova 300 MHz spectrometer.
Trimethylsilylations of ∆4-AEDIONE, 6α- and 6β-OH-∆4-AEDIONE
Silylation for GC-MS analysis was performed by incubation of 1 µg ∆4-AEDIONE, 6α-
or 6β-OH-∆4-AEDIONE in 50 µl of derivatization reagent for 30 min at 80°C in a
sealed glass tube. The reagents used were MSTFA/NH4I/ethanethiol (1000:2:3;v/w/v)
[2] and MSTFA/KOAc/imidazole (1000:20:20;v/w/w) [1]. After derivatization reaction
mixtures were directly injected for analysis.
For NMR analysis the derivatization reactions were performed by incubation of 10 mg
of the respective steroids in 7.25 ml of the derivatization reagents mentioned above.
The reactions were performed in an atmosphere of dry nitrogen in a Schlenk vessel.
Under continuous stirring the incubation took place at 80°C for 30 min. Besides by
NMR analysis, product formation was always checked by GC-MS analysis of the
reaction mixture, after dilution with heptane. After completion of the reaction the
reaction mixture was evaporated to dryness under reduced pressure of an oil pump.
NMR analyses were performed on samples dissolved in C6D6.
Synthesis of 17-methoxy-testosterone
17β-Methoxy-androst-4-ene-3-one (methoxy-T) was synthesized based on Floresca
et al. [5]. However, because of its easier removal from the product, THF was used
instead of DMF as the solvent in the following procedure:
To a suspension of 0.264 g (11 mmol) of NaH (freed of oil by washing with hexane)
in 50 ml of THF was added 2.88 g (10 mmol) of testosterone (T). The suspension
was stirred for an hour at room temperature and subsequently, 14.2 g (100 mmol) of
methyl iodide was quickly added dropwise. No noticeable development of heat
occurred.
After stirring for 72 hours at room temperature, the initially turbid suspension had
changed into an almost homogeneous slightly yellow solution, indicating that almost
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all the NaH had been consumed. A sample of approximately 0.5 ml was drawn and
processed by respectively diluting with water, extracting the aqueous phase with
diethyl ether, drying the ether solution over magnesium sulfate, filtering and
evaporating the volatile constituents. Analysis of the semi-solid residue using 1H- and
13C-NMR (CDCl3) revealed the presence of methoxy-T and testosterone in a ratio of
approximately 3:2. Furthermore, TLC (silica; chloroform-acetone 10:1 v.v.) showed
that small amounts (not detectable with NMR) of at least two other compounds were
present.
After adding an additional 0.1 g (4 mmol) of NaH, the mixture was refluxed for 5
hours. Analysis by NMR and TLC of a new sample indicated that almost no T was left
and that, together with one main product, small amounts of at least three other
products were present.
Water (5 ml) was added dropwise while the reaction mixture was cooled in an ice
bath. The volatile constituents were removed at a Rotavap and the slightly yellow
solid residue was submitted to an oil pump vacuum until constant weight (5.0 g).
After adding 20 ml of dry diethyl ether the mixture was vigorously stirred for half an
hour after which the insoluble white solid was removed by filtration over a glass filter
(G3). The solid was treated with diethyl ether in this way two more times. Removal of
the solvent from the combined filtrates at a Rotavap afforded 3.42 g of a slightly
yellow sticky solid. This was submitted to column chromatography on silica using
CHCl3 as eluent to yield pure methoxy-T. NMR analysis was performed on samples
dissolved in CD3OD and CD3CN. The melting point (uncorrected) was determined
with a Mettler FP5/FP51.
Preparative trimethylsilylation of methoxy-T in MSTFA/NH4I/ethanethiol
In a Schlenk vessel equipped with a magnetic stirring bar were brought: 30.2 mg (0.1
mmol) of methoxy-T and a solution of 14.5 mg (0.1 mmol) of NH4I and 15 µl of
ethane thiol in 3 ml of MSTFA. The vessel, with the vigorously stirred reaction
mixture, was immersed in an oil bath of 80oC and heating and stirring were continued
for 30 min. Immediately after bringing the colorless reaction mixture to room
temperature, a sample was drawn and submitted to GC-MS.
The volatile constituents of the reaction mixture were removed in an oil pump vacuum
at room temperature affording a slightly yellow solid. The solid was pure (as
established by GC-MS) and was identified as the 3,5-enolTMS ether by means of
NMR and GC-MS.
Since the product was expected to be thermally unstable, no effort was made to
determine the melting point. Moreover, because of suspected chemical instability
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under acid and basic conditions, the use of solvents with an acidic character like
chloroform was avoided in all manipulations of the material. NMR analysis was
performed with C6D6 as solvent.
Preparative trimethylsilylation of methoxy-T in MSTFA/KOAc
This reaction was conducted in the same way as the preparative trimethylsilylation in
MSTFA/NH4I/ethanethiol, but with a solution of 100 mg of potassium acetate in 5 ml
of MSTFA as the trimethylsilylating reagent. No imidazole was added in order to
prevent problems with the interpretation of NMR spectra. Again GC-MS analysis was
performed on a sample drawn immediately after bringing the reaction mixture to room
temperature.
Evaporation of the volatile constituents under reduced pressure of an oil pump at
room temperature afforded a slightly yellow sticky solid. After adding 3 ml of dry
benzene the mixture was vigorously stirred for 30 min. Subsequently, the solution
was removed from the solid sticking against the stirring bar and the walls of the
Schlenk vessel and filtered through a small plug of glass wool in a Pasteur pipet
contained in another Schlenk vessel. The contents of the reaction vessel were
treated with benzene two more times followed by evaporation of the solvent under
reduced pressure. A white sticky residue was obtained. A sample was dissolved in
C6D6 and analyzed with NMR.
Isomerization of 2,4-dienolTMS methoxy-T
This reaction was conducted by a modification of a procedure described in the
literature [6]. In contrast to the compounds investigated by these authors, the
steroidal trimethylsilyl ethers in the present study are solids. Therefore, it was
necessary to use a solvent. For reasons of inertness and boiling point the choice was
made for toluene, which was applied in the following procedure:
The NMR sample of the preceding MSTFA/KOAc derivatization experiment was
recovered in the original Schlenk vessel and after evaporating the NMR solvent C6D6
under reduced pressure, 2 ml of dry toluene was added. This resulted in a
homogeneous solution to which 5 mg of triethylamine hydrochloride was added.
Subsequently, the reaction mixture was heated in an oil bath of 100oC during half an
hour. A sample for GC-MS analysis was drawn immediately after bringing the
reaction mixture to room temperature. Afterwards, the solvent was evaporated under
an oil pump vacuum at room temperature, leaving an off-white solid residue. This
was dissolved in C6D6 and analyzed with NMR.
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Hydrogen-deuterium exchange (1)
Because KOAc is the basic catalyst used in the preparative derivatizations, the same
base dissolved in CD3OD was used initially in an effort to bring about H-D exchange
in methoxy-T. Unfortunately, this experiment showed that no H-D exchange occurred
under the influence of KOAc in CD3OD, even at temperatures up to 50oC.
For that reason also an experiment with a much stronger base, i.e. NaOCD3 in
CD3OD, was performed. Therefore, a stock solution of NaOCD3 was prepared in a
Schlenk vessel by dissolving approximately 50 mg of sodium in 1 ml of CD3OD.
In a NMR tube 19.3 mg (0.0639 mmol) of methoxy-T was dissolved in 0.8 ml of
CD3OD and a 1H-NMR spectrum was recorded. Subsequently, stock solution of
NaOCD3 was added with a microsyringe, until the solution showed pH 8-9 on moist
indicator paper. The occurrence of H-D exchange was monitored by recording 1H-
NMR spectra with regular intervals of time and comparing the relative height of the
integrals of (clusters of) signals using the integral of the C18-protons as internal
standard. Also, GC-MS analyses were performed as a function of time.
Hydrogen-deuterium exchange (2)
H-D exchange was performed with a weaker base, i.e. LiOC6H5 in CD3OD. To
prepare a stock solution of lithium phenolate in CD3OD, 57 mg (0.61 mmol) of phenol
was dissolved in 5 ml of diethyl ether, contained in a Schlenk vessel equipped with a
magnetic stirring bar. Subsequently, approximately 20 mg (3 mmol) of lithium powder
was added and the mixture was stirred at room temperature. After approximately one
hour the mixture became white turbid, presumably by a limited solubility of lithium
phenolate in ether. The mixture cleared up slowly after addition of 5 ml of THF.
After stirring during 60 hours the mixture appeared as a colorless, clear solution with
small pieces of lithium powder floating in it. The solution was transferred into a
syringe and immediately filtered through a small plug of glass wool in a Pasteur pipet
contained in a second Schlenk vessel. The solvents were evaporated under reduced
pressure and the white solid residue was submitted at room temperature to an oil
pump vacuum for 2 hours. Subsequently, 2 ml of CD3OD was added and after stirring
for a few minutes this solvent was also evaporated under reduced pressure, leaving
a white solid residue that was submitted to oil pump vacuum for 1 hour. Finally, 1.5
ml of CD3OD was added.
In a NMR tube 18.7 mg (0.0619 mmol) of methoxy-T was dissolved in 0.8 mL of
CD3OD and a 1H-NMR spectrum was recorded. Subsequently, stock solution of
LiOC6H5 was added with a microsyringe, until the solution showed pH 8-9 on moist
indicator paper. The occurrence of H-D exchange was monitored by recording 1H-
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NMR spectra with regular intervals of time as indicated above. Also, several GC-MS
analyses were performed as a function of time.
RESULTS AND DISCUSSION
MSTFA/NH4I/ethanethiol derivatization of (hydroxy metabolites of) ∆4-AEDIONE
After silylation of 6α- and 6β-OH-∆4-AEDIONE with MSTFA/NH4I/ethanethiol on an
analytical scale, full scan GC-MS analysis of the reaction mixture resulted in
coeluting peaks, that could not be separated by modification of the temperature
program.
Also upon derivatization on a preparative scale, the respective derivatives were
identical as shown by GC-MS and NMR analyses (see Figure 1).
Derivatization of ∆4-AEDIONE resulted in one derivative that was detected as a
single peak in the chromatogram (see Figure 3).
MSTFA/KOAc/imidazole derivatization of (hydroxy metabolites of) ∆4-AEDIONE
After trimethylsilylation on an analytical scale of 6α- and 6β-OH-∆4-AEDIONE with
MSTFA/KOAc/imidazole, full scan GC-MS analysis resulted in peaks with different
retention times and mass spectra (see Figure 2).
The product of the reaction on a preparative scale could not be analyzed by NMR,
because imidazole could not be removed from the material.
Derivatization of ∆4-AEDIONE resulted in two chromatographic peaks, of which the
minor one showed the same retention time and mass spectrum as the peak that was
obtained with MSTFA/NH4I/ethanethiol (see Figure 3).
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Figure 1: Mass spectrum (A) and the 1H NMR spectra (B and C) of the product obtained
upon MSTFA/NH4I/ethanthiol derivatization of 6α-OH-∆4-AEDIONE and 6β-OH-
∆4-AEDIONE, respectively.
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Figuur 2: Total ion current chromatograms (A1 and A2) and mass spectra of the silylation
products of 6α-OH-∆4-AEDIONE (B) and 6β-OH-∆4-AEDIONE (C) using
MSTFA/KOAc/imidazole.
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Figure 3: Total ion current chromatograms from silylation products of ∆4-AEDIONE using
MSTFA/NH4I/ethanethiol (A1) and MSTFA/imidazole/KOAc (A2), as well as the
corresponding mass spectra (B and C).
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Synthesis of methoxy-T
A yield of 460 mg (15 %) of pure methoxy-T was obtained: mp 122-123oC (litt. 121-
122oC [5]); 1H NMR (CDCl3): δ  	
	3), 1.16 (s, 3, C-19 CH3), 3.20 (t, J
= 8.4 Hz, 1, CHOCH3), 3.31 (s, 3, OCH3), 5.69 (s, 1, vinylic H) ppm; 13C NMR
(CDCl3): δ 11.5 (C-18), 17.3 (C-19), 20.7 (C-11), 23.2 (C-15), 27.5 (C-16), 31.5 (C-6),
32.7 (C-7), 33.9 (C-2), 35.4 (C-1 or C-12), 35.7 (C-1 or C-12), 37.6 (C-8), 38.6 (C-
10), 42.7 (C-13), 50.7 (C-14), 53.8 (C-9), 57.8 (OCH3), 90.4 (C-17), 123.8 (C-4),
171.1 (C-5), 199.3 (C-3) ppm.
The total ion current chromatogram of the substance, showed one single peak at
9.22 min, with a corresponding full scan mass spectrum as shown in Figure 4.
Molecular mass was detected at m/z 302. The main fragments were at m/z 287
([M-CH3]+), m/z 260 (A-ring fragmentation). In addition, several m/z values of
fragments from other ring fragmentations were observed.
Figure 4: Full scan mass spectrum of methoxy-T.
Preparative trimethylsilylation of methoxy-T in MSTFA/NH4I/ethanethiol
A single peak was detected in the full scan chromatogram of the reaction mixture.
The chromatogram and the corresponding recorded mass spectrum are shown in
Figure 5.
1H NMR (CD3OD): δ  trimethylsilyl), 0.78 (s, 3, C-18 CH3), 0.96 (s, 3, C-19
CH3), 3.29 (t, J = 8.4 Hz, 1, CHOCH3), 3.31 (s, 3, OCH3), 5.13 (m, 1, H6), 5.23 (d, J =
1.9 Hz, 1, H4) ppm; 13C NMR (CD3OD): δ 0.3, 11.9, 19.4, 22.0, 24.3, 28.6, 28.7, 32.5,
33.1, 35.3, 35.9, 39.0, 44.0, 49.0 (This signal coincides with the central peak of the
CD3OD signal, as confirmed by a 13C spectrum of the same material in CD3CN),
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53.1, 58.2, 92.2, 110.2, 119.5, 142.2, 151.4 ppm. GC-MS analysis of the NMR
sample afforded the same result as the GC-MS of the reaction mixture as depicted in
Figure 5.
Figure 5: Total ion current chromatogram of the reaction mixture after derivatization on
preparative scale of methoxy-T in MSTFA/NH4I/ethanethiol (A) and the
corresponding mass spectrum of the main product (B).
Preparative trimethylsilylation of methoxy-T in MSTFA/KOAc
The total ion current chromatogram of the sample drawn immediately after the
reaction revealed the presence of two peaks with retention times 9.14 min. and 9.92
min, respectively. The peak with retention time 9.92 min afforded a mass spectrum
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that was identical with the mass spectrum of the 3,5-dienolTMS ether as depicted in
Figure 5.
The peak at 9.14 min represented a mixture of the 2,4-dienolTMS ether with a
smaller quantity of non-derivatized methoxy-T. This is illustrated by the extracted ion
chromatogram of m/z 374.3 and 302.3 in Figure 6. Based on the same m/z values,
the area ratio of methoxy-T/2,4-dienolTMS/3,5-dienolTMS was 0.2 : 0.8 : 1.0.
 
1H-NMR (C6D6) of the residue also revealed that the material was a mixture of
methoxy-T, 2,4-dienolTMS ether and 3,5-dienolTMS ether. However, based on the
integrals of the corresponding vinylic protons, the ratio was approximately 3.2 : 5.2 :
1.0. 1H-NMR (C6D6) 2,4-dienolTMS ether: δ 0.86 (C-18 CH3), 1.03 (C-19 CH3), 3.29
(t, J = 8.4 Hz, CHOCH3), 3.20 (s, OCH3), 4.85 (m, H2), 5.60 (s, H4) ppm.
Immediately after recording the NMR spectrum, a sample was drawn from the NMR
tube and analyzed by GC-MS. The area ratio of methoxy-T/2,4-dienolTMS/3,5-
dienolTMS obtained from the extracted ion chromatogram was 1.0 : 1.9 : 1.0.
This experiment showed that both the 2,4-dienolTMS and 3,5-dienolTMS derivatives
of methoxy-T are formed by this derivatization method. The stability of the 2,4-dienol
isomer is very low, as was indicated by the relatively increasing concentration of non-
silylated methoxy-T upon processing a sample for NMR analysis. Because no
methoxy-T formation was detected after processing a sample for NMR analysis of the
3,5-dienolTMS product of MSTFA/NH4I/ethanethiol derivatization, it has to be
concluded that derivative decomposition occurs only with the 2,4-dienol isomer.
However, this conclusion could not be confirmed by the change in area ratio of both
dienolTMS ethers before and after NMR analysis.
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Figure 6: Extracted ion chromatogram (A; m/z 302.3 and 374.3) of the reaction mixture
after derivatization of methoxy-T in MSTFA/KOAc on preparative scale, and the
corresponding full scan mass spectra recorded at 9.14 (B) and 9.87 min (C),
respectively.
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Isomerization reaction
Full scan GC-MS analysis immediately performed after the isomerization experiment,
revealed the presence of two peaks with retention times 8.99 min and 9.91 min,
respectively, with an area ratio of approximately 0.3 : 1.0 in the extracted ion
chromatogram (see Figure 7). The peak with retention time 8.98 min showed a mass
spectrum fully identical with that of non-derivatized methoxy-T. The mass spectrum of
the peak with retention time 9.91 was identical with that of the 3,5-dienolTMS ether.
No 2,4-dienolTMS ether could be detected. 1H NMR analysis confirmed the material
to be a mixture of methoxy-T and its 3,5-dienolTMS ether in a ratio of approximately
1.7 : 1.0.
This experiment showed that the 2,4-dienolTMS ether was converted to either
methoxy-T or the 3,5-dienolTMS ether. As the detected ratio of methoxy-T vs. its 3,5-
dienolTMS ether decreased during the isomerization experiment (either established
by NMR of GC-MS), it was concluded that the major part of the 2,4-dienolTMS ether
was converted to the 3,5-dienol ether.
Hydrogen-deuterium exchange experiment (1)
It appeared that 3 signal clusters decreased as a function of time, i.e. the signal of
the vinylic proton at 5.69 ppm and two clusters of signals at respectively 2.5 and 2.3
ppm, each representing 2 protons. The results of the measurements are depicted in
Figure 8.  Protons at C2 and C6 could not be assigned to these signal clusters.
Therefore, the H-D exchange with NaOCD3 in CD3OD does not allow a decisive
conclusion with respect to the relative acidities of the protons at C2 and C6.
This experiment showed that under the applied conditions H-D exchange occurs at
three positions in the molecule, including the vinylic proton at C4. The fact that
exchange of the vinylic proton occurred, implies proton abstraction at C6, which is in
an allylic position with respect to the double bond (see Scheme 7).
These observations lead to the conclusion that NaOCD3 is too strong, i.e. not
selective enough, to differentiate between protons of different acidity. For this reason
also an experiment with a weaker base, i.e. LiOC6H5 in CD3OD, was performed.
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Figure 7: Extracted ion chromatogram (A; m/z 374.3 and 302.3) and the corresponding
mass spectra (B and C) of the products of MSTFA/KOAc derivatization of
methoxy-T after isomerization by triethylamine.HCl.
A
40 80 120 160 200 240 280 320
0
2000
4000
6000
8000
10000
12000
m/z
abundance Scan 304 (8.98 min):
55
71
91
105
147
260 287
302
40 80 120 160 200 240 280 320 360 4000
10000
20000
30000
40000
50000
m/z
abundance
Scan 374 (9.91 min):
73
105 193208 359
374
8.4 8.8 9.2 9.6 10.0 10.20
8000
16000
24000
32000
40000
48000
time (min)
abundance
Ion 374.30 (374.00 to 375.00):
9.91
Ion 302.30 (302.00 to 303.00):
8.98
B
C
CHAPTER 8

-180-
Figure 8: Decay of signals in the 1H NMR spectrum of methoxy-T upon H-D exchange
using NaOCD3 in CD3OD.
Scheme 7: Deprotonation-redeuteration sequence at C4 and C6 of methoxy-T upon
H-D exchange with NaOCD3 in CD3OD.
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Hydrogen-deuterium exchange experiment (2)
It appeared that LiOC6H5 in CD3OD caused decrease of the same 3 (clusters of)
signals as NaOCD3 in CD3OD, although with a lower velocity. The results of the
measurements are displayed in Figure 9. This result implies that also the H-D
exchange with LiOC6H5 in CD3OD does not allow a decisive conclusion with respect
to the relative acidities of the protons at C2 and C6.
Figure 9: Decay of signals in the 1H NMR spectrum of methoxy-T upon H-D exchange
using LiOC6H5 in CD3OD
A C-H correlation was performed to assign the clusters of signals around 2.5 and 2.3
ppm to the respective protons at C2 and C6. In addition, help of the 1H- and 13C NMR
spectral data of steroids already available in the literature [7,8] was used. The
correlation revealed that the cluster of signals around 2.5 ppm in the 1H spectrum of
methoxy-testosterone originates from 1 proton at C2 and 1 proton at C6. The same is
the case with the cluster of signals around 2.3 ppm. Therefore, it was concluded that
protons corresponding to the cluster of signals around 2.5 ppm are exchanged much
faster than other exchangeable protons in the molecule, and are therefore most
acidic. However, the C-H correlation does not answer the question whether the most
acidic protons reside at C2 or at C6.
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GC-MS analyses provided decisive information on this question. As was already
indicated in Figure 4, the fragmentation pattern of methoxy-T shows a fragmentation
of the A-ring corresponding to a m/z value of 260 ([M-C2H2O]•+). This implies that C2
and its hydrogen atoms are removed from the remaining fragment.
During the complete H-D exchange period of 7 days, GC-MS analyses showed
incorporation of up to 4 deuterium atoms into methoxy-T, as the m/z value
corresponding to the molecular mass increased from 302 to 306 (see Figure 10C).
After 7 days, 2 deuterium atoms were incorporated into the [M-C2H2O]•+ fragment.
This implies that 2 deuterium atoms had been incorporated at C2.
After 6 hours one proton was incorporated into the steroid, as the m/z value of [M]•+
was completely shifted to 303, while the m/z value of [M-C2H2O]•+ remained at 260 in
the same relative abundance (Figure 10A). This proved that the first deuterium atom
that is incorporated into the molecule is situated at C2. Thus, decisive proof was
obtained that one of the protons at C2 is the most acidic one in the molecule.
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Figure 10: Mass spectra of samples obtained during H-D exchange on methoxy-T after 6
hours (A), 70 hours (B) and 7 days (C).
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Kinetically versus thermodynamically controlled derivatization
Donike et al. [2] stated that product formation during derivatization is dependent upon
the nature of the solvent, the catalyst, the silylating reagent, and the structure of the
steroid. However, to explain the differences in product formation in this study the
critical variables should be described as:
1. Stability of the endproduct. Endothermic reactions generally lead to the formation
of those products with the highest thermodynamic stability [4], i.e. the 3,5-
dienolTMS derivative, as shown by the isomerization experiment.
2. Activation energy of enolization. As was shown by the H-D exchange
experiments, the protons at C2 are more acidic than the protons at C6, explained
by the α-position of C2-protons with respect to the carboxyl group. Rephrased, the
activation energy of proton extraction from C2, leading to 2,4-dienolate anion
formation, is lower than proton extraction from C6 that leads to 3,5-dienolate anion
formation. Therefore, product formation under basic conditions, i.e.
MSTFA/KOAc/imidazole, is kinetically controlled and is independent from
(thermodynamic) stability of the reaction products.
The thermodynamic vs. kinetic control of enolization can be explained by a diagram
of Gibb’s free energy levels (G) of the keto- and enol-structures with the
corresponding intermediates (see Figure 11).
The Hammond postulate states that in general the product of highest stability will be
produced fastest. This implies that a higher Gibb’s free energy of an endproduct
corresponds to a higher energy level of the transition-state. However, as is the case
in the trimethylsilylation of 3-keto-androst-4-ene steroids, thermodynamics and
kinetics do not necessarily need to correspond.
Product formation of kinetic controlled reactions will only be determined by the
difference in Gibb’s free energy between endproducts (indicated as ∆G0) in case of
equilibrium. In a non-equilibrium situation, the difference in energies of the respective
transition states (∆∆G‡) will be the critical factor. This allows the formation of
thermodynamically least stable, but kinetically most favorable reaction products, as
was proven for the studied base catalyzed enolization.
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Figure 11: Gibb’s free energy profile for base mediated enolization of 3-keto-4,5-ene-
steroids with kinetically vs. thermodynamically determined product formation.
Implications for steroid analysis
In Chapters 5-7, 6α- and 6β-OH-∆4-AEDIONE were analyzed as metabolites of
∆4-AEDIONE. As the applied derivatization reagent was MSTFA/NH4I/ethanethiol,
concentrations of the two metabolites were combined in one value. To obtain a more
stereospecific steroid profile a basic derivatization reagent as
MSTFA/KOAc/imidazole should be applied. However, as shown above,
fragmentation of 2,4-dienolTMS derivatives is extensively higher than of the
3,5-dienolTMS isomers, corresponding to the lower thermodynamic stability.
Significantly lower analytical sensitivity will therefore be obtained for the mentioned
steroids after MSTFA/KOAc/imidazole derivatization.
3,5-dienol
2,4-dienol
3-keto-androst-4-ene steroid
G
∆GO
2,4-dienolate-anion
3,5-dienolate-anion
∆∆G
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ARTIFACT FORMATION DUE TO ETHYL THIO-
INCORPORATION INTO SILYLATED STEROID
STRUCTURES
ABSTRACT
For the application of gas chromatography-mass spectrometry (GC-MS) in steroid
analysis, trimethylsilylation of target substances in a mixture of N-methyl-N-
trimethylsilyltrifluoroacetamide (MSTFA), ammonium iodide and ethanethiol is
frequently applied. However, using this mixture to silylate the steroids androsterone
and etiocholanolone obtained from a urine matrix, the formation of artifacts was
established.
The artifacts were identified as ethyl thio-containing products of the respective
trimethylsilyl derivatives. The conversion of the studied products increased slowly as
a function of time, was dependent on the presence of the urine matrix and was
significantly accelerated by adding diethyl disulfide to the reagent before incubation.
Also ethyl thio-incorporation into testosterone and epitestosterone was established. A
mechanism for ethyl thio-incorporation at the C16-position is proposed.
The conversion that was achieved after 120 hours of sample storage at room
temperature was insufficient to significantly influence the analysis of androsterone
and etiocholanolone under the studied circumstances. However, the results provide
fundamental insight into the mechanism of silylation and the occurring side-reactions.
Moreover, when investigating the formation of new metabolites the ethyl thio-
incorporation can create false interpretations.
CHAPTER 9

-188-
INTRODUCTION
One of the challenging fields in doping analysis has been the mass spectrometric
determination of steroids of either exogenous or endogenous origin. Since its
introduction in steroid analysis in the eighties by Donike et al. [1], N-methyl-N-
trimethylsilyltrifluoroacetamide (MSTFA) has been extensively used as a powerful
trimethylsilyl donor in the derivatization procedure. One of the most reported
derivatization techniques is the application of a mixture of MSTFA/ammonium
iodide/ethanethiol. MSTFA reacts in situ with ammonium iodide (NH4I) to produce
trimethyliodosilane (TMSI) that has been reported as the most powerful trimethylsilyl
donor available [1]. TMSI reacts with adequate speed to produce both trimethylsilyl
(TMS) ether and trimethylsilyl enol (TMS enol) ether derivatives (see Figure 1).
Figure 1:
 Derivatization of androsterone to its per-TMS ether derivative.
Ethanethiol1 is added to reduce the formed iodine to hydrogen iodide in order to
prevent iodine incorporation into the steroid nucleus. As a result, diethyl disulfide is
produced during the derivatization reaction [2]. Diethyl disulfide formation depends
on the amount of ammonium iodide and ethanethiol added to the extract and the
chosen experimental conditions as reaction time and temperature. Usually a mixture
of MSTFA/NH4I/ethanethiol is used in a ratio of 1000:2:3 (v/w/v).
When applying this procedure, it is assumed that other reactants than TMSI present
in the reaction mixture are inert to the steroids to be analyzed. However, as will be
described in this paper, incorporation of an ethyl thio-group with steroid structures
occurs during the described derivatization procedure.
In this study artifact formation was suspected in derivatized urine sample extracts. An
excretion study with [2,2,4,6,6,16,16-7H2]-androst-4-ene-3,17-dione (d7-∆4-
AEDIONE) showed that these artifacts were either metabolically or chemically related
to ∆4-AEDIONE.  Experiments are described to prove incorporation of an ethyl thio-
group into the main metabolites of ∆4-AEDIONE: androsterone and etiocholanolone.
                                                     
1
 Ethanethiol is frequently used as a replacement of dithioerythreitol [2].
O
HO
OTMS
TMSO
H H
MSTFA/NH4I/ethanethiol
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As diethyl disulfide is formed as side-product during the described derivatization
procedure, an experiment is described to investigate the role of ethanethiol and
diethyl disulfide as reagent in ethyl thio-incorporation. Repeated measurements over
time give insight into the significance of the side-reactions as compared to the
desired derivatization reactions. Also ethyl thio-incorporation into testosterone and
epitestosterone was established.
EXPERIMENTAL
Chemicals
Reference steroids: Androst-5-en-3β-ol-17-one (dehydroepiandrosterone), androst-4-
en-17α-ol-3-one (epitestosterone), 5α−androstan-3α-ol-17-one (androsterone),
5β−androstan-3α-ol-17-one (etiocholanolone), 5α-androstane-3α,17β-diol, androst-4-
ene-3,17-dione and androst-5-ene-3β,17β-diol, 17α-methylandrost-4-ene-11α,17β-
diol-3-one (11α-hydroxy-methyltestosterone), and diethyl disulfide were obtained
from Sigma, St. Louis, Missouri, USA. [2,2,4,6,6,16,16-7H2]--Androst-4-ene-3,17-
dione (purity 98.4%) was obtained from C/D/N Isotopes, Pointe-Claire, Quebec,
Canada.   
N-Methyl-N-trimethylsilyltrifluoroacetamide was obtained from Aldrich Chemical
Company, Milwaukee, Wisconsin, USA. Ammonium iodide was obtained from Fluka
Chemie, Buchs, Switzerland. Ethanethiol was obtained from Acros Organics, New
Jersey, USA. Diethyl ether was obtained from Merck, Darmstadt, Germany.
A crude solution of Helix pomatia (type HP-2, containing 110.000 IU/ml of
β−glucuronidase and 1000-5000 IU/ml of arylsulfatase) was obtained from Sigma, St.
Louis, Missouri, USA. Columns for solid phase extraction were IST Isolute C18
columns (200 mg, non-endcapped) obtained from Sopachem, Lunteren, The
Netherlands.
Gas chromatography and mass spectrometry
GC-MS analysis was performed with a Hewlett Packard gas chromatograph (Model
5890, Agilent Technologies, Waldbronn, Germany) coupled to a Hewlett Packard
quadrupole mass spectrometer (Model 5972A). Ionization was performed in the
electron ionization mode at 70 eV. Gas chromatography was performed with a HP-1
fused silica column (length 18 m, inner diameter 0.2 mm, film thickness 0.11 µm).
Through electronic pressure control the column flow (helium) was constant: 1 ml/min.
CHAPTER 9

-190-
Sample injection of 1 µl was performed in split mode (ratio 1:10). A Hewlett Packard
autosampler (Model 7673) was used for auto-injection. The injector temperature was
set at 250°C. The oven temperature program used was: initial temperature 180°C,
2°/min to 225°C, 30°/min up to 310°C, held for 5 minutes. The interface temperature
was set at 280°C.
Confirmation of artifact formation
Two products (X, Y) that were suspected to be analytical artifacts, were discovered
during the full scan mode analyses of urine samples obtained from an excretion
study with d7-∆4-AEDIONE. In this study 50 mg of d7-∆4-AEDIONE was administered
to a healthy male subject (age: 29 years). Urine samples were collected during 24
hours before and 24 hours after administration.
11α-Hydroxy-methyltestosterone (5 µg) was added as internal standard to 4 ml of
urine. Solid-phase extraction was performed with C18 columns. Before applying urine
samples, the column material was preconditioned by washing with 4 ml of methanol
and equilibrating with 2 ml of water. Inorganic material was removed from the column
by washing with 2 ml of water. The organic material was collected by elution with 4 ml
of methanol. After evaporation to dryness, 2 ml of acetate buffer (0.1 M, pH 5.2) was
added to the extract. Hydrolysis was performed by adding 100 µl of Helix pomatia
and incubating for 1 hour at 55°C. Steroids were isolated from the buffer solution by
extracting with 5 ml of diethyl ether (twice). After extraction the phase separation was
stimulated by centrifugation (4000 rpm, 5 min). The organic layer was removed and
evaporated to dryness under a gentle stream of nitrogen at 40°C. The extract was
dried overnight over P2O5/KOH under reduced pressure. One µl of the incubation
mixture was directly injected.
Screening of the urine extracts was performed in selected ion monitoring (SIM)
mode. ∆4-AEDIONE was monitored at m/z 430 representing [M]•+. AO and EO were
monitored at m/z 434 and 419, representing [M]•+ and [M-15]+, respectively. The
suspected artifacts X and Y were monitored at m/z 494 and 479. The monitored m/z
values corresponding to labeled AO and EO (m/z 440 and 425) and artifacts X and Y
(m/z 499 and 484), were chosen on the basis of the maximum area response. These
m/z values were established by SIM monitoring of the m/z range 434 to 441 for AO
and EO and m/z 494 to 501 for X and Y, respectively.
Derivatization of synthetic steroids
To study the source of formation of X and Y as analytical artifacts, synthetic steroids
(25 µg) were derivatized as described above and analyzed for X and Y. Some of the
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most relevant endogenous steroids in relation to doping analysis were selected: AO,
EO, testosterone (T), epitestosterone (E), ∆4-AEDIONE, dehydroepiandrosterone
(DHEA) and androst-5-ene-3β,17β-diol (∆5-AEDIOL).
Influence of diethyl disulfide on ethyl thio-incorporation with AO and EO
To prove the reactivity of diethyl disulfide in the incorporation of an ethyl thio-group,
the derivatization of synthetic AO and EO was performed under the following
conditions:
1. 25 µg of AO in 100 µl of MSTFA/NH4I/ethanethiol (1000:2:3; v/w/v)
2. 25 µg of EO in 100 µl of MSTFA/NH4I/ethanethiol (1000:2:3; v/w/v)
3. 25 µg of AO in 100 µl of MSTFA/NH4I/ethanethiol/diethyl disulfide (1000:2:3:3;
v/w/v/v)
4. 25 µg of EO in 100 µl of MSTFA/NH4I/ethanethiol/diethyl disulfide (1000:2:3:3;
v/w/v/v)
To every sample 25 µg of 5α-androstane-3α,17β-diol (ADIOL) was added as internal
standard. Incubation was performed at 80°C for 30 min. The derivatization mixtures
were analyzed on day 0 (immediately after derivatization), day 7 and day 12 (the
samples were kept at room temperature between the analyses).  The area ratios,
Y/AO and X/EO were determined by monitoring ions of the derivatives at m/z 494 (X
and Y) and m/z 434 (AO and EO).
Time dependence of ethyl thio-derivative formation
To study the time dependent ethyl thio-derivative production in more detail, the
following samples were prepared for analysis and analyzed repeatedly for 120 hours
(once every 4 hours):
1. 10 µg of AO and 10 µg of EO in 100 µl of MSTFA/NH4I/ethanethiol
(1000:2:3; v/w/v)
2. 10 µg of AO and 10 µg of EO in 100 µl of  MSTFA/NH4I/ethanethiol/diethyl
disulfide (1000:2:3:50; v/w/v/v)
3. Extract of 3 ml of blank urine in 100 µl of MSTFA/NH4I/ethanethiol
(1000:2:3; v/w/v)
4. Extract of 3 ml of blank urine  in 100 µl of MSTFA/NH4I/ethanethiol/diethyl
disulfide (1000:2:3:50; v/w/v/v)
ADIOL (10 µg) was used as internal standard.  Urine sample cleanup was performed
as described above. GC-MS analysis of the per-TMS derivatives was performed by
selected ion monitoring of the ions at m/z 434 (AO and EO), 494 (X and Y) and 436
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(ADIOL). The area ratios of AO, EO, X and Y vs. ADIOL, respectively, were
calculated and graphically presented as a function of time of analysis.
Ethyl thio-incorporation with T and E
T and E (25 µg) were derivatized in 100 µl of MSTFA/NH4I/ethanethiol/diethyl
disulfide (1000:2:3:50; v/w/v/v) for 30 minutes at 80°C. After 12 days of storage in
glass vials at room temperature, full scan mass spectra were recorded.
Statistics
Confidence intervals of 95% were calculated for the regression coefficient ‘a’ (slope
of the linear regression line for the area ratio as a function of time). Significance of
production of X and Y and loss of AO and EO were tested using the hypothesis H0:
a=0 and H1: a>0 or H1:a<0. Statistical analysis was performed with SPSS 9.0.
RESULTS
Confirmation of artifact formation
In all urine samples two unknown compounds (X and Y) were detected at m/z 494
and m/z 479 (see Figure 2). The identity and origin of these products were unknown.
After administration of d7-∆4-AEDIONE and at the retention times of X and Y (16.40
and 16.55, respectively), a signal at m/z 499 and 484 was also detected. These were
suspected to be labeled derivatives of X and Y. The signals of X and Y could also be
observed in full scan mode, but concentrations of the two products were too low to
obtain representative full scan mass spectra.
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Figure 2: Selected ion chromatograms of non-deuterated (chromatogram A: m/z 494 and
479) and deuterated (chromatogram B: m/z 499 and 484) products X and Y
Derivatization of synthetic steroids
In the derivatization mixtures containing the per-TMS derivatives of AO and EO,
minor quantities were detected of respectively Y and X. Other steroids studied did not
result in product formation, as determined by the analysis of the selected ions at m/z
494 and 479, respectively. Concentrations of X and Y were too low for obtaining
representative full scan mass spectra.
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Influence of diethyl disulfide on ethyl thio-incorporation
The results are summarized in Table 1. After 12 days incubation it was possible to
obtain representative full scan spectra for the derivatives of X and Y (Figure 3).
Table 1: Area ratio of ions at m/z 494 and 434 of 4 mixtures over 12 days.
Mixture Day 0 Day 7 Day 12
1 AO in MSTFA/NH4I/ethanethiol 0.0111 0.0416 NA*
2 EO in MSTFA/NH4I/ethanethiol 0.0068 0.0357 NA*
3 AO in MSTFA/NH4I/ethanethiol/diethyl disulfide 0.140 0.927 2.17
4 EO in MSTFA/NH4I/ethanethiol/diethyl disulfide 0.104 0.694 1.48
* NA = not analyzed
Time dependence of ethyl thio-derivative formation
A significant (p<0.05) and approximate constant production rate of X and Y occurred
in all four reaction mixtures (Figure 4). However, when MSTFA/NH4I/ethanethiol was
applied, the area of X and Y remained smaller than 1 percent compared to the
derivatives of AO and EO (Figure 5) after 120 hours.  In case of
MSTFA/NH4I/ethanethiol/diethyl disulfide derivatization of a urine sample extract, the
areas of X and Y approached 5 percent of the areas of respectively per-TMS EO and
AO after 120 hours incubation at room temperature. Also in this case the
concentrations of silylated AO and EO decreased significantly (p<0.05).
When the two studied derivatization methods were applied to one urine sample
extract that was split into two separate fractions, different recoveries of derivatization
were obtained. MSTFA/NH4I/ethanethiol derivatization of AO and EO led to
significantly smaller recoveries of the silylated products compared to the
MSTFA/NH4I/ethanethiol/diethyl disulfide derivatization (approximately 70%). As can
be observed in Figure 5, these recoveries showed an approximate linear increase
with increasing incubation time, to 85-90% of the recovery obtained with the
MSTFA/NH4I/ethanethiol/diethyl disulfide method.  Differences in conversion were
not present in case of derivatization of synthetic AO and EO.
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Figure 3: Full scan mass spectra of products X and Y as determined in a urine sample
extract incubated in MSTFA/NH4I/ethanethiol/diethyl disulfide (1000:2:3:50;
v/w/v/v).
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Figure 4: Ratios of X/ADIOL and Y/ADIOL as a function of time after derivatization.
x
 - Incubation of a urine extract in MSTFA/NH4I/ethanethiol/diethyl disulfide
(1000:2:3:50; v/w/v/v).
 - Incubation of a urine extract in MSTFA/NH4I/ethanethiol (1000:2:3; v/w/v)).
 - Incubation of synthetic AO and EO in MSTFA/NH4I/ethanethiol/diethyl
disulfide (1000:2:3:50; v/w/v/v).
- Incubation of synthetic AO and EO in MSTFA/NH4I/ethanethiol (1000:2:3;
v/w/v).
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Figure 5: Ratios of AO/ADIOL and EO/ADIOL as a function of time after derivatization.
x 
- Incubation of a urine extract in MSTFA/NH4I/ethanethiol/diethyl disulfide
(1000:2:3:50; v/w/v/v).
 - Incubation of a urine extract in MSTFA/NH4I/ethanethiol (1000:2:3; v/w/v)).
 - Incubation of synthetic AO and EO in MSTFA/NH4I/ethanethiol/diethyl
disulfide (1000:2:3:50; v/w/v/v).
 - Incubation of synthetic AO and EO in MSTFA/NH4I/ethanethiol (1000:2:3;
v/w/v).
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Ethyl thio-incorporation with T and E
Total ion current chromatograms of the derivatization mixtures and the mass spectra
of the ethyl thio-products of T and E, are shown in Figures 6 and 7.
Figure 6: A.Total ion current chromatogram of silylated synthetic testosterone (12 days
after derivatization). B.Full scan mass spectrum of the obtained ethyl thio-
derivative.
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Figure 7: A.Total ion current chromatogram of silylated synthetic epitestosterone (12
days after derivatization). B.Full scan mass spectrum of the obtained ethyl
thio-derivative.
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DISCUSSION
X and Y were proven to be analytical artifacts, formed during the derivatization
reaction in the MSTFA/NH4I/ethanethiol (1000:2:3;v/w/v) medium. X and Y were
initially observed in blank urine samples. The response of X and Y in the steroid
profile increased after administration ∆4-AEDIONE or DHEA (data not shown). When
d7-∆4-AEDIONE was administered in the described excretion study, besides the
signal at m/z 494 and 479 also the signals at m/z 499 and 484 increased. These
were suspected to be X and Y containing 5 deuterium atoms, which matched either a
metabolically or chemically relation of X and Y to the administered labeled
∆4-AEDIONE. When the observed signal at m/z 494 is assumed to be corresponding
to the molecular mass of X and Y, the product formation could not be explained by
metabolism, as androgens have a molecular mass range of 430-436 Da and
hydroxylated androgen metabolites a range of 518-524 Da.
When chemical side-reactions are considered, a mass of 494 Da could represent the
incorporation of an ethyl thio-group into the steroid structure of AO and EO, causing
a shift in molecular mass of 60 Da. The increasing signal during repeated GC-MS
analysis of one urine sample, illustrated the production of X and Y as a function of
time in the derivatization mixture and made the optional source metabolism a less
likely explanation. The detection of a significant signal at m/z 494 after derivatization
of synthetic AO and EO proved these steroids to be the source of respectively Y and
X. Additional proof for ethyl thio-incorporation as the source of the artifact formation
was obtained by the extensive acceleration of incorporation after diethyl disulfide was
added to the derivatization medium.
The obtained spectra of X and Y show little specific fragmentation. Significant ions in
the spectra represent losses usually observed in TMS-derivatization (Table 2).
Table 2: Suggested fragmentation for X and Y (see Figure 3).
m/z Relative signal X/Y (%) Loss Fragmentation
494 100.0/91.1 [M]•+ [M]•+
479 95.0/100.0 [M-15]+ [M-CH3]+
404 2.2/4.1 [M-90]•+ [M-TMSOH]•+
389 13.2/15.1 [M-90-15]+ [M-TMSOH-CH3]+
327 3.9/1.5 [M-90-15-62]+ [M-TMSOH-CH3-CH3CH2SH]+
The reagent MSTFA/NH4I/dithioerythreitol was established by Donike et al. [1] for
application in doping analysis of steroids. Nowadays dithioerythreitol is frequently
replaced by ethanethiol to prevent chromatographic interference. The essence of
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ethanethiol is preventing iodine incorporation into the steroid nucleus [2]. Upon
decomposition of TMSI, iodine is formed that can add to the steroid nucleus. To
prevent this side-reaction to occur, iodine is reduced by ethanethiol to form hydrogen
iodide and diethyl disulfide.
From Table 1 and Figures 4 and 5 can be concluded that diethyl disulfide is more
reactive towards ethyl thio-incorporation than ethanethiol. This could explain the
relatively extensive ethyl thio-incorporation that occurs during derivatization of urine
extracts compared to synthetic substance derivatization, as the total concentration of
target compounds for derivatization is much higher in urine extracts than in that case
of synthetic substances. That results in higher diethyl disulfide levels and therefore
higher ethyl thio-derivative formation. Consequently, a matrix effect can be defined
for trimethylsilylation with the described method, corresponding to the scientifically
established matrix effect in steroid analysis [3].
As the mass of the molecular ion increases by 60 Da, it must be expected that a
proton is replaced by a -SCH2CH3 group, leaving the double bond at C16-C17 intact. A
hypothetical mechanism for such incorporation is proposed in Figure 8. According to
this mechanism, the TMS-moiety from the derivatized AO or EO is removed from the
steroid by nucleophilic attack of diethyl disulfide on the silicon atom under
simultaneous addition of an ethyl thio-group with C16. Subsequently, the generated
17-ketogroup is silylated again. Unfortunately, due to the lack of specific
fragmentation of X and Y it was impossible to confirm the structure as proposed in
Figure 8.
When ∆4-AEDIONE is orally administered, it is rapidly metabolized, showing AO and
EO as the main metabolites [4]. Because AO and EO are present in the urine matrix
in relatively high concentrations as compared to other androgens as T, E and
∆4-AEDIONE, the studied derivatives were presumable products of those steroids
and could easily be detected. This does however not imply that no ethyl thio-
incorporation occurs with other steroids present in the matrix. For example, T and E
are interesting compounds to study regarding ethyl thio-incorporation for two
reasons. First, the α,β−unsaturated 3-keto moiety could result in different quantities
of product formation. Second, as the urinary testosterone/epitestosterone ratio (T/E
ratio) is applied to establish use of testosterone, this ratio could be affected by
significant ethyl thio-incorporation.
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Figure 8: Hypothetical mechanism for ethyl thio-incorporation with AO and EO TMS-
derivatives. Step 1: AO/EO are silylated to their per-TMS derivatives. Step 2: The
TMS-moiety is lost by nucleophilic attack of EtSSEt on the silicon atom under
simultaneous incorporation of the ethyl thio-group with C16. Step 3: The keto
group is silylated again by in situ formed TMSI.
As shown in Figures 4 and 5, significant ethyl thio-incorporation will only affect the
analysis of per-TMS AO and EO, when extra diethyl disulfide is added to accelerate
the incorporation. The application of MSTFA/NH4I/ethanethiol (1000:2:3;v/w/v) did not
result in a significant change in the area of AO and EO after 120 hours. This is in
agreement with the reported 48 hour stability (at room temperature) or 5-6 days
stability (at 4°C) of per-TMS derivatives of steroids in general [5].  The stability
estimate of days to weeks reported as by Donike [1] should be considered as an
overestimation.
In this case, the role of ethyl thio-incorporation was of purely theoretical interest.
However, the presented results give theoretical insight into less accessible aspects of
a derivatization procedure that is often applied in steroid analysis. Although the
results described in this paper are incomplete to obtain a fully detailed mechanistic
overview on the ethyl thio-incorporation in steroid analysis, it illustrates the still
insufficient knowledge of the silylation mechanism. In particular, the role of diethyl
disulfide has been considered insufficiently.  Moreover, when investigating the
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formation of new metabolites the ethyl thio-incorporation can create
misinterpretations.
The ethyl thio-incorporation could become of practical relevance when derivatized
samples are re-analyzed that were stored at room temperature for several days. Also
the influence of ethyl thio-incorporation on the quantitative analysis of T and E and
the analysis of anabolic steroids at ppb level should be considered. To avoid
significant differences in steroid quantification due to artifact formation, deuterated
internal standards should be considered as a necessity.
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DISCUSSION: PERSPECTIVES OF STEROID PROFILING
REVIEWED
STEROID PROFILING AND TESTOSTERONE
Initially, the abuse of steroids in sports was focussed on chemically modified
derivatives of testosterone. These steroids were of exogenous origin, so detection of
the respective substances or the metabolites was sufficient to prove administration.
In order to detect the abuse of popular steroids as methandienone (Dianabol),
methenolone (Primobolan) and stanazolol (Winstrol) [1] “straightforward analysis”
with gas chromatoghraphy-mass spectrometry (GC-MS) was considered to be
adequate.
After the abuse of testosterone (T) was suspected during the Olympic Games of
Moscow in 1980 more attention was paid to the abuse of steroids of endogenous
origin. Therefore, endogenous steroid profiling techniques were developed for the
detection of administration of T [2,3] and its metabolite with high anabolic potency
5α-dihydrotestosterone (5α-DHT) [4,5]. As described in Chapter 1 the ratio of
testosterone to epitestosterone (T/E ratio) has been used until today for the detection
of T abuse.  Since 1982 the International Olympic Committee (IOC) has accepted
the T/E ratio as method for the detection of T [3].
Besides T and E, usually GC-MS analysis of the main metabolites androsterone
(AO), etiocholanolone (EO), stereoisomers of androstanediol, 5α-DHT and main
biosynthetic precursors as dehydroepiandrosterone (DHEA), androst-5-ene-3β,17β-
diol (∆5-AEDIOL) and androst-4-ene-3,17-dione (∆4-AEDIONE) is applied in routine
procedures of doping analysis for the purpose of interpretation of an elevated T/E
ratio.
Although the T/E ratio was generally and effectively applied in doping analysis,
occasional critical comments appeared about the validity of the method by e.g.
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lawyers involved in doping cases. In particular, the application of the same decision
criteria for females as for males was attacked.  As discussed in Chapter 1, several
variables determine the intra- and intersubject reference values of the T/E ratio.
Although amongst doping laboratories there is a general conviction of the validity of
the T/E ratio, there is still insufficient published data about the influence of variables
as race, menstrual cycle, use of contraceptives, age, exercise, etc. The controversy
can therefore mostly be assigned to the availability of scientific data.
An example of one of the variables that effectively influences intra-individual values
of the T/E ratio is the consumption of ethanol. As described in Chapter 3, the T/E
ratio increases immediately after first alcohol administration. Although the effect is
more significant for females compared to males, Chapter 2 shows that both sexes
are at risk of an incidental T/E value above 6 after drinking a volume in the order of a
bottle of wine (dose of 1.2 g ethanol per kg bodyweight, corresponding to a plasma
concentration 1-2‰). The significance of the effect was dependent upon the mean
basal intra-subject T/E ratio. Doping laboratories should therefore be equipped with a
validated methodology to establish urine alcohol concentrations in case recent
alcohol consumption is claimed.
STEROID PROFILING AND FOOD SUPPLEMENTS
Although already during the eighties experiments were performed with nasal
administration of ∆4-AEDIONE in former Eastern Germany [6], this steroid did not
become widely commercially available until the late nineties. Stimulated by
accessibility via the Internet “food supplements” containing steroids became popular
marketing products. Unlike Europe, food supplements containing testosterone
precursors as DHEA and ∆4-AEDIONE are available as non-prescriptive substances
in the United States.
DHEA and ∆4-AEDIONE were the first steroids that became widely available in food
supplement formulations. The popularity of these products was illustrated by the
case of the baseball player Mark McGwire [7], who publicly admitted and defended
the use of ∆4-AEDIONE. In 1997 and 1998 respectively, DHEA and ∆4-AEDIONE
were placed on the IOC list of forbidden substances. In 1999 these were followed by
androst-5-ene-3β,17β-diol (∆5-AEDIOL), androst-4-ene-3β,17β-diol (∆4-AEDIOL),
androst-5-ene-3,17-dione (∆5-AEDIONE), 19-norandrost-4-ene-3,17-dione (19-nor-
∆4-AEDIONE), 19-norandrost-5-ene-3,17-dione (19-nor-∆5-AEDIONE) and 19-
norandrost-4-ene-3β,17β-diol (19-nor-∆4-AEDIOL).
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To detect food supplement steroids in doping analysis, profiling techniques are
mostly applied as were originally developed for detection of T administration [2,3],
with the T/E ratio as one of the main parameters.  However, these profiling
techniques were developed in times that T precursors as DHEA and ∆4-AEDIONE
were not generally available.
The increased number of abused endogenous steroids has complicated the
interpretation of steroid profiles. As shown in Chapters 4-7 both oral DHEA and
∆4-AEDIONE administration result in an increased T/E ratio. As oral administration of
∆5-AEDIOL, ∆4-AEDIOL and ∆5-AEDIONE has a comparable effect [7,8] it is a very
unspecific parameter for all these steroids. The same conclusion can be drawn for
other previously mentioned parameters as AO, EO, stereoisomers of androstanediol
and 5α-DHT, which are main metabolites of all these food supplement steroids.
Efficient identification of the abused steroids by the present methodology is therefore
not possible.
Regarding 19-norsteroids found in food supplements, applied analytical techniques
are limited to the screening of 19-norandrosterone (19-nor-AO) and 19-
noretiocholanolone (19-nor-EO). As these are the main metabolites of 19-nor-∆4-
AEDIONE, 19-nor-∆5-AEDIONE, 19-nor-∆4-AEDIOL as well as 19-nortestosterone
(nandrolone) [1,7,8], also no identification of the administered steroid can be
performed by this methodology.
Providing this specific information on the identity can be of particular relevance in
case of unintentional steroid administration by polluted food supplement products, as
has frequently been claimed in recent years [13,14]. Furthermore, there is increasing
scientific acceptance for the concept of natural presence of 19-nor-AO and 19-nor-
EO in low concentrations in urine [9,10], as well as the concept of natural excretion
of these steroids after consumption of meat [11,12]. To determine the, either
endogenous or exogenous, source of 19C- or 19-norsteroids, more specificity of the
analytical method is required as is available today.
As explained in Chapter 3, profiling of oxygenated metabolites of food supplement
steroids could provide essential information that can aid the identification of the
abused substances. To obtain a more specific steroid profile for the detection of food
supplement steroids, the metabolism was studied of the model compounds DHEA
and ∆4-AEDIONE with a main focus on oxygenated metabolites.
To compare the studied metabolites as parameters in steroid profiling, they were
described by means of sensitivity and specificity. For the metabolites, sensitivity was
defined as the increase of excretion rate, compared to the mean basal excretion rate
(see Table 1, Chapter 6). AO and EO are mostly considered as sensitive parameters
for the detection of DHEA and/or ∆4-AEDIONE [7,8]. The steroids that showed a
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larger sensitivity for DHEA than AO or EO were (see Chapter 4 and 5): DHEA, 7β-
hydroxy-DHEA, ∆5-AEDIOL, 7-keto-AO, 6α/β-OH-∆4-AEDIONE, 16α-OH-AO and
16α-OH-EO. Higher sensitivity for detection of ∆4-AEDIONE was observed for 4-OH-
∆4-AEDIONE and 6α/β-OH-∆4-AEDIONE.
To quantitatively describe specificity in this experimental setup (regarding only the
administration of two food supplement steroids), the sensitivity of a metabolite for
administration of DHEA can divided by the sensitivity for the administration of
∆4-ADIONE (or vice versa). Table 10.1 summarizes quantitative values for specificity
of each parameter for respectively DHEA and ∆4-AEDIONE. The best specificity for
DHEA administration is supplied by 7β-OH-DHEA, DHEA, 7-keto-AO, ∆5-AEDIOL,
16α-OH-DHEA and 7-keto-DHEA. The best specificity for ∆4-AEDIONE was supplied
by 4-OH-∆4-AEDIONE, T, E and 6α/β-OH-T.
Table 1: Quantitative values for specificity of the studied parameters for
the administration of DHEA and ∆4-AEDIONE. Specificity for
∆4-AEDIONE is the reciprocal value of the specificity for DHEA.
Parameter Specificity for DHEA Specificity for ∆4-AEDIONE
7β-OH-DHEA 36.3 <0.1
DHEA 17.5 0.1
7-keto-AO 15.2 0.1
∆5-AEDIOL 10.3 0.1
16α-OH-DHEA 8.4 0.1
16α-OH-AO 0.9 1.1
7-keto-DHEA 5.3 0.2
16α-OH-EO 1.7 0.6
AO 0.5 2.0
7α-OH-DHEA 0.5 1.9
EO 0.4 2.7
6α/β-OH-∆4-AEDIONE 0.3 3.6
16α-OH-∆4-AEDIONE 1.2 0.8
T 0.2 5.4
E 0.2 5.0
6α/β-OH-T 0.2 5.0
4-OH-∆4-AEDIONE <0.1 62.8
As described in the Appendix, administration of one of the most recently available
supplement steroids 7-keto-DHEA, or its analogue 3-acetyl-7-keto-DHEA [16], can
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also lead to production of oxygenated DHEA metabolites as 7α-OH-DHEA, 7β-OH-
DHEA, 7-keto-DHEA and 7-keto-AO. As 7-keto-DHEA is not on the IOC list of
forbidden substances, excluding the administration of this steroid is necessary for the
analysis of DHEA abuse by means of oxygenated metabolites.  As shown in the case
study, no non-oxygenated metabolites are formed after oral administration of 7-keto-
DHEA-acetate. Therefore, profiling non-oxygenated metabolites still remains
necessary, as those show no sensitivity for 7-keto-DHEA.
The described experiments show that measurement of oxygenated and non-
oxygenated steroids can provide sensitive and specific information that is needed for
identification of the administered steroid.
More research is needed to study the specific metabolism of other mentioned food
supplement steroids, leading to additional parameters to evaluate. To facilitate the
interpretation of the larger number of parameters in doping analysis, multivariate
statistical analysis could be applied as was done previously for profiling non-specific
T metabolites [17].
ISOTOPE RATIO MASS SPECTROMETRY AND STEROID PROFILING
Since the Olympic Games of Nagano, Gas Chromatography-Combustion-Isotope
Ratio Mass Spectrometry (GC-C-IRMS) is applied as confirmation method for abuse
of “endogenous” steroids. This technique is able to distinguish between endogenous
and exogenous steroids by quantitative analysis of the 13C/12C isotope ratio after
combustion to CO2, as explained in Chapter 1.
Analytical procedures for GC-C-IRMS analysis are reported for the analysis of T [18-
21], E, DHEA, 5α-DHT [21,22], hydrocortisone and cortisone [24]. The analysis is
mostly performed on metabolites of the steroids under investigation as ∆5-AEDIOL
[22], AO, EO [25], stereoisomers of androstanediols [19,21,25], tetrahydrocortisol
and tetrahydrocortisone [24]. GC-C-IRMS can therefore be considered as a similar
technique as regular steroid profiling, with the extra ability to differentiate between
metabolites of endogenous and metabolites of exogenous origin. The development
of this technique resulted in major advancement in discriminative power of doping
analysis regarding steroids of endogenous vs. exogenous origin. However, when
specificity is regarded no real innovation was established.
GC-C-IRMS is still mostly used for confirmation purposes, as extensive and laborious
sample cleanup is required. For T analysis some methodologies have been reported
that are suitable for fast and efficient screening purposes [24,26]. However, the main
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contribution of GC-C-IRMS is still the confirmation of T abuse after detecting a high
T/E ratio, e.g. in cases of an increased T/E ratio caused by alcohol consumption.
Furthermore, could this technique be used to eliminate the ketoconazole test
(Chapter 1, Appendix A), in which an athlete is required to self-administer a relatively
large dose of ketoconazole. This should be avoided as based on ethics and potential
side effects.
GC-C-IRMS can form an excellent combination with profiling of suggested steroid
parameters to combine specificity and sensitivity with discrimination between
endogenous and exogenous steroids, for the detection of food supplement steroids.
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APPENDIX
CASE STUDY: METABOLISM OF 3-ACETYL-7-KETO-
DHEA
INTRODUCTION
Examples of steroids that recently have appeared on the food supplement market are
7-keto-dehydroepiandrosterone (7-keto-DHEA) and its analogue 3-acetyl-7-keto-
DHEA. As 7-keto-DHEA is one of the metabolites of DHEA (see Chapters 4 and 6),
an overlapping metabolic profile can be expected after oral administration of these
steroids.
In relation to doping analysis (3-acetyl-7)-keto-DHEA can be of relevance, when the
analysis of DHEA is concerned. DHEA has been declared as doping agent by the
International Olympic Committee (IOC) since 1997. As described in Chapter 3,
insufficient analytical methodology is available for specific determination of DHEA
abuse. When profiling oxygenated metabolites is considered for the detection of
DHEA abuse, selective analysis of DHEA and (3-acetyl-)7-keto-DHEA is required,
because the latter are not on the IOC list of forbidden substances.
In this study 3-acetyl-7-keto-acetate was orally administered to one male volunteer.
Timed urine samples were collected previous and after administration, which were
analyzed for androgens and oxygenated metabolites of DHEA (see Chapter 3).
EXPERIMENTAL
DHEA administration
Urine samples of one male (age: 30 years) were collected every 2 hours and
overnight during two successive days. On the second day at 9 a.m. two capsules
each containing 50 mg 3-acetyl-7-oxo-DHEA (7-Keto Fuel, Twinlab®, New York,
USA) were orally administered. For each collected urine sample the exact void time,
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volume and specific gravity (Urine Specific Gravity Refractometer, Atago, Japan) was
recorded. Samples were stored at -20°C until time of analysis.
Analytical procedure
The analytical procedure is described in detail in Chapter 4. The following
parameters were quantified: dehydroepianderosterone (DHEA), androst-5-ene-
3β,17β-diol (∆5-AEDIOL), testosterone (T), epitestosterone (E), androsterone (AO),
etiocholanolone (EO), 7-keto-DHEA, 7α-hydroxy-dehydroepiandrosterone (7α-OH-
DHEA), 7β-hydroxy-dehydroepiandrosterone (7β-OH-DHEA), 7-keto-androsterone
(7-keto-AO), 16α-hydroxy-dehydroepiandrosterone (16α-OH-DHEA), 16α-hydroxy-
androsterone (16α-OH-AO) and 16α-hydroxy-etiocholanolone (16α-OH-EO).
RESULTS
The calculated excretion rates (in µg/hour) of the analyzed non-oxygenated and
oxygenated steroids are illustrated as a function of time in Figures 1 and 2,
respectively. Of the oxygenated steroids, only those that were oxygenated at C7 (7α-
OH-DHEA, 7β-OH-DHEA, 7-keto-DHEA and 7-keto-AO) showed an increased
excretion rate during 15-20 hours after time of administration. 7-Keto-AO excretion
was increased during 30 hours. No increased excretion rate of non-oxygenated
steroids was observed. Relevant steroid ratios are shown in Figure 3. The T/E,
AO/EO and 16α-OH-AO/16α-OH-EO ratio were not significantly affected. The 7β-
OH-DHEA/7α-OH-DHEA ratio was increased during 20 hours.
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Figure 1: Excretion rates of non-oxygenated steroids as a function of time. At time point 20
hours 3-acetyl-7-keto-DHEA was orally administered.
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Figure 2: Excretion rates of oxygenated steroids as a function of time. At time point 20
hours 3-acetyl-7-keto-DHEA was orally administered.
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Figure 3: Ratios of excretion rates as a function of time. At time point 20 hours 3-acetyl-7-
keto-DHEA was orally administered.
DISCUSSION
Application of (3-acetyl-)7-keto-DHEA
Claims for the pharmacological effect of 7-keto-DHEA and 3-acetyl-7-keto-DHEA are
basically similar as for DHEA. It is still unclear what the precise function of DHEA is
within the human body, except for being a biosynthetic precursor for androgens as T.
Maximum DHEA plasma concentration can be detected around the age of 20,
followed by a steady decrease during aging [1,2]. Several studies have presented
evidence that replacement therapy of 25-50 mg/day increases androgen
concentrations and improves the feeling of well being in males and females of
advanced age [3,4] and in females with adrenal insufficiency [5].
The detection of 7-keto-DHEA in human urine samples was first reported by
Fukushima et al. [6]. Suggestive evidence is reported that oxygenated metabolites as
7-keto-DHEA, show physiological effects explaining some of the effects of DHEA, as
antiglucocorticosteroid [7] and thermogenic activity [8,9]. There is a lack of
knowledge about the significance of claimed effects of 7-keto-DHEA on e.g. memory
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function and the immune system. Therefore, therapeutic potential of 7-keto-DHEA as
drug or its usefulness as food supplement to replace DHEA, are highly suggestive
[10].
 A pharmacokinetic study has been reported with escalating dose levels of 3-acetyl-
7-keto-DHEA in 22 male subjects in a randomized, double blind, placebo-controlled
design [10]. It was shown that oral administration of 3-acetyl-7-keto-DHEA was safe
up to dose levels of 200 mg/day for 4 weeks. The main metabolic route led to the
production of 7-keto-DHEA sulfate and limited androgen production occurred.  This
supported the claim that 7-keto-DHEA does not result in activation of androgen or
estrogen receptors.
(3-Acetyl-)7-keto-DHEA in doping analysis
Administration of 100 mg (3-acetyl-)7-keto-DHEA leads to significantly increased
excretion of several oxygenated steroids, that were previously classified as DHEA
metabolites (see Chapters 4 and 7). Therefore, a potential risk for false positive
results is introduced.
However, clear differences were observed as compared to the excretion data after
DHEA administration. In the present experiment the excretion of androgens and
16α-hydroxy metabolites was not significantly affected. The latter even showed a
limited decrease in excretion rate between 15-25 hours after time of administration.
Regarding the steroid ratios, only the 7β-OH-DHEA/7α-OH-DHEA ratio showed a
comparable effect as was observed for DHEA administration. The AO/EO, 16α-OH-
AO/16α-OH-EO and the T/E ratio were not significantly affected in the present study.
Concluding, this case study clearly illustrates that interpretation of a combined profile
of androgens, oxygenated DHEA metabolites and corresponding steroid ratios, can
provide a clear distinction between the administration of DHEA and (3-acetyl-)7-keto-
DHEA.
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Summary
Quantitative analysis of endogenous steroids (referred to as steroid profiling) is
applied in doping analysis to detect the abuse of steroids that also have an
endogenous origin, e.g. testosterone. The concentration of testosterone versus
epitestosterone (T/E ratio) in urine is considered as the most sensitive parameter for
detection of testosterone abuse. In Chapter 1 the validity of the T/E ratio is discussed
by reviewing several factors that can influence this ratio, possibly leading to false-
positive results. Despite these influential factors, the T/E ratio has been applied since
the early eighties and can still not be displaced by the more recently developed
isotope ratio mass spectrometry.
Chapter 2 describes an experiment in which the relation was investigated between
the metabolism of alcohol and the increase of the T/E ratio. Male and female subjects
consumed an average dose of alcohol (1.2 g/kg bodyweight). Urine and plasma
samples were analyzed for testosterone, epitestosterone and for several precursors
and metabolites of testosterone. All subjects showed an increase of the T/E ratio,
during 10-12 hours after the start of consumption. However, the effect was
significantly higher in females than in males. The chance of a T/E ratio increasing
above the criterion of the International Olympic Committee (T/E = 6) by recreational
alcohol consumption is realistic and should be taken into account, especially in out-
of-competition doping control. Although the cause of T/E increase is not completely
understood, simultaneous utilization of cofactors for both steroid biosynthesis and
ethanol metabolism seems to play a predominant role.
Since steroid containing food supplements have become easily available, a
frequently occurring abuse of steroids as dehydroepiandrosterone (DHEA) and
androst-4-ene-3,17-dione (∆4-AEDIONE) in sports is suspected. As described in
Chapter 3, detection of these steroids in doping analysis is mostly performed by
profiling techniques originally developed for detection of testosterone administration.
After oral administration of DHEA or ∆4-AEDIONE the T/E ratio and the excretion
rate of metabolites as androsterone and etiocholanolone increases (Chapters 4-7).
Profiling of these parameters can therefore not lead to specific information about the
identity of the administered substance.
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Chapters 4 and 5 describe excretion studies with respectively deuterium-labeled
DHEA and ∆4-AEDIONE. Several oxygenated metabolites of these steroids were
identified. The relative increase of the excretion rates after administration showed
that the analysis of oxygenated steroids provides information of equal sensitivity as
profiling the “regular” non-oxygenated metabolites.
Chapters 6 and 7 describe excretion studies with non-labeled DHEA and
∆4-AEDIONE. Urine samples were analyzed for oxygenated and non-oxygenated
metabolites of both steroids. Sensitivity and specificity of each studied parameter
were established. The most sensitive parameters for DHEA were 7β-hydroxy-DHEA,
androst-5-ene-3β,17β-diol, 7-keto-androsterone, 6α/β-hydroxy-∆4-AEDIONE, 16α-
hydroxy-androsterone, 16α-hydroxy-etiocholanolone, androsterone, etiocholanolone
and DHEA itself. High sensitivity for detection of ∆4-AEDIONE was observed for
4- and 6α/β-hydroxy-∆4-AEDIONE, androsterone, etiocholanolone and testosterone.
The most specific metabolites for DHEA (corresponding to a high increase in
excretion rate after administration of DHEA and no or a low increase after
administration of ∆4-AEDIONE) were 7β- and 16α-hydroxy-DHEA, 7-keto-DHEA,
7-keto-androsterone, androst-5-ene-3β,17β-diol and DHEA itself. The most specific
metabolites for ∆4-AEDIONE were 4-hydroxy-∆4-AEDIONE, testosterone,
epitestosterone and 6α/β-hydroxy-testosterone. Concluding, the analysis of
oxygenated metabolites can lead to additional information about the identity of the
administered steroid, despite the relatively low conversion to these metabolites
compared to the conversion to non-oxygenated metabolites.
Chapter 8 describes the derivatization of 3-keto-4-ene steroids. The
trimethylsilylation of these steroids in a reagent of MSTFA/NH4I/ethanethiol results in
3,5-dienolTMS derivatives. This is in contrast to the basic reagent
MSTFA/KOAc/imidazole that mainly leads to the corresponding 2,4-dienolTMS
isomers. An isomerization experiment proved that the 3,5-dienolTMS derivative of the
model steroid 17-methoxy testosterone is more stable than the 2,4-dienolTMS
isomer. The formation of thermodynamically least favorable 2,4-dienolTMS products
was explained by hydrogen-deuterium exchange experiments. These showed that
the protons at C2 are more acidic than the protons at C6. This leads to the formation
of kinetically favorable 2,4-dienol products under the basic conditions of the
MSTFA/KOAc/imidazole reagent.
Chapter 9 describes artifact formation that occurs during the derivatization of
androsterone and etiocholanolone in MSTFA/NH4I/ethanethiol. These artifacts were
identified as ethyl thio-containing products of the respective trimethylsilyl derivatives.
The conversion was significantly accelerated by addition of diethyl disulfide to the
reagent prior to incubation. A mechanism is proposed for ethyl thio-incorporation at
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the C16-position. In this experiment the conversion to the artifacts was insufficient to
significantly influence the analysis of androsterone and etiocholanolone. However,
when the formation of new metabolites is investigated, the ethyl thio-incorporation
can lead to false interpretations.
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Samenvatting
Kwantitatieve analyse van endogene steroïden, ofwel steroïd profilering, wordt
toegepast in doping analyse voor de detectie van steroïden die tevens een endogene
oorsprong hebben, bijv. testosteron. De concentratie van testosteron versus die van
epitestosteron (T/E ratio) in urine wordt hierbij beschouwd als de meest gevoelige
parameter voor de detectie van testosteron misbruik. In hoofdstuk 1 wordt de
validiteit van de T/E ratio besproken middels een overzicht van de factoren die deze
ratio beïnvloeden en mogelijk leiden tot vals-positieve resultaten. Ondanks deze
beïnvloedende factoren wordt de T/E ratio toch sinds begin tachtiger jaren gebruikt
en is nog steeds niet verdrongen door de meer recentelijk ontwikkelde isotopen ratio
massaspectrometrie.
Hoofdstuk 2 beschrijft een experiment waarbij de relatie onderzocht werd tussen het
metabolisme van alcohol en de toename van de T/E ratio. Mannelijke en vrouwelijke
proefpersonen consumeerden een gemiddelde dosis alcohol (1,2 g/kg
lichaamsgewicht). Urine- en plasmamonsters werden geanalyseerd op testosteron,
epitestosteron en op verschillende precursors en metabolieten van testosteron. Alle
proefpersonen vertoonden een verhoging van de T/E ratio, gedurende ongeveer
10-12 uur na start van consumptie. Echter, het effect bij vrouwen was groter dan bij
mannen. De kans dat de T/E ratio stijgt tot boven het criterium van het Internationale
Olympische Comité (T/E = 6) door recreatieve alcoholconsumptie is daarom
realistisch. Met name bij “out-of-competition” doping controles moet men hiermee
rekening houden. Hoewel de oorzaak van de T/E ratio toename niet volledig is
opgehelderd, lijkt het gelijktijdig gebruik van co-factoren tijdens de biosynthese van
steroïden en alcohol metabolisme een overheersende rol te spelen.
Nadat in de negentiger jaren steroïden bevattende voedingssupplementen
gemakkelijk verkrijgbaar werden, vermoedde men een frequent voorkomend gebruik
van steroïden als dehydroepiandrosteron (DHEA) en androst-4-een-3,17-dion
(∆4-AEDIONE) in de sport. Zoals beschreven in hoofdstuk 3, wordt de detectie van
deze steroïden in doping analyse meestal uitgevoerd met profileringstechnieken
zoals die zijn ontwikkeld voor de detectie van testosteron.
Na orale toediening van DHEA of ∆4-AEDIONE verhoogt de T/E ratio en de
excretiesnelheid van metabolieten als androsteron en etiocholanolon (hoofdstukken
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4-7). Profilering van deze parameters kan daarom niet leiden tot specifieke informatie
over de identiteit van de toegediende verbinding.
Hoofdstukken 4 en 5 beschrijven excretiestudies met respectievelijk gedeutereerd
DHEA en ∆4-AEDIONE. Verschillende geoxygeneerde metabolieten van deze
steroïden werden geïdentificeerd. De toename van de excretiesnelheden na
toediening toonde aan dat de analyse van geoxygeneerde steroïden informatie van
vergelijkbare gevoeligheid oplevert als de profilering van “reguliere” niet-
geoxygeneerde metabolieten.
Hoofdstukken 6 en 7 beschrijven excretiestudies met respectievelijk niet-
gedeutereerd DHEA en ∆4-AEDIONE. Urinemonsters werden geanalyseerd op
geoxygeneerde en niet-geoxygeneerde metabolieten van beide steroïden.
Gevoeligheid en specificiteit werden bepaald van iedere bestudeerde parameter. De
meest gevoelige parameters voor DHEA waren 7β-hydroxy-DHEA, androst-5-een-
3β,17β-diol, 7-keto-androsteron, 6α/β-hydroxy-∆4-AEDIONE, 16α-hydroxy-
androsteron, 16α-hydroxy-etiocholanolon, androsteron, etiocholanolon en DHEA zelf.
Hoge gevoeligheid voor de detectie van  ∆4-AEDIONE werd waargenomen voor
4- en 6α/β-hydroxy-∆4-AEDIONE, androsteron, etiocholanolon en testosteron. De
meest specifieke metabolieten voor DHEA (corresponderend met een sterke
toename van de excretiesnelheid na toediening van DHEA en geen of een beperkte
toename na toediening van ∆4-AEDIONE) waren 7β- en 16α-hydroxy-DHEA, 7-keto-
DHEA, 7-keto-androsteron, androst-5-een-3β,17β-diol en DHEA zelf. De meest
specifieke metabolieten voor ∆4-AEDIONE waren 4-hydroxy-∆4-AEDIONE,
testosteron, epitestosteron en 6α/β-hydroxy-testosteron. Concluderend, de analyse
van geoxygeneerde metabolieten kan leiden tot additionele informatie over de
identiteit van het toegediende steroïd, ondanks de relatief lage conversie naar deze
metabolieten vergeleken met de conversie naar niet-geoxygeneerde metabolieten.
Hoofdstuk 8 beschrijft de derivatisering van 3-keto-4-een-steroïden. De
trimethylsilylering van deze steroïden in het reagens MSTFA/NH4I/ethaanthiol
resulteert in 3,5-dienolTMS derivaten. Daarentegen resulteert derivatisering in het
reagens MSTFA/KOAc/imidazol voornamelijk in de corresponderende 2,4-dienolTMS
isomeren.  Een isomerisatie-experiment toonde aan dat het 3,5-dienolTMS derivaat
van het modelsteroïd 17-methoxytestosteron stabieler is dan de 2,4-dienolTMS
isomeer. De vorming van het thermodynamisch minst voordelige 2,4-dienolTMS
produkt werd verklaard door waterstof-deuterium uitwisselingsexperimenten. Deze
toonden aan dat de protonen op C2 zuurder zijn dan de protonen op C6. Onder
basische condities van MSTFA/KOAc/imidazol leidt dit tot de vorming van het
kinetisch voordelige 2,4-dienol produkt.
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Hoofdstuk 9 beschrijft de vorming van artefacten, die gevormd worden tijdens de
derivatisering van androsteron en etiocholanolon in MSTFA/NH4I/ethaanthiol. Deze
artefacten werden geïdentificeerd als ethylthio-bevattende produkten van de
respectievelijke trimethylsilyl derivaten. De conversie werd aanzienlijk versneld door
het toevoegen van diethyl disulfide aan het reagens voor incubatie. Een mechanisme
wordt voorgesteld voor ethylthio-invoeging op de C16-positie. In dit experiment was
de conversie naar de bestudeerde artefacten onvoldoende om de analyse van
androsteron en etiocholanolon significant te beïnvloeden. Wanneer de vorming van
nieuwe metabolieten echter bestudeerd wordt kan de vorming van de ethylthio-
artefacten tot verkeerde interpretaties leiden.
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